Document_and_Entity_Informatio
Document and Entity Information | 9 Months Ended | |
Sep. 30, 2013 | Oct. 31, 2013 | |
Document And Entity Information [Abstract] | ' | ' |
Document Type | '10-Q | ' |
Amendment Flag | 'false | ' |
Document Period End Date | 30-Sep-13 | ' |
Document Fiscal Year Focus | '2013 | ' |
Document Fiscal Period Focus | 'Q3 | ' |
Entity Registrant Name | 'ALERE INC. | ' |
Entity Central Index Key | '0001145460 | ' |
Current Fiscal Year End Date | '--12-31 | ' |
Entity Filer Category | 'Large Accelerated Filer | ' |
Entity Common Stock, Shares Outstanding | ' | 81,881,428 |
Consolidated_Statements_of_Ope
Consolidated Statements of Operations (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, except Per Share data, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Income Statement [Abstract] | ' | ' | ' | ' |
Net product sales | $509,038 | $459,813 | $1,538,876 | $1,399,025 |
Services revenue | 240,660 | 226,415 | 705,127 | 652,704 |
Net product sales and services revenue | 749,698 | 686,228 | 2,244,003 | 2,051,729 |
License and royalty revenue | 4,184 | 5,188 | 13,113 | 11,333 |
Net revenue | 753,882 | 691,416 | 2,257,116 | 2,063,062 |
Cost of net product sales | 258,234 | 223,612 | 764,501 | 671,664 |
Cost of services revenue | 124,993 | 120,131 | 369,961 | 331,550 |
Cost of net product sales and services revenue | 383,227 | 343,743 | 1,134,462 | 1,003,214 |
Cost of license and royalty revenue | 2,009 | 1,898 | 5,264 | 5,394 |
Cost of net revenue | 385,236 | 345,641 | 1,139,726 | 1,008,608 |
Gross profit | 368,646 | 345,775 | 1,117,390 | 1,054,454 |
Operating expenses: | ' | ' | ' | ' |
Research and development | 40,498 | 40,562 | 122,452 | 120,009 |
Sales and marketing | 159,587 | 160,644 | 475,465 | 478,544 |
General and administrative | 142,377 | 105,837 | 418,396 | 347,757 |
Loss on disposition | 5,885 | ' | 5,885 | ' |
Operating income (loss) | 20,299 | 38,732 | 95,192 | 108,144 |
Interest expense, including amortization of original issue discounts and deferred financing costs | -53,420 | -54,861 | -203,272 | -161,119 |
Other income (expense), net | -8,869 | -1,072 | -8,276 | 14,570 |
Loss before benefit for income taxes | -41,990 | -17,201 | -116,356 | -38,405 |
Benefit for income taxes | -17,148 | -10,677 | -36,152 | -12,621 |
Loss before equity earnings of unconsolidated entities, net of tax | -24,842 | -6,524 | -80,204 | -25,784 |
Equity earnings of unconsolidated entities, net of tax | 5,753 | 3,007 | 13,238 | 10,417 |
Net income (loss) | -19,089 | -3,517 | -66,966 | -15,367 |
Less: Net income attributable to non-controlling interests | 359 | 286 | 601 | 137 |
Net loss attributable to Alere Inc. and Subsidiaries | -19,448 | -3,803 | -67,567 | -15,504 |
Preferred stock dividends | -5,367 | -5,352 | -15,926 | -15,940 |
Net loss available to common stockholders | ($24,815) | ($9,155) | ($83,493) | ($31,444) |
Basic and diluted net loss per common share attributable to Alere Inc. and Subsidiaries: | ($0.30) | ($0.11) | ($1.03) | ($0.39) |
Weighted-average shares-basic and diluted | 81,735 | 80,792 | 81,417 | 80,492 |
Consolidated_Statements_of_Com
Consolidated Statements of Comprehensive Income (Loss) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Statement Of Income And Comprehensive Income [Abstract] | ' | ' | ' | ' |
Net income (loss) | ($19,089) | ($3,517) | ($66,966) | ($15,367) |
Other comprehensive income (loss), before tax: | ' | ' | ' | ' |
Changes in cumulative translation adjustment | 67,268 | 39,695 | -42,515 | 38,857 |
Unrealized gains on available for sale securities | ' | 141 | ' | 931 |
Unrealized gains on hedging instruments | 20 | 10 | 31 | 465 |
Minimum pension liability adjustment | -369 | -98 | 335 | -218 |
Other comprehensive income (loss), before tax | 66,919 | 39,748 | -42,149 | 40,035 |
Income tax benefit related to items of other comprehensive income (loss) | ' | 360 | ' | 360 |
Other comprehensive income (loss), net of tax | 66,919 | 39,388 | -42,149 | 39,675 |
Comprehensive income (loss) | 47,830 | 35,871 | -109,115 | 24,308 |
Less: Comprehensive income attributable to non-controlling interests | 359 | 286 | 601 | 137 |
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | $47,471 | $35,585 | ($109,716) | $24,171 |
Consolidated_Balance_Sheets
Consolidated Balance Sheets (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Current assets: | ' | ' |
Cash and cash equivalents | $353,993 | $328,346 |
Restricted cash | 7,905 | 3,076 |
Marketable securities | 820 | 904 |
Accounts receivable, net of allowances of $70,978 and $36,396 at September 30, 2013 and December 31, 2012, respectively | 568,873 | 524,332 |
Inventories, net | 370,448 | 337,121 |
Deferred tax assets | 58,177 | 67,722 |
Prepaid expenses and other current assets | 114,601 | 145,236 |
Total current assets | 1,474,817 | 1,406,737 |
Property, plant and equipment, net | 544,271 | 534,469 |
Goodwill | 3,103,495 | 3,048,405 |
Other intangible assets with indefinite lives | 58,953 | 36,451 |
Finite-lived intangible assets, net | 1,747,538 | 1,834,225 |
Restricted cash - non-current | 29,045 | ' |
Deferred financing costs, net, and other non-current assets | 86,489 | 108,857 |
Investments in unconsolidated entities | 101,822 | 90,491 |
Deferred tax assets | 8,189 | 8,293 |
Total assets | 7,154,619 | 7,067,928 |
Current liabilities: | ' | ' |
Short-term debt | 25 | ' |
Current portion of long-term debt | 47,701 | 60,232 |
Current portion of capital lease obligations | 6,533 | 6,684 |
Accounts payable | 194,991 | 169,974 |
Accrued expenses and other current liabilities | 447,228 | 411,919 |
Total current liabilities | 696,478 | 648,809 |
Long-term liabilities: | ' | ' |
Long-term debt, net of current portion | 3,790,532 | 3,628,675 |
Capital lease obligations, net of current portion | 14,926 | 12,917 |
Deferred tax liabilities | 352,859 | 428,188 |
Other long-term liabilities | 209,683 | 166,635 |
Total long-term liabilities | 4,368,000 | 4,236,415 |
Commitments and contingencies (Note 17) | ' | ' |
Stockholders' equity: | ' | ' |
Series B preferred stock, $0.001 par value (liquidation preference: $709,763 at September 30, 2013 and December 31, 2012); Authorized: 2,300 shares; Issued: 2,065 shares at September 30, 2013 and December 31, 2012; Outstanding: 1,774 shares at September 30, 2013 and December 31, 2012 | 606,468 | 606,468 |
Common stock, $0.001 par value; Authorized: 200,000 shares; Issued: 89,533 shares at September 30, 2013 and 88,576 shares at December 31, 2012; Outstanding: 81,854 shares at September 30, 2013 and 80,897 shares at December 31, 2012 | 90 | 89 |
Additional paid-in capital | 3,314,698 | 3,299,935 |
Accumulated deficit | -1,632,540 | -1,564,973 |
Treasury stock, at cost, 7,679 shares at September 30, 2013 and December 31, 2012 | -184,971 | -184,971 |
Accumulated other comprehensive income (loss) | -18,275 | 23,874 |
Total stockholders' equity | 2,085,470 | 2,180,422 |
Non-controlling interests | 4,671 | 2,282 |
Total equity | 2,090,141 | 2,182,704 |
Total liabilities and equity | $7,154,619 | $7,067,928 |
Consolidated_Balance_Sheets_Pa
Consolidated Balance Sheets (Parenthetical) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, except Per Share data, unless otherwise specified | ||
Statement Of Financial Position [Abstract] | ' | ' |
Accounts receivable, allowances | $70,978 | $36,396 |
Series B preferred stock, par value | $0.00 | $0.00 |
Series B preferred stock, liquidation preference | $709,763 | $709,763 |
Series B preferred stock, shares authorized | 2,300 | 2,300 |
Series B preferred stock, shares issued | 2,065 | 2,065 |
Series B preferred stock, shares outstanding | 1,774 | 1,774 |
Common stock, par value | $0.00 | $0.00 |
Common stock, shares authorized | 200,000 | 200,000 |
Common stock, shares issued | 89,533 | 88,576 |
Common stock, shares outstanding | 81,854 | 80,897 |
Treasury stock, shares | 7,679 | 7,679 |
Consolidated_Statements_of_Cas
Consolidated Statements of Cash Flows (USD $) | 9 Months Ended | |
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 |
Cash Flows from Operating Activities: | ' | ' |
Net income (loss) | ($66,966) | ($15,367) |
Adjustments to reconcile net loss to net cash provided by operating activities: | ' | ' |
Non-cash interest expense, including amortization of original issue discounts and write-off of deferred financing costs | 14,088 | 16,087 |
Depreciation and amortization | 326,689 | 322,371 |
Non-cash charges for sale of inventories revalued at the date of acquisition | 1,880 | 4,681 |
Non-cash stock-based compensation expense | 14,462 | 11,868 |
Impairment of inventory | 243 | 295 |
Impairment of long-lived assets | 4,101 | 274 |
(Gain) loss on sale of fixed assets | 1,849 | -4,194 |
Equity earnings of unconsolidated entities, net of tax | -13,238 | -10,417 |
Deferred income taxes | -73,655 | -43,619 |
Loss on extinguishment of debt | 35,603 | ' |
Loss on disposition | 5,885 | ' |
Bargain purchase gain | -5,707 | ' |
Other non-cash items | 6,674 | 5,736 |
Changes in assets and liabilities, net of acquisitions: | ' | ' |
Accounts receivable, net | -57,310 | -8,261 |
Inventories, net | -72,727 | -15,596 |
Prepaid expenses and other current assets | -9,132 | 4,171 |
Accounts payable | 15,981 | -16,743 |
Accrued expenses and other current liabilities | 37,242 | 24,116 |
Other non-current liabilities | -6,857 | -21,639 |
Net cash provided by (used in) operating activities | 159,105 | 253,763 |
Cash Flows from Investing Activities: | ' | ' |
(Increase) decrease in restricted cash | -33,881 | 5,771 |
Purchases of property, plant and equipment | -90,908 | -97,309 |
Proceeds from sale of property, plant and equipment | 5,831 | 22,383 |
Cash received from disposition | 32,000 | ' |
Cash paid for acquisitions, net of cash acquired | -166,196 | -384,780 |
Cash received from sales of marketable securities | ' | 271 |
Cash received from (paid for) equity method investments | 11,262 | 6,556 |
(Increase) decrease in other assets | 19,244 | -9,313 |
Net cash used in investing activities | -222,648 | -456,421 |
Cash Flows from Financing Activities: | ' | ' |
Cash paid for financing costs | -9,798 | -2,313 |
Cash paid for contingent purchase price consideration | -27,496 | -16,248 |
Proceeds from issuance of common stock, net of issuance costs | 17,555 | 14,260 |
Proceeds from issuance of long-term debt | 460,141 | 198,288 |
Payments on long-term debt | -455,157 | -42,553 |
Net proceeds under revolving credit facilities | 138,768 | 91,162 |
Borrowings from (payments on) short-term debt | 25 | -6,240 |
Cash paid for dividends | -15,970 | -15,970 |
Excess tax benefits on exercised stock options | 434 | 277 |
Principal payments on capital lease obligations | -5,341 | -4,925 |
Other | -18,953 | -2,811 |
Net cash provided by financing activities | 84,208 | 212,927 |
Foreign exchange effect on cash and cash equivalents | 4,982 | -7,188 |
Net increase in cash and cash equivalents | 25,647 | 3,081 |
Cash and cash equivalents, beginning of period | 328,346 | 299,173 |
Cash and cash equivalents, end of period | $353,993 | $302,254 |
Basis_of_Presentation_of_Finan
Basis of Presentation of Financial Information | 9 Months Ended |
Sep. 30, 2013 | |
Accounting Policies [Abstract] | ' |
Basis of Presentation of Financial Information | ' |
(1) Basis of Presentation of Financial Information | |
The accompanying consolidated financial statements of Alere Inc. are unaudited. In the opinion of management, the unaudited consolidated financial statements contain all adjustments considered normal and recurring and necessary for their fair statement. Interim results are not necessarily indicative of results to be expected for the year. These interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these consolidated financial statements do not include all of the information and footnotes necessary for a complete presentation of financial position, results of operations, comprehensive income and cash flows. Our audited consolidated financial statements for the year ended December 31, 2012 included information and footnotes necessary for such presentation and were included in our Annual Report on Form 10-K, as amended, filed with the Securities and Exchange Commission, or SEC, on March 1, 2013. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements and notes thereto for the year ended December 31, 2012. | |
Certain reclassifications of prior period amounts have been made to conform to current period presentation. These reclassifications had no effect on net income or equity. | |
Certain amounts presented may not recalculate directly, due to rounding. |
Cash_and_Cash_Equivalents
Cash and Cash Equivalents | 9 Months Ended |
Sep. 30, 2013 | |
Cash And Cash Equivalents [Abstract] | ' |
Cash and Cash Equivalents | ' |
(2) Cash and Cash Equivalents | |
We consider all highly-liquid cash investments with original maturities of three months or less at the date of acquisition to be cash equivalents. At September 30, 2013, our cash equivalents consisted of money market funds. |
Restricted_Cash
Restricted Cash | 9 Months Ended |
Sep. 30, 2013 | |
Text Block [Abstract] | ' |
Restricted Cash | ' |
(3) Restricted Cash | |
As of September 30, 2013, we had a total of $36.9 million in restricted cash, of which $29.0 million was classified as non-current on our consolidated balance sheet. The $29.0 million secures a foreign bank loan arrangement that we entered into during the three months ended September 30, 2013 and will remain on deposit for a two-year period under the current terms of the loan arrangement. |
Inventories
Inventories | 9 Months Ended | ||||||||
Sep. 30, 2013 | |||||||||
Inventory Disclosure [Abstract] | ' | ||||||||
Inventories | ' | ||||||||
(4) Inventories | |||||||||
Inventories are stated at the lower of cost (first in, first out) or market and are comprised of the following (in thousands): | |||||||||
September 30, 2013 | December 31, 2012 | ||||||||
Raw materials | $ | 115,441 | $ | 99,498 | |||||
Work-in-process | 83,571 | 89,895 | |||||||
Finished goods | 171,436 | 147,728 | |||||||
$ | 370,448 | $ | 337,121 | ||||||
StockBased_Compensation
Stock-Based Compensation | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | ' | ||||||||||||||||
Stock-Based Compensation | ' | ||||||||||||||||
(5) Stock-based Compensation | |||||||||||||||||
We recorded stock-based compensation expense in our consolidated statements of operations for the three and nine months ended September 30, 2013 and 2012, respectively, as follows (in thousands): | |||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||
Cost of net revenue | $ | 287 | $ | 269 | $ | 797 | $ | 801 | |||||||||
Research and development | 1,111 | 752 | 2,641 | 2,379 | |||||||||||||
Sales and marketing | 975 | 751 | 2,597 | 2,581 | |||||||||||||
General and administrative | 3,289 | 1,854 | 8,427 | 6,107 | |||||||||||||
5,662 | 3,626 | 14,462 | 11,868 | ||||||||||||||
Benefit for income taxes | (1,511 | ) | (536 | ) | (2,869 | ) | (1,951 | ) | |||||||||
$ | 4,151 | $ | 3,090 | $ | 11,593 | $ | 9,917 | ||||||||||
Net_Loss_Per_Common_Share
Net Loss Per Common Share | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Earnings Per Share [Abstract] | ' | ||||||||||||||||
Net Loss Per Common Share | ' | ||||||||||||||||
(6) Net Loss per Common Share | |||||||||||||||||
The following table sets forth the computation of basic and diluted net loss per common share for the periods presented (in thousands, except per share data): | |||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||
Numerator: | |||||||||||||||||
Net loss | $ | (19,089 | ) | $ | (3,517 | ) | $ | (66,966 | ) | $ | (15,367 | ) | |||||
Preferred stock dividends | (5,367 | ) | (5,352 | ) | (15,926 | ) | (15,940 | ) | |||||||||
Less: Net income attributable to non-controlling interest | 359 | 286 | 601 | 137 | |||||||||||||
Net loss available to common stockholders | $ | (24,815 | ) | $ | (9,155 | ) | $ | (83,493 | ) | $ | (31,444 | ) | |||||
Denominator: | |||||||||||||||||
Weighted-average common shares outstanding—basic and diluted | 81,735 | 80,792 | 81,417 | 80,492 | |||||||||||||
Basic and diluted net loss per common share attributable to Alere Inc. and Subsidiaries | $ | (0.30 | ) | $ | (0.11 | ) | $ | (1.03 | ) | $ | (0.39 | ) | |||||
The following potential dilutive securities were not included in the calculation of diluted net loss per common share because the inclusion thereof would be antidilutive (in thousands): | |||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||
Denominator: | |||||||||||||||||
Options to purchase shares of common stock | 10,239 | 9,730 | 10,239 | 9,730 | |||||||||||||
Warrants | 4 | 4 | 4 | 4 | |||||||||||||
Conversion shares related to 3% convertible senior subordinated notes | 3,411 | 3,411 | 3,411 | 3,411 | |||||||||||||
Conversion shares related to subordinated convertible promissory notes | 27 | 27 | 27 | 27 | |||||||||||||
Conversion shares related to Series B convertible preferred stock | 10,239 | 10,239 | 10,239 | 10,239 | |||||||||||||
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding | 23,920 | 23,411 | 23,920 | 23,411 | |||||||||||||
Stockholders_Equity_and_NonCon
Stockholders' Equity and Non-Controlling Interests | 9 Months Ended | ||||||||||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||||||||||
Equity [Abstract] | ' | ||||||||||||||||||||||||
Stockholders' Equity and Non-Controlling Interests | ' | ||||||||||||||||||||||||
(7) Stockholders’ Equity and Non-controlling Interests | |||||||||||||||||||||||||
(a) Preferred Stock | |||||||||||||||||||||||||
For the three and nine months ended September 30, 2013, Series B preferred stock dividends amounted to $5.3 million and $15.9 million, respectively, and for the three and nine months ended September 30, 2012, Series B preferred stock dividends amounted to $5.4 million and $15.9 million, respectively, which reduced earnings available to common stockholders for purposes of calculating net loss per common share for each of the respective periods. As of September 30, 2013, $5.3 million of Series B preferred stock dividends was accrued. As of October 15, 2013, payments have been made covering all dividend periods through September 30, 2013. | |||||||||||||||||||||||||
The Series B preferred stock dividends for the three and nine months ended September 30, 2013 and 2012 were paid in cash. | |||||||||||||||||||||||||
(b) Changes in Stockholders’ Equity and Non-controlling Interests | |||||||||||||||||||||||||
A summary of the changes in stockholders’ equity and non-controlling interests comprising total equity for the nine months ended September 30, 2013 and 2012 is provided below (in thousands): | |||||||||||||||||||||||||
Nine Months Ended September 30, | |||||||||||||||||||||||||
2013 | 2012 | ||||||||||||||||||||||||
Total | Non- | Total | Total | Non- | Total | ||||||||||||||||||||
Stockholders’ | controlling | Equity | Stockholders’ | controlling | Equity | ||||||||||||||||||||
Equity | Interests | Equity | Interests | ||||||||||||||||||||||
Equity, beginning of period | $ | 2,180,422 | $ | 2,282 | $ | 2,182,704 | $ | 2,229,234 | $ | 2,340 | $ | 2,231,574 | |||||||||||||
Exercise of common stock options, warrants and shares issued under employee stock purchase plan | 17,555 | — | 17,555 | 14,261 | — | 14,261 | |||||||||||||||||||
Issuance of common stock for settlement of an acquisition-related contingent consideration obligation | — | — | — | 1,243 | — | 1,243 | |||||||||||||||||||
Preferred stock dividends | (15,970 | ) | — | (15,970 | ) | (15,970 | ) | — | (15,970 | ) | |||||||||||||||
Stock-based compensation related to grants of common stock options | 14,462 | — | 14,462 | 11,868 | — | 11,868 | |||||||||||||||||||
Excess tax benefits on exercised stock options | (1,283 | ) | — | (1,283 | ) | (437 | ) | — | (437 | ) | |||||||||||||||
Non-controlling interest from acquisition | — | 1,788 | 1,788 | — | — | — | |||||||||||||||||||
Purchase of subsidiary shares from non-controlling interests | — | — | — | (35,079 | ) | — | (35,079 | ) | |||||||||||||||||
Dividend relating to non-controlling interest | — | — | — | — | (236 | ) | (236 | ) | |||||||||||||||||
Net income (loss) | (67,567 | ) | 601 | (66,966 | ) | (15,504 | ) | 200 | (15,304 | ) | |||||||||||||||
Total other comprehensive income (loss) | (42,149 | ) | — | (42,149 | ) | 39,675 | — | 39,675 | |||||||||||||||||
Equity, end of period | $ | 2,085,470 | $ | 4,671 | $ | 2,090,141 | $ | 2,229,291 | $ | 2,304 | $ | 2,231,595 |
Business_Combinations
Business Combinations | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Business Combinations [Abstract] | ' | ||||||||||||||||
Business Combinations | ' | ||||||||||||||||
(8) Business Combinations | |||||||||||||||||
Acquisitions are accounted for using the acquisition method and the acquired companies’ results have been included in the accompanying consolidated financial statements from their respective dates of acquisition. During the three and nine months ended September 30, 2013, we expensed acquisition-related costs of $0.5 million and $1.8 million, respectively, in general and administrative expense. During the three and nine months ended September 30, 2012, we expensed acquisition-related costs of $0.8 million and $6.1 million, respectively, in general and administrative expense. | |||||||||||||||||
Our business acquisitions have historically been made at prices above the fair value of the assets acquired and liabilities assumed, resulting in goodwill, based on our expectations of synergies and other benefits of combining the businesses. These synergies and benefits include elimination of redundant facilities, functions and staffing; use of our existing commercial infrastructure to expand sales of the products of the acquired businesses; and use of the commercial infrastructure of the acquired businesses to expand product sales in a cost-efficient manner. | |||||||||||||||||
Net assets acquired are recorded at their fair value and are subject to adjustment upon finalization of the fair value analysis. We are not aware of any information that indicates the final fair value analysis will differ materially from the preliminary estimates. The estimated useful lives of the individual categories of intangible assets were based on the nature of the applicable intangible asset and the expected future cash flows to be derived from the intangible asset. Amortization of intangible assets with finite lives is recognized over the shorter of the respective lives of the agreement or the period of time the intangible assets are expected to contribute to future cash flows. We amortize our finite-lived intangible assets based on patterns on which the respective economic benefits are expected to be realized. | |||||||||||||||||
(a) Acquisitions in 2013 | |||||||||||||||||
(i) Epocal | |||||||||||||||||
On February 1, 2013, we acquired Epocal, Inc., or Epocal, located in Ottawa, Canada, a provider of technologies that support blood gas and electrolyte testing at the point of care. The preliminary aggregate purchase price was approximately $248.5 million, which consisted of $173.5 million in cash and a contingent consideration obligation with an aggregate acquisition date fair value of $75.0 million. The operating results of Epocal are included in our professional diagnostics reporting unit and business segment. The amount allocated to goodwill from this acquisition is not deductible for tax purposes. | |||||||||||||||||
(ii) Other acquisitions in 2013 | |||||||||||||||||
During the nine months ended September 30, 2013, we acquired the following businesses for a preliminary aggregate purchase price of $47.7 million, which included cash payments totaling $35.8 million, contingent consideration obligations with an aggregate acquisition date fair value of $1.3 million, deferred purchase price consideration with an acquisition date fair value of $0.6 million and an $8.0 million bargain purchase gain. | |||||||||||||||||
• | certain assets of PT Mega Medika Mandiri, or Mega Medika, located in South Jakarta, Indonesia, a distributor of infectious disease products to the Indonesian marketplace as well as materials for vaccines to a pharmaceutical customer (Acquired January 2013) | ||||||||||||||||
• | Discount Diabetic, LLC, or Discount Diabetic, located in Phoenix, Arizona, a provider of blood glucose monitoring products, including diabetes testing systems and test strips and other products (Acquired April 2013) | ||||||||||||||||
• | the Medicare fee for service assets of Liberty Medical, or the Liberty business, located in Port St. Lucie, Florida, a leading mail order provider of diabetes testing supplies serving the needs of both Type 1 and Type 2 diabetic patients (Acquired April 2013) | ||||||||||||||||
• | 51% share in Cardio Selfcare B.V., subsequently renamed Alere Health Services B.V., or Alere Health Services, located in Ede, the Netherlands, a developer of innovative software for the healthcare industry that develops and licenses software and sells medical devices to enable patients to perform medical self-care, including thrombosis self-care (Acquired May 2013) | ||||||||||||||||
• | 74.9% interest in Pantech Proprietary Limited, or Pantech, located in Durban, South Africa, a supplier of rapid diagnostic test kits, including HIV, malaria, syphilis, drugs of abuse, 10 parameter urine sticks, glucometers and glucose sticks (Acquired July 2013) | ||||||||||||||||
The operating results of Mega Medika, Discount Diabetic, the Liberty business, Alere Health Services, and Pantech are included in our professional diagnostics reporting unit and business segment. | |||||||||||||||||
Our consolidated statement of operations for the three and nine months ended September 30, 2013 included revenue totaling approximately $26.6 million and $59.5 million, respectively, related to these businesses. Goodwill has been recognized in the Mega Medika, Alere Health Services and Pantech acquisitions and amounted to approximately $1.6 million. The goodwill related to the Mega Medika acquisition is deductible for tax purposes. | |||||||||||||||||
With respect to our acquisition of the Liberty business, the purchase price of the acquisition has been allocated to the net tangible and intangible assets acquired, with the excess of the fair value of assets acquired over the purchase price recorded as a bargain purchase gain. The $8.0 million bargain purchase gain has been recorded in other income (expense), net in our consolidated statement of operations and is not recognized for tax purposes. The bargain purchase gain resulted from our operating cost structure which we believe will allow us to operate this business more cost effectively than the sellers. | |||||||||||||||||
A summary of the preliminary fair values of the net assets acquired for the acquisitions consummated in 2013 is as follows (in thousands): | |||||||||||||||||
Epocal | Other | Total | |||||||||||||||
Current assets(1) | $ | 12,089 | $ | 12,968 | $ | 25,057 | |||||||||||
Property, plant and equipment | 1,267 | 1,669 | 2,936 | ||||||||||||||
Goodwill | 99,449 | 1,629 | 101,078 | ||||||||||||||
Intangible assets | 164,400 | 42,920 | 207,320 | ||||||||||||||
Other non-current assets | 17,610 | 29 | 17,639 | ||||||||||||||
Total assets acquired | 294,815 | 59,215 | 354,030 | ||||||||||||||
Current liabilities | 2,627 | 5,398 | 8,025 | ||||||||||||||
Non-current liabilities | 43,727 | 6,202 | 49,929 | ||||||||||||||
Total liabilities assumed | 46,354 | 11,600 | 57,954 | ||||||||||||||
Net assets acquired | 248,461 | 47,615 | 296,076 | ||||||||||||||
Less: | |||||||||||||||||
Contingent consideration | 75,000 | 1,264 | 76,264 | ||||||||||||||
Non-controlling interest | — | 1,774 | 1,774 | ||||||||||||||
Bargain purchase gain | — | 8,023 | 8,023 | ||||||||||||||
Deferred purchase price consideration | — | 768 | 768 | ||||||||||||||
Cash paid | $ | 173,461 | $ | 35,786 | $ | 209,247 | |||||||||||
(1) | Includes approximately $3.3 million of acquired cash. | ||||||||||||||||
The following are the intangible assets acquired and their respective fair values and weighted-average useful lives (dollars in thousands): | |||||||||||||||||
Epocal | Other | Total | Weighted- | ||||||||||||||
average | |||||||||||||||||
Useful Life | |||||||||||||||||
Core technology and patents | $ | 119,700 | $ | — | $ | 119,700 | 20.0 years | ||||||||||
Software | — | 804 | 804 | 10.0 years | |||||||||||||
Trademarks and trade names | 20,500 | 10 | 20,510 | 19.2 years | |||||||||||||
Customer relationships | — | 36,290 | 36,290 | 11.4 years | |||||||||||||
Other | — | 5,816 | 5,816 | 3.0 years | |||||||||||||
In-process research and development | 24,200 | — | 24,200 | N/A | |||||||||||||
Total intangible assets | $ | 164,400 | $ | 42,920 | $ | 207,320 | |||||||||||
(b) Acquisitions in 2012 | |||||||||||||||||
During 2012, we acquired the following businesses for a preliminary aggregate purchase price of $494.5 million, which included cash payments totaling $418.9 million and contingent consideration obligations with aggregate acquisition date fair values of $75.6 million. | |||||||||||||||||
• | Reatrol Comercializacao De Produtos De Saude, LDA, subsequently renamed Alere Lda, located in Vila Nova de Gaia, Portugal, a distributor of products for drugs of abuse testing (Acquired January 2012) | ||||||||||||||||
• | Kullgren Holding AB, or Kullgren, located in Gensta, Sweden, a company that manufactures and distributes high-quality intimacy and pharmaceutical products (Acquired February 2012) | ||||||||||||||||
• | Wellogic ME FZ-LLC, or Wellogic UAE, located in Dubai, United Arab Emirates, a company that provides development services to Alere Wellogic, LLC, which acquired the assets of Method Factory, Inc. (d/b/a Wellogic), or Wellogic, in December 2011 (Acquired February 2012) | ||||||||||||||||
• | certain assets, primarily including customer and patient lists, of AmMed Direct LLC, or AmMed, located near Nashville, Tennessee, a privately-owned mail-order provider of home-diabetes testing products and supplies (Acquired March 2012) | ||||||||||||||||
• | eScreen, Inc., or eScreen, headquartered in Overland Park, Kansas, a technology-enabled provider of employment drug screening solutions for hiring and maintaining healthier and more efficient workforces (Acquired April 2012) | ||||||||||||||||
• | MedApps Holding Company, Inc., or MedApps, headquartered in Scottsdale, Arizona, a developer of innovative remote health monitoring solutions that deliver efficient cost-effective connectivity between patient, care provider and electronic medical records (Acquired July 2012) | ||||||||||||||||
• | Amedica Biotech, Inc., or Amedica, located in Hayward, California, a company focused on the development and manufacture of in vitro diagnostic tests (Acquired July 2012) | ||||||||||||||||
• | DiagnosisOne, Inc., or DiagnosisOne, located in Lowell, Massachusetts, a software company that provides clinical analytics technology and data-driven content to hospitals, physician groups, insurers and governments (Acquired July 2012) | ||||||||||||||||
• | Seelen Care Laege-og & Hospitalsartikler ApS, or Seelen, located in Holstebro, Denmark, a distributor of consumables, instruments and equipment to doctors, specialists and physiotherapists (Acquired August 2012) | ||||||||||||||||
• | certain assets of Diagnostik Nord, or Diagnostik, located in Schwerin, Germany, a company focused on the sale of drug screening and in vitro diagnostic medical devices and a provider of diagnostic solutions (Acquired September 2012) | ||||||||||||||||
• | Healthcare Connections Limited, or HCC, located in Buckinghamshire, United Kingdom, an occupational health provider specializing in employment medical programs, preventative health schemes and drug and alcohol sample collection services (Acquired November 2012) | ||||||||||||||||
• | the diagnostic division of Medial spol. s.r.o., subsequently renamed Alere s.r.o., located in Prague, Czech Republic, a distributor of laboratory diagnostic devices, devices operating in the point-of-care testing regime, diagnostic kits and tests for biochemistry, hematology, and microbiology (Acquired November 2012) | ||||||||||||||||
• | certain assets of Quantum Diagnostics, or Quantum Australia, located in Australia, an on-line medical supply company that provides a range of affordable drug and alcohol tests for personal, business and professional medical use (Acquired November 2012) | ||||||||||||||||
• | certain assets of NationsHealth, Inc. (now named Convey Health Solutions, Inc.) and certain assets of its subsidiary United States Pharmaceutical Group, LLC (now d/b/a Convey Health Solutions), or, collectively, NationsHealth, headquartered in Sunrise, Florida, a privately-owned mail-order provider of diabetes home-testing products and supplies, and a share acquisition of NationsHealth’s subsidiary in the Philippines, or NationsHealth Philippines (Acquired December 2012) | ||||||||||||||||
• | Branan Medical Corporation, or Branan, headquartered in Irvine, California, a manufacturer of drugs of abuse testing products (Acquired December 2012) | ||||||||||||||||
The operating results of Alere Lda, AmMed, eScreen, MedApps, Amedica, Seelen, Diagnostik, HCC, Alere s.r.o., Quantum Australia, NationsHealth and Branan are included in our professional diagnostics reporting unit and business segment. The operating results of Wellogic UAE and DiagnosisOne are included in our health information solutions reporting unit and business segment. The operating results of Kullgren are included in our consumer diagnostics reporting unit and business segment. | |||||||||||||||||
Our consolidated statement of operations for the three and nine months ended September 30, 2012 included revenue totaling approximately $14.4 million and $26.3 million, respectively, related to the businesses that were acquired during that period. Goodwill has been recognized in all of these acquisitions and amounted to approximately $239.3 million. Goodwill related to the acquisitions of AmMed, Diagnostik and the U.S.-based assets of NationsHealth, which totaled $8.2 million, is deductible for tax purposes. The goodwill related to the remaining 2012 acquisitions is not deductible for tax purposes. | |||||||||||||||||
A summary of the preliminary fair values of the net assets acquired for the acquisitions consummated in 2012 is as follows (in thousands): | |||||||||||||||||
Current assets(1) | $ | 47,228 | |||||||||||||||
Property, plant and equipment | 9,029 | ||||||||||||||||
Goodwill | 240,576 | ||||||||||||||||
Intangible assets | 325,223 | ||||||||||||||||
Other non-current assets | 17,261 | ||||||||||||||||
Total assets acquired | 639,317 | ||||||||||||||||
Current liabilities | 28,214 | ||||||||||||||||
Non-current liabilities | 116,580 | ||||||||||||||||
Total liabilities assumed | 144,794 | ||||||||||||||||
Net assets acquired | 494,523 | ||||||||||||||||
Less: | |||||||||||||||||
Contingent consideration | 75,620 | ||||||||||||||||
Cash paid | $ | 418,903 | |||||||||||||||
(1) | Includes approximately $3.8 million of acquired cash. | ||||||||||||||||
The following are the intangible assets acquired and their respective fair values and weighted-average useful lives (dollars in thousands): | |||||||||||||||||
Amount | Weighted- | ||||||||||||||||
average | |||||||||||||||||
Useful Life | |||||||||||||||||
Core technology and patents | $ | 148,103 | 18.7 years | ||||||||||||||
Trademarks and trade names | 19,390 | 18.3 years | |||||||||||||||
Customer relationships | 136,485 | 18.1 years | |||||||||||||||
Non-competition agreements | 1,118 | 5.1 years | |||||||||||||||
Other | 15,227 | 9.2 years | |||||||||||||||
In-process research and development | 4,900 | N/A | |||||||||||||||
Total intangible assets | $ | 325,223 |
Restructuring_Plans
Restructuring Plans | 9 Months Ended | ||||||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||||||
Restructuring And Related Activities [Abstract] | ' | ||||||||||||||||||||
Restructuring Plans | ' | ||||||||||||||||||||
(9) Restructuring Plans | |||||||||||||||||||||
The following table sets forth aggregate restructuring charges recorded in our consolidated statements of operations for the three and nine months ended September 30, 2013 and 2012 (in thousands): | |||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||
Statement of Operations Caption | 2013 | 2012 | 2013 | 2012 | |||||||||||||||||
Cost of net revenue | $ | 3,556 | $ | 1,080 | $ | 4,908 | $ | 2,069 | |||||||||||||
Research and development | 1,100 | — | 1,745 | 638 | |||||||||||||||||
Sales and marketing | 218 | 927 | 1,476 | 1,954 | |||||||||||||||||
General and administrative | 2,820 | 1,232 | 11,501 | 5,471 | |||||||||||||||||
Total operating expenses | 7,694 | 3,239 | 19,630 | 10,132 | |||||||||||||||||
Interest expense, including amortization of original issue discounts and deferred financing costs | 111 | 48 | 228 | 158 | |||||||||||||||||
Total charges | $ | 7,805 | $ | 3,287 | $ | 19,858 | $ | 10,290 | |||||||||||||
(a) 2013 Restructuring Plans | |||||||||||||||||||||
In 2013, management developed cost reduction efforts within our professional diagnostics business segment, including businesses in our United States, Europe and Asia Pacific regions. Additionally, management is continuing to improve efficiencies within our health information solutions business segment, including winding down a small portion of this business, which resulted in charges associated with the impairment of related fixed and intangible assets. The following table summarizes the restructuring activities related to our 2013 restructuring plans for the three and nine months ended September 30, 2013 (in thousands): | |||||||||||||||||||||
Three Months Ended September 30, 2013 | |||||||||||||||||||||
Professional | Health | Total | |||||||||||||||||||
Diagnostics | Information | ||||||||||||||||||||
Solutions | |||||||||||||||||||||
Severance-related costs | $ | 3,876 | $ | 1,340 | $ | 5,216 | |||||||||||||||
Facility and transition costs | 1,107 | 327 | 1,434 | ||||||||||||||||||
Other exit costs | — | 2 | 2 | ||||||||||||||||||
Cash charges | 4,983 | 1,669 | 6,652 | ||||||||||||||||||
Fixed asset and inventory impairments | 470 | — | 470 | ||||||||||||||||||
Other non-cash charges | — | (20 | ) | (20 | ) | ||||||||||||||||
Total charges | $ | 5,453 | $ | 1,649 | $ | 7,102 | |||||||||||||||
Nine Months Ended September 30, 2013 | |||||||||||||||||||||
Professional | Health | Total | |||||||||||||||||||
Diagnostics | Information | ||||||||||||||||||||
Solutions | |||||||||||||||||||||
Severance-related costs | $ | 5,960 | $ | 1,398 | $ | 7,358 | |||||||||||||||
Facility and transition costs | 1,457 | 568 | 2,025 | ||||||||||||||||||
Other exit costs | — | 2 | 2 | ||||||||||||||||||
Cash charges | 7,417 | 1,968 | 9,385 | ||||||||||||||||||
Fixed asset and inventory impairments | 470 | 170 | 640 | ||||||||||||||||||
Intangible asset impairments | — | 2,596 | 2,596 | ||||||||||||||||||
Other non-cash charges | — | (20 | ) | (20 | ) | ||||||||||||||||
Total charges | $ | 7,887 | $ | 4,714 | $ | 12,601 | |||||||||||||||
We anticipate incurring approximately $1.1 million and $0.3 million in additional costs under our 2013 restructuring plans related to our professional diagnostics business and health information solutions business segments, respectively, in the United States and Europe and may develop additional plans over the remainder of 2013. As of September 30, 2013, $4.7 million in severance and facility exit costs arising under our 2013 restructuring plans remain unpaid. | |||||||||||||||||||||
(b) 2012 Restructuring Plans | |||||||||||||||||||||
In 2012, management developed cost reduction plans within our professional diagnostics business segment, including the integration of our businesses in Brazil, Europe and the United States. Additionally, management developed new plans to continue our efforts to reduce costs within our health information solutions business segment, including the termination of certain projects, which resulted in charges for the impairment of related fixed and intangible assets. The following table summarizes the restructuring activities related to our 2012 restructuring plans for the three and nine months ended September 30, 2013 and 2012 and since inception (in thousands): | |||||||||||||||||||||
Three Months Ended | Nine Months Ended | Since | |||||||||||||||||||
September 30, | September 30, | Inception | |||||||||||||||||||
Professional Diagnostics | 2013 | 2012 | 2013 | 2012 | |||||||||||||||||
Severance-related costs(1) | $ | (614 | ) | $ | 691 | $ | (526 | ) | $ | 3,009 | $ | 4,206 | |||||||||
Facility and transition costs | — | — | 82 | — | 201 | ||||||||||||||||
Cash charges | (614 | ) | 691 | (444 | ) | 3,009 | 4,407 | ||||||||||||||
Fixed asset impairments | — | 55 | — | 55 | 304 | ||||||||||||||||
Total charges | $ | (614 | ) | $ | 746 | $ | (444 | ) | $ | 3,064 | $ | 4,711 | |||||||||
-1 | Severance-related costs for the three and nine months ended September 30, 2013 includes the reversal of an amount previously accrued which relates to a settlement resulting from a labor dispute. | ||||||||||||||||||||
Three Months Ended | Nine Months Ended | Since | |||||||||||||||||||
September 30, | September 30, | Inception | |||||||||||||||||||
Health Information Solutions | 2013 | 2012 | 2013 | 2012 | |||||||||||||||||
Severance-related costs | $ | 14 | $ | 516 | $ | 2,362 | $ | 1,735 | $ | 5,407 | |||||||||||
Facility and transition costs | — | 465 | 4,271 | 590 | 5,505 | ||||||||||||||||
Other exit costs | 82 | 5 | 134 | 5 | 149 | ||||||||||||||||
Cash charges | 96 | 986 | 6,767 | 2,330 | 11,061 | ||||||||||||||||
Fixed asset and inventory impairments | — | — | 75 | — | 2,764 | ||||||||||||||||
Intangible asset impairments | — | — | — | — | 2,988 | ||||||||||||||||
Other non-cash charges | — | — | (953 | ) | — | (984 | ) | ||||||||||||||
Total charges | $ | 96 | $ | 986 | $ | 5,889 | $ | 2,330 | $ | 15,829 | |||||||||||
We anticipate incurring approximately $0.5 million in additional transition and other facility costs under these plans related primarily to our health information solutions business segment through 2014. As of September 30, 2013, $3.8 million in severance and facility exit costs under these plans remain unpaid. | |||||||||||||||||||||
(c) 2011, 2010 and 2008 Restructuring Plans | |||||||||||||||||||||
In 2011, management executed a company-wide cost reduction plan which impacted our corporate and other business segment, as well as the health information solutions and professional diagnostics business segments. Management also developed plans within our professional diagnostics business segment to consolidate operating activities among certain of our U.S., European and Asia Pacific subsidiaries, including transferring the manufacturing of our Panbio products from Australia to our Standard Diagnostics facility in South Korea and eliminating redundant costs among our newly-acquired Axis-Shield subsidiaries. Additionally, within our health information solutions business segment, management executed plans to further reduce costs and improve efficiencies, as well as cease operations at our GeneCare Medical Genetics Center, Inc., or GeneCare, facility in Chapel Hill, North Carolina and transfer the majority of our Quality Assured Services, Inc. operation in Orlando, Florida to our facility in Livermore, California. | |||||||||||||||||||||
In 2010, management developed several plans to reduce costs and improve efficiencies within our health information solutions and professional diagnostics business segments. Additionally in 2008, management developed and initiated plans to transition the business of Cholestech to our San Diego, California facility. | |||||||||||||||||||||
The following table summarizes the restructuring activities related to our 2011, 2010 and 2008 restructuring plans for the three and nine months ended September 30, 2013 and 2012 and since inception (in thousands): | |||||||||||||||||||||
Three Months Ended | Nine Months Ended | Since | |||||||||||||||||||
September 30, | September 30, | Inception | |||||||||||||||||||
Professional Diagnostics | 2013 | 2012 | 2013 | 2012 | |||||||||||||||||
Severance-related costs | $ | 46 | $ | 639 | $ | 242 | $ | 2,914 | $ | 19,955 | |||||||||||
Facility and transition costs | 112 | 464 | 442 | 1,348 | 7,669 | ||||||||||||||||
Other exit costs | 14 | 16 | 45 | 52 | 743 | ||||||||||||||||
Cash charges | 172 | 1,119 | 729 | 4,314 | 28,367 | ||||||||||||||||
Fixed asset and inventory impairments | 350 | 290 | 350 | 424 | 6,724 | ||||||||||||||||
Intangible asset impairments | 686 | — | 686 | — | 686 | ||||||||||||||||
Total charges | $ | 1,208 | $ | 1,409 | $ | 1,765 | $ | 4,738 | $ | 35,777 | |||||||||||
Three Months Ended | Nine Months Ended | Since | |||||||||||||||||||
September 30, | September 30, | Inception | |||||||||||||||||||
Health Information Solutions | 2013 | 2012 | 2013 | 2012 | |||||||||||||||||
Severance-related costs | $ | — | $ | — | $ | — | $ | — | $ | 6,901 | |||||||||||
Facility and transition costs | — | 114 | — | (59 | ) | 8,010 | |||||||||||||||
Other exit costs | 13 | 27 | 47 | 101 | 559 | ||||||||||||||||
Cash charges | 13 | 141 | 47 | 42 | 15,470 | ||||||||||||||||
Fixed asset and inventory impairments | — | — | — | 85 | 1,114 | ||||||||||||||||
Intangible asset impairments | — | — | — | — | 2,935 | ||||||||||||||||
Other non-cash charges | — | — | — | — | 761 | ||||||||||||||||
Total charges | $ | 13 | $ | 141 | $ | 47 | $ | 127 | $ | 20,280 | |||||||||||
Three Months Ended | Nine Months Ended | Since | |||||||||||||||||||
September 30, | September 30, | Inception | |||||||||||||||||||
Corporate and Other | 2013 | 2012 | 2013 | 2012 | |||||||||||||||||
Severance-related costs | $ | — | $ | 5 | $ | — | $ | 31 | $ | 1,219 | |||||||||||
Cash charges | — | 5 | — | 31 | 1,219 | ||||||||||||||||
Fixed asset and inventory impairments | — | — | — | — | 3 | ||||||||||||||||
Total charges | $ | — | $ | 5 | $ | — | $ | 31 | $ | 1,222 | |||||||||||
We anticipate incurring approximately $0.5 million in additional costs under these plans related primarily to our professional diagnostics business segment. A majority of these additional costs relate to the transfer of the Panbio product manufacturing to Korea and are for severance and facility exit costs. We do not anticipate incurring significant additional costs under these plans related to our health information solutions business segment. As of September 30, 2013, $2.2 million in cash charges remain unpaid, primarily related to severance and facility lease obligations. | |||||||||||||||||||||
(d) Restructuring Reserves | |||||||||||||||||||||
The following table summarizes our restructuring reserves related to the plans described above, of which $8.7 million is included in accrued expenses and other current liabilities and $2.0 million is included in other long-term liabilities on our accompanying consolidated balance sheets (in thousands): | |||||||||||||||||||||
Severance- | Facility and | Other Exit | Total | ||||||||||||||||||
related | Transition | Costs | |||||||||||||||||||
Costs | Costs | ||||||||||||||||||||
Balance, December 31, 2012 | $ | 3,167 | $ | 2,429 | $ | 622 | $ | 6,218 | |||||||||||||
Cash charges | 9,436 | 6,820 | 228 | 16,484 | |||||||||||||||||
Payments | (7,515 | ) | (4,149 | ) | (227 | ) | (11,891 | ) | |||||||||||||
Currency adjustments | (72 | ) | 5 | — | (67 | ) | |||||||||||||||
Balance, September 30, 2013 | $ | 5,016 | $ | 5,105 | $ | 623 | $ | 10,744 | |||||||||||||
LongTerm_Debt
Long-Term Debt | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Debt Disclosure [Abstract] | ' | ||||||||||||||||
Long-Term Debt | ' | ||||||||||||||||
(10) Long-term Debt | |||||||||||||||||
We had the following long-term debt balances outstanding (in thousands): | |||||||||||||||||
September 30, 2013 | December 31, 2012 | ||||||||||||||||
A term loans(1)(2) | $ | 843,750 | $ | 878,438 | |||||||||||||
B term loans(1) | 906,500 | 913,438 | |||||||||||||||
Incremental B-1 term loans(1) | 245,625 | 247,500 | |||||||||||||||
Incremental B-2 term loans(1) | 195,470 | 196,739 | |||||||||||||||
Revolving line of credit(1) | 170,000 | 22,500 | |||||||||||||||
7.25% Senior notes | 450,000 | 450,000 | |||||||||||||||
7.875% Senior notes | — | 1,809 | |||||||||||||||
9% Senior subordinated notes | — | 392,933 | |||||||||||||||
8.625% Senior subordinated notes | 400,000 | 400,000 | |||||||||||||||
6.5% Senior subordinated notes | 425,000 | — | |||||||||||||||
3% Convertible senior subordinated notes | 150,000 | 150,000 | |||||||||||||||
Other lines of credit | 150 | 31,957 | |||||||||||||||
Other | 51,738 | 3,593 | |||||||||||||||
3,838,233 | 3,688,907 | ||||||||||||||||
Less: Current portion | (47,701 | ) | (60,232 | ) | |||||||||||||
$ | 3,790,532 | $ | 3,628,675 | ||||||||||||||
(1) | Incurred under our secured credit facility. | ||||||||||||||||
(2) | Includes “A” term loans and “Delayed Draw” term loans under our secured credit facility. | ||||||||||||||||
In connection with our significant long-term debt issuances, we recorded interest expense, including amortization and write-offs of deferred financing costs and original issue discounts, in our accompanying consolidated statements of operations for the three and nine months ended September 30, 2013 and 2012, respectively, as follows (in thousands): | |||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||
Secured credit facility (1) | $ | 25,809 | $ | 27,474 | $ | 78,741 | $ | 77,422 | |||||||||
7.25% Senior notes | 8,535 | — | 25,371 | — | |||||||||||||
7.875% Senior notes (2) | — | 5,763 | 137 | 17,276 | |||||||||||||
9% Senior subordinated notes (3) | — | 10,373 | 54,043 | 31,090 | |||||||||||||
8.625% Senior subordinated notes | 9,273 | 9,274 | 27,820 | 27,823 | |||||||||||||
6.5% Senior subordinated notes | 7,172 | — | 10,185 | — | |||||||||||||
3% Senior subordinated convertible notes | 1,246 | 1,246 | 3,738 | 3,738 | |||||||||||||
$ | 52,035 | $ | 54,130 | $ | 200,035 | $ | 157,349 | ||||||||||
(1) | Includes “A” term loans, including the “Delayed-Draw” term loans; “B” term loans; “Incremental B-1” term loans; “Incremental B-2” term loans; and revolving line of credit loans. For the three and nine months ended September 30, 2013, the amounts include $0.4 million and $2.2 million, respectively, related to the amortization of fees paid for certain debt modifications. For the three and nine months ended September 30, 2012, the amount includes $1.3 million and $4.0 million, respectively, related to the amortization of fees paid for certain debt modifications. | ||||||||||||||||
(2) | For the nine months ended September 30, 2013, this amount includes an approximate $0.2 million loss recorded in connection with the repurchase of our 7.875% senior notes. | ||||||||||||||||
(3) | An approximate $35.6 million loss in connection with the repurchase of our 9% senior subordinated notes has been included in the nine-month period ended September 30, 2013. Included in the $35.6 million is $19.0 million related to tender offer consideration and call premium which has been classified within cash flow from financing activities in our consolidated statement of cash flows. | ||||||||||||||||
(a) Secured Credit Facility | |||||||||||||||||
The following summarizes the material terms of our secured credit facility that have changed significantly since December 31, 2012. All other terms of our secured credit facility as described in our Annual Report on Form 10-K, as amended, for the year ended December 31, 2012, but omitted below, have not changed since that date. | |||||||||||||||||
On March 22, 2013, we and certain of our subsidiaries entered into a fourth amendment to the credit agreement that governs our secured credit facility, or the credit agreement. The fourth amendment provides for 50 basis point reductions in the interest rate margins applicable to the “B” term loans, the “Incremental B-1” term loans and the “Incremental B-2” term loans and certain other changes. Under the terms of the credit agreement as amended by the fourth amendment, the “B” term loans, the “Incremental B-1” term loans and the “Incremental B-2” term loans bear interest at a rate per annum of, at our option, either (i) the Base Rate, as defined in the credit agreement, plus an applicable margin, which varies between 2.00% and 2.75% depending on our consolidated secured leverage ratio, or (ii) the Eurodollar Rate, as defined in the credit agreement, plus an applicable margin, which varies between 3.00% and 3.75% depending on our consolidated secured leverage ratio. Interest on “B” term loans, “Incremental B-1” term loans and “Incremental B-2” term loans based on the Eurodollar Rate is subject to a 1.00% floor with respect to the base Eurodollar Rate. | |||||||||||||||||
(b) 6.5% Senior Subordinated Notes | |||||||||||||||||
On May 24, 2013, we sold a total of $425.0 million aggregate principal amount of 6.5% senior subordinated notes due 2020, or the 6.5% senior subordinated notes, in a private placement to initial purchasers, who agreed to resell the notes only to qualified institutional buyers and to persons outside the United States. We sold the 6.5% senior subordinated notes at an initial offering price of 100%. Net proceeds from this offering amounted to $417.7 million, which were net of the underwriters’ commissions and offering expenses totaling approximately $7.3 million. | |||||||||||||||||
The 6.5% senior subordinated notes were issued under a supplemental indenture dated May 24, 2013, or the 6.5% Indenture. The 6.5% senior subordinated notes accrue interest at the rate of 6.5% per annum. Interest on the 6.5% senior subordinated notes is payable semi-annually on June 15 and December 15, beginning on December 15, 2013. The 6.5% senior subordinated notes mature on June 15, 2020, unless earlier redeemed. | |||||||||||||||||
We may, at our option, redeem the 6.5% senior subordinated notes, in whole or part, at any time (which may be more than once) on or after June 15, 2016, by paying the principal amount of the notes being redeemed plus a declining premium, plus accrued and unpaid interest to (but excluding) the redemption date. The premium declines from 3.250% during the twelve months on and after June 15, 2016 to 1.625% during the twelve months on and after June 15, 2017 to zero on and after June 15, 2018. In addition, we may, at our option, at any time (which may be more than once) before May 24, 2015, redeem up to 10% of the aggregate principal amount of the 6.5% senior subordinated notes in each of the two twelve-month periods preceding May 24, 2015 at a redemption price of 103% of the principal amount thereof plus accrued and unpaid interest to (but excluding) the redemption date. In addition, at any time (which may be more than once) prior to June 15, 2016, we may, at our option, redeem up to 35% of the aggregate principal amount of the 6.5% senior subordinated notes with money that we raise in certain equity offerings, so long as (i) we pay 106.5% of the principal amount of the notes being redeemed, plus accrued and unpaid interest to (but excluding) the redemption date; (ii) we redeem the 6.5% senior subordinated notes within 90 days of completing such equity offering; and (iii) at least 65% of the aggregate principal amount of the 6.5% senior subordinated notes remains outstanding afterwards. In addition, at any time (which may be more than once) prior to June 15, 2016, we may, at our option, redeem some or all of the 6.5% senior subordinated notes by paying the principal amount of the 6.5% senior subordinated notes being redeemed plus a make-whole premium, plus accrued and unpaid interest to (but excluding) the redemption date. | |||||||||||||||||
If a change of control occurs, subject to specified conditions, we must give holders of the 6.5% senior subordinated notes an opportunity to sell their notes to us at a purchase price of 101% of the principal amount of the notes, plus accrued and unpaid interest to (but excluding) the date of the purchase. | |||||||||||||||||
If we or our subsidiaries engage in asset sales, we or they generally must either invest the net cash proceeds from such sales in our or their businesses within a specified period of time, repay senior indebtedness or make an offer to purchase a principal amount of the 6.5% senior subordinated notes equal to the excess net cash proceeds, subject to certain exceptions. The purchase price of the 6.5% senior subordinated notes would be 100% of their principal amount, plus accrued and unpaid interest. | |||||||||||||||||
The 6.5% Indenture provides that we and our subsidiaries must comply with various customary covenants. These covenants limit our ability, and the ability of our subsidiaries, to, among other things, incur additional debt; pay dividends on our or their capital stock or redeem, repurchase or retire our or their capital stock or subordinated debt; make certain investments; create liens on assets; transfer or sell assets; engage in transactions with our or their affiliates; create restrictions on the ability of our or their subsidiaries to pay dividends or make loans, asset transfers or other payments to us and our subsidiaries; issue capital stock of subsidiaries; engage in any business, other than our or their existing businesses and related businesses; enter into sale and leaseback transactions; incur layered indebtedness; and consolidate or merge with any person (other than certain affiliates) or transfer all or substantially all of our assets or the aggregate assets of us and our subsidiaries. These covenants are subject to certain important exceptions and qualifications, which are set forth in the 6.5% Indenture. At any time the 6.5% senior subordinated notes are rated investment grade, certain covenants will be suspended with respect to them. | |||||||||||||||||
The 6.5% Indenture contains customary events of default entitling the trustee or the holders of the 6.5% senior subordinated notes to declare all amounts owed pursuant to the 6.5% senior subordinated notes immediately payable if any such event of default occurs. | |||||||||||||||||
The 6.5% senior subordinated notes are our senior subordinated unsecured obligations, are subordinated in right of payment to all of our existing and future senior debt, including our borrowings under our secured credit facility and our 7.25% senior notes, and are equal in right of payment with our 8.625% senior subordinated notes and our 3% convertible senior subordinated notes. Our obligations under the 6.5% senior subordinated notes and the 6.5% Indenture are fully and unconditionally guaranteed, jointly and severally, on a senior subordinated unsecured basis by certain of our domestic subsidiaries, and the obligations of such domestic subsidiaries under their guarantees are subordinated in right of payment to all of their existing and future senior debt. See Note 21 for guarantor financial information. | |||||||||||||||||
(c) 9% Senior Subordinated Notes | |||||||||||||||||
On May 24, 2013, we used $200.6 million of the net proceeds of our sale of the 6.5% senior subordinated notes to purchase $190.6 million outstanding principal amount of our 9% senior subordinated notes due 2016, or the 9% senior subordinated notes, pursuant to our tender offer for these notes. The purchased 9% senior subordinated notes represented approximately 47.7% of the total then-outstanding principal amount of the 9% senior subordinated notes. | |||||||||||||||||
On June 24, 2013, we redeemed the remaining $209.4 million outstanding principal amount of the 9% senior subordinated notes pursuant to our optional redemption right under the indenture under which the 9% senior subordinated notes were issued, and we subsequently terminated this indenture. |
Derivative_Financial_Instrumen
Derivative Financial Instruments | 9 Months Ended | ||||||||||
Sep. 30, 2013 | |||||||||||
Derivative Instruments And Hedging Activities Disclosure [Abstract] | ' | ||||||||||
Derivative Financial Instruments | ' | ||||||||||
(11) Derivative Financial Instruments | |||||||||||
We may manage our economic and transaction exposure to certain market-based risks through the use of derivative instruments. Our objective for holding derivative instruments has been to reduce volatility of net earnings and cash flows associated with changes in interest rates and foreign currency exchange rates. We do not hold or issue derivative financial instruments for speculative purposes. | |||||||||||
Foreign Currency Risk | |||||||||||
In connection with our acquisition of Axis-Shield, we acquired a number of foreign currency forward contracts. The specific risk hedged in these contracts was the undiscounted foreign currency spot rate risk on forecasted foreign currency revenue. As of December 31, 2012, all of the acquired foreign currency forward contracts were settled. We report the effective portion of the gain or loss on a cash flow hedge as a component of other comprehensive income, and it was subsequently reclassified into net earnings in the period in which the hedged transaction affected net earnings or the forecasted transaction was no longer probable of occurring. | |||||||||||
The following table summarizes the effect of derivative instruments in our accompanying consolidated statement of operations (in thousands): | |||||||||||
Derivative Instruments | Location of Gain | Amount of Gain | Amount of Gain | ||||||||
Recognized in Income | Recognized | Recognized | |||||||||
During the Three | During the Nine | ||||||||||
Months Ended | Months Ended | ||||||||||
September 30, | September 30, | ||||||||||
2012 | 2012 | ||||||||||
Foreign currency forward contracts | Other comprehensive income (loss) | $ | 10 | $ | 465 | ||||||
Total gain | Other comprehensive income (loss) | $ | 10 | $ | 465 | ||||||
Fair_Value_Measurements
Fair Value Measurements | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Fair Value Disclosures [Abstract] | ' | ||||||||||||||||
Fair Value Measurements | ' | ||||||||||||||||
(12) Fair Value Measurements | |||||||||||||||||
We apply fair value measurement accounting to value our financial assets and liabilities. Fair value measurement accounting provides a framework for measuring fair value under U.S. GAAP and requires expanded disclosures regarding fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. | |||||||||||||||||
Described below are the three levels of inputs that may be used to measure fair value: | |||||||||||||||||
Level 1—Quoted prices in active markets for identical assets or liabilities. | |||||||||||||||||
Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. | |||||||||||||||||
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. | |||||||||||||||||
The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2013 and December 31, 2012, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands): | |||||||||||||||||
Description | September 30, 2013 | Quoted Prices in | Significant Other | Unobservable Inputs | |||||||||||||
Active Markets | Observable Inputs | (Level 3) | |||||||||||||||
(Level 1) | (Level 2) | ||||||||||||||||
Assets: | |||||||||||||||||
Marketable securities | $ | 820 | $ | 820 | $ | — | $ | — | |||||||||
Total assets | $ | 820 | $ | 820 | $ | — | $ | — | |||||||||
Liabilities: | |||||||||||||||||
Contingent consideration obligations (1) | $ | 234,559 | $ | — | $ | — | $ | 234,559 | |||||||||
Total liabilities | $ | 234,559 | $ | — | $ | — | $ | 234,559 | |||||||||
Description | December 31, 2012 | Quoted Prices in | Significant Other | Unobservable Inputs | |||||||||||||
Active Markets | Observable Inputs | (Level 3) | |||||||||||||||
(Level 1) | (Level 2) | ||||||||||||||||
Assets: | |||||||||||||||||
Marketable securities | $ | 904 | $ | 904 | $ | — | $ | — | |||||||||
Total assets | $ | 904 | $ | 904 | $ | — | $ | — | |||||||||
Liabilities: | |||||||||||||||||
Contingent consideration obligations (1) | $ | 176,172 | $ | — | $ | — | $ | 176,172 | |||||||||
Total liabilities | $ | 176,172 | $ | — | $ | — | $ | 176,172 | |||||||||
(1) | We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out criteria estimates and a probability assessment with respect to the likelihood of achieving the various earn-out criteria. The measurement is based upon significant inputs not observable in the market. Significant increases or decreases in any of these inputs could result in a significantly higher or lower fair value measurement. Changes in the fair value of these contingent consideration obligations are recorded as income or expense within operating income in our consolidated statements of operations. | ||||||||||||||||
Changes in the fair value of our Level 3 contingent consideration obligations during the nine months ended September 30, 2013 were as follows (in thousands): | |||||||||||||||||
Fair value of contingent consideration obligations, January 1, 2013 | $ | 176,172 | |||||||||||||||
Acquisition date fair value of contingent consideration obligations recorded | 76,269 | ||||||||||||||||
Net reclassifications | (12 | ) | |||||||||||||||
Foreign currency | (150 | ) | |||||||||||||||
Payments | (36,703 | ) | |||||||||||||||
Present value accretion | 7,359 | ||||||||||||||||
Adjustments, net (income) expense | 11,624 | ||||||||||||||||
Fair value of contingent consideration obligations, September 30, 2013 | $ | 234,559 | |||||||||||||||
At September 30, 2013 and December 31, 2012, the carrying amounts of cash and cash equivalents, restricted cash, receivables, accounts payable and other current liabilities approximated their estimated fair values. | |||||||||||||||||
The carrying amount and estimated fair value of our long-term debt were $3.8 billion and $3.9 billion, respectively, at September 30, 2013. The carrying amount and estimated fair value of our long-term debt were $3.7 billion at December 31, 2012. The estimated fair value of our long-term debt was determined using market sources that were derived from available market information (Level 2 in the fair value hierarchy) and may not be representative of actual values that could have been or will be realized in the future. |
Defined_Benefit_Pension_Plan
Defined Benefit Pension Plan | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Compensation And Retirement Disclosure [Abstract] | ' | ||||||||||||||||
Defined Benefit Pension Plan | ' | ||||||||||||||||
(13) Defined Benefit Pension Plan | |||||||||||||||||
Our subsidiary in England, Unipath Ltd., has a defined benefit pension plan established for certain of its employees. The net periodic benefit costs are as follows (in thousands): | |||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||
Service cost | $ | — | $ | — | $ | — | $ | — | |||||||||
Interest cost | 182 | 199 | 543 | 596 | |||||||||||||
Expected return on plan assets | (156 | ) | (152 | ) | (465 | ) | (457 | ) | |||||||||
Amortization of prior service costs | 103 | 104 | 308 | 312 | |||||||||||||
Net periodic benefit cost | $ | 129 | $ | 151 | $ | 386 | $ | 451 |
Financial_Information_by_Segme
Financial Information by Segment | 9 Months Ended | ||||||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||||||
Segment Reporting [Abstract] | ' | ||||||||||||||||||||
Financial Information by Segment | ' | ||||||||||||||||||||
(14) Financial Information by Segment | |||||||||||||||||||||
Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of the chief executive officer and members of senior management. Our reportable operating segments are professional diagnostics, health information solutions, consumer diagnostics and corporate and other. Our operating results include license and royalty revenue which are allocated to professional diagnostics and consumer diagnostics on the basis of the original license or royalty agreement. We evaluate performance of our operating segments based on revenue and operating income (loss). Segment information for the three and nine months ended September 30, 2013 and 2012 is as follows (in thousands): | |||||||||||||||||||||
Professional | Health | Consumer | Corporate | Total | |||||||||||||||||
Diagnostics | Information | Diagnostics | and | ||||||||||||||||||
Solutions | Other | ||||||||||||||||||||
Three Months Ended September 30, 2013: | |||||||||||||||||||||
Net revenue | $ | 590,801 | $ | 134,233 | $ | 28,848 | $ | — | $ | 753,882 | |||||||||||
Operating income (loss) | $ | 53,189 | $ | (7,203 | ) | $ | 3,347 | $ | (29,034 | ) | $ | 20,299 | |||||||||
Depreciation and amortization | $ | 88,835 | $ | 22,600 | $ | 1,063 | $ | 287 | $ | 112,785 | |||||||||||
Non-cash charge associated with acquired inventory | $ | 708 | $ | — | $ | — | $ | — | $ | 708 | |||||||||||
Restructuring charge | $ | 6,033 | $ | 1,661 | $ | — | $ | — | $ | 7,694 | |||||||||||
Stock-based compensation | $ | — | $ | — | $ | — | $ | 5,662 | $ | 5,662 | |||||||||||
Loss on disposition | $ | 5,885 | $ | — | $ | — | $ | — | $ | 5,885 | |||||||||||
Three Months Ended September 30, 2012: | |||||||||||||||||||||
Net revenue | $ | 531,442 | $ | 135,078 | $ | 24,896 | $ | — | $ | 691,416 | |||||||||||
Professional | Health | Consumer | Corporate | Total | |||||||||||||||||
Diagnostics | Information | Diagnostics | and | ||||||||||||||||||
Solutions | Other | ||||||||||||||||||||
Operating income (loss) | $ | 63,298 | $ | (14,357 | ) | $ | 4,615 | $ | (14,824 | ) | $ | 38,732 | |||||||||
Depreciation and amortization | $ | 85,030 | $ | 24,313 | $ | 1,167 | $ | 239 | $ | 110,749 | |||||||||||
Restructuring charge | $ | 2,139 | $ | 1,095 | $ | — | $ | 5 | $ | 3,239 | |||||||||||
Stock-based compensation | $ | — | $ | — | $ | — | $ | 3,626 | $ | 3,626 | |||||||||||
Nine Months Ended September 30, 2013: | |||||||||||||||||||||
Net revenue | $ | 1,777,055 | $ | 403,215 | $ | 76,846 | $ | — | $ | 2,257,116 | |||||||||||
Operating income (loss) | $ | 185,925 | $ | (32,855 | ) | $ | 9,031 | $ | (66,909 | ) | $ | 95,192 | |||||||||
Depreciation and amortization | $ | 258,485 | $ | 64,062 | $ | 3,296 | $ | 846 | $ | 326,689 | |||||||||||
Non-cash charge associated with acquired inventory | $ | 1,880 | $ | — | $ | — | $ | — | $ | 1,880 | |||||||||||
Restructuring charge | $ | 9,162 | $ | 10,468 | $ | — | $ | — | $ | 19,630 | |||||||||||
Stock-based compensation | $ | — | $ | — | $ | — | $ | 14,462 | $ | 14,462 | |||||||||||
Loss on disposition | $ | 5,885 | $ | — | $ | — | $ | — | $ | 5,885 | |||||||||||
Nine Months Ended September 30, 2012: | |||||||||||||||||||||
Net revenue | $ | 1,589,909 | $ | 404,452 | $ | 68,701 | $ | — | $ | 2,063,062 | |||||||||||
Operating income (loss) | $ | 196,728 | $ | (46,379 | ) | $ | 7,679 | $ | (49,884 | ) | $ | 108,144 | |||||||||
Depreciation and amortization | $ | 245,911 | $ | 72,152 | $ | 3,604 | $ | 704 | $ | 322,371 | |||||||||||
Non-cash charge associated with acquired inventory | $ | 4,681 | $ | — | $ | — | $ | — | $ | 4,681 | |||||||||||
Restructuring charge | $ | 7,750 | $ | 2,351 | $ | — | $ | 31 | $ | 10,132 | |||||||||||
Stock-based compensation | $ | — | $ | — | $ | — | $ | 11,868 | $ | 11,868 | |||||||||||
Assets: | |||||||||||||||||||||
As of September 30, 2013 | $ | 6,243,064 | $ | 555,563 | $ | 213,764 | $ | 142,228 | $ | 7,154,619 | |||||||||||
As of December 31, 2012 | $ | 6,214,847 | $ | 593,172 | $ | 192,748 | $ | 67,161 | $ | 7,067,928 | |||||||||||
The following tables summarize our net revenue from the professional diagnostics and health information solutions reporting segments by groups of similar products and services for the three and nine months ended September 30, 2013 and 2012 (in thousands): | |||||||||||||||||||||
Professional Diagnostics Segment: | Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||||||
Cardiology | $ | 116,281 | $ | 122,372 | $ | 349,650 | $ | 386,795 | |||||||||||||
Infectious disease | 172,739 | 136,561 | 520,289 | 425,398 | |||||||||||||||||
Toxicology | 166,536 | 156,074 | 481,469 | 437,736 | |||||||||||||||||
Diabetes | 53,150 | 35,670 | 178,138 | 100,628 | |||||||||||||||||
Other | 78,607 | 78,077 | 235,992 | 230,519 | |||||||||||||||||
Net product sales and services revenue | 587,313 | 528,754 | 1,765,538 | 1,581,076 | |||||||||||||||||
License and royalty revenue | 3,488 | 2,688 | 11,517 | 8,833 | |||||||||||||||||
Professional diagnostics net revenue | $ | 590,801 | $ | 531,442 | $ | 1,777,055 | $ | 1,589,909 | |||||||||||||
Health Information Solutions Segment: | Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||||||
Disease and case management | $ | 56,554 | $ | 57,383 | $ | 163,258 | $ | 165,277 | |||||||||||||
Wellness | 22,223 | 24,290 | 75,753 | 80,881 | |||||||||||||||||
Women’s & children’s health | 28,431 | 29,136 | 86,767 | 90,220 | |||||||||||||||||
Patient self-testing services | 27,025 | 24,269 | 77,437 | 68,074 | |||||||||||||||||
Health information solutions net revenue | $ | 134,233 | $ | 135,078 | $ | 403,215 | $ | 404,452 | |||||||||||||
Related_Party_Transactions
Related Party Transactions | 9 Months Ended | ||||||||
Sep. 30, 2013 | |||||||||
Related Party Transactions [Abstract] | ' | ||||||||
Related Party Transactions | ' | ||||||||
(15) Related Party Transactions | |||||||||
In May 2007, we completed the formation of Swiss Precision Diagnostics GmbH, or SPD, our 50/50 joint venture with P&G, for the development, manufacturing, marketing and sale of existing and to-be-developed consumer diagnostic products, outside the cardiology, diabetes and oral care fields. Upon completion of the arrangement to form the joint venture, we ceased to consolidate the operating results of our consumer diagnostic products business related to the joint venture and instead account for our 50% interest in the results of the joint venture under the equity method of accounting. | |||||||||
We had a net receivable from the joint venture of $3.2 million and $2.3 million as of September 30, 2013 and December 31, 2012, respectively. Included in the $3.2 million receivable balance as of September 30, 2013 is approximately $1.9 million of costs incurred in connection with our 2008 SPD-related restructuring plans. Included in the $2.3 million receivable balance as of December 31, 2012 is approximately $1.6 million of costs incurred in connection with our 2008 SPD-related restructuring plans. We have also recorded a long-term receivable totaling approximately $13.0 million and $14.6 million as of September 30, 2013 and December 31, 2012, respectively, related to the 2008 SPD-related restructuring plans. Additionally, customer receivables associated with revenue earned after the joint venture was completed have been classified as other receivables within prepaid and other current assets on our accompanying consolidated balance sheets in the amount of $10.0 million and $6.9 million as of September 30, 2013 and December 31, 2012, respectively. In connection with the joint venture arrangement, the joint venture bears the collection risk associated with these receivables. Sales to the joint venture under our manufacturing agreement totaled $21.2 million and $56.5 million during the three and nine months ended September 30, 2013, respectively, and $15.9 million and $47.4 million during the three and nine months ended September 30, 2012, respectively. Additionally, services revenue generated pursuant to the long-term services agreement with the joint venture totaled $0.3 million and $0.9 million during the three and nine months ended September 30, 2013, respectively, and $0.3 million and $0.9 million during the three and nine months ended September 30, 2012, respectively. Sales under our manufacturing agreement and long-term services agreement are included in net product sales and services revenue, respectively, in our accompanying consolidated statements of operations. | |||||||||
Under the terms of our product supply agreement, the joint venture purchases products from our manufacturing facilities in the U.K. and China. The joint venture in turn sells a portion of those tests back to us for final assembly and packaging. Once packaged, the tests are sold to P&G for distribution to third-party customers in North America. As a result of these related transactions, we have recorded $10.0 million and $7.3 million of trade receivables which are included in accounts receivable on our accompanying consolidated balance sheets as of September 30, 2013 and December 31, 2012, respectively, and $25.4 million and $21.3 million of trade accounts payable which are included in accounts payable on our accompanying consolidated balance sheets as of September 30, 2013 and December 31, 2012, respectively. During the nine months ended September 30, 2013 and 2012, we received $10.8 million and $6.1 million, respectively, in cash from SPD as a return of capital. | |||||||||
The following table summarizes our related party balances with SPD within our consolidated balance sheets (in thousands): | |||||||||
Balance Sheet Caption: | September 30, 2013 | December 31, 2012 | |||||||
Accounts receivable, net of allowances | $ | 9,984 | $ | 7,317 | |||||
Prepaid expenses and other current assets | $ | 13,221 | $ | 9,161 | |||||
Deferred financing costs, net, and other non-current assets | $ | 12,955 | $ | 14,629 | |||||
Accounts payable | $ | 25,437 | $ | 21,258 |
Other_Arrangements
Other Arrangements | 9 Months Ended |
Sep. 30, 2013 | |
Text Block [Abstract] | ' |
Other Arrangements | ' |
(16) Other Arrangements | |
On February 19, 2013, we entered into an agreement with the Bill and Melinda Gates Foundation, or the Gates Foundation, whereby we were awarded a grant by the Gates Foundation in the amount of $21.6 million to support the development and commercialization of a validated, low-cost, nucleic-acid assay for clinical Tuberculosis, or TB, detection and drug-resistance test cartridges and adaptation of an analyzer platform capable of operation in rudimentary laboratories in low-resource settings. In connection with this agreement, we also entered into a loan agreement with the Gates Foundation, or the Gates Loan Agreement, which provides for the making of subordinated term loans by the Gates Foundation to us from time to time, subject to the achievement of certain milestones, in an aggregate principal amount of up to $20.6 million. Funding under the Gates Loan Agreement will be used in connection with the purchase of equipment for an automated high-throughput manufacturing line and other uses as necessary for the manufacture of the TB and HIV-related products. All loans under the Gates Loan Agreement are evidenced by promissory notes that we have executed and delivered to the Gates Foundation, bear interest at the rate of 3% per annum and, except to the extent earlier repaid by us, mature and are required to be repaid in full on December 31, 2019. As of September 30, 2013, we had borrowed no amounts under the Gates Loan Agreement. As of September 30, 2013, we had received approximately $7.9 million in grant-related funding from the Gates Foundation, which was recorded as restricted cash and deferred grant funding. The deferred grant funding is classified within accrued expenses and other current liabilities on our accompanying consolidated balance sheet. As qualified expenditures are incurred under the terms of the grant, we use the deferred funding to recognize a reduction of our related qualified research and development expenditures. For the three and nine months ended September 30, 2013, we incurred approximately $1.9 million and $4.3 million, respectively, of qualified expenditures, for which we reduced our deferred grant funding balance and recorded an offset to our research and development expenses. |
Material_Contingencies
Material Contingencies | 9 Months Ended | |||
Sep. 30, 2013 | ||||
Commitments And Contingencies Disclosure [Abstract] | ' | |||
Material Contingencies | ' | |||
(17) Material Contingencies | ||||
Acquisition-related Contingent Consideration Obligations | ||||
The following summarizes our principal contractual acquisition-related contingent consideration obligations as of September 30, 2013 that have changed significantly since December 31, 2012. Other acquisition-related contingent consideration obligations that were presented in our Annual Report on Form 10-K, as amended, for the year ended December 31, 2012, but which are omitted below, represent those that have not changed significantly since that date. | ||||
• | Accordant | |||
With respect to Accordant, the terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain revenue and cash collection targets starting after the second anniversary of the acquisition date and completed prior to the third anniversary of the acquisition date. An earn-out totaling $4.5 million was earned and accrued as of December 31, 2012. A payment of $1.5 million was made during each of the first, second and third quarters of 2013. No further payment obligations are outstanding as of September 30, 2013. | ||||
• | Alere Healthcare | |||
With respect to Alere Healthcare, the terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain revenue and operating income targets during each of the calendar years 2010 through 2012. The 2012 portion of the earn-out totaling $0.3 million, which was previously accrued at December 31, 2012, was paid during the second quarter of 2013. No further contingent consideration obligations related to this acquisition exist as of September 30, 2013. | ||||
• | Alere S.A. | |||
With respect to Alere S.A., the terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain revenue and EBITDA targets during each of the calendar years 2011 through 2016. The remaining earn-out was settled for BRL 6.9 million (approximately $3.1 million). A payment of BRL 2.9 million was paid during the third quarter of 2013 and the remaining BRL 4.0 million will be paid in 48 equal monthly installments beginning in August 2013. No further contingent consideration obligations related to this acquisition exist as of September 30, 2013. | ||||
• | Amedica | |||
With respect to Amedica, the terms of the acquisition agreement require us to make earn-out payments upon successfully meeting certain financial targets during each of the calendar years 2012 and 2013. The 2012 portion of the earn-out totaling $6.9 million, which was previously accrued at December 31, 2012, was paid during the second quarter of 2013. The maximum remaining amount of the earn-out payments is $8.1 million. | ||||
• | Branan | |||
With respect to Branan, the terms of the acquisition agreement require us to pay earn-outs upon successfully achieving various regulatory product approval milestones by the second anniversary of the acquisition date. Four milestones were achieved during 2012, resulting in an accrual totaling approximately $2.0 million as of December 31, 2012. During the first quarter of 2013, two additional milestones were achieved, resulting in an incremental accrual of $1.0 million. Payment of these earn-outs was made during the first quarter of 2013. The maximum remaining amount of the earn-out payments is $1.8 million. | ||||
• | Epocal | |||
With respect to Epocal, the terms of the acquisition agreement require us to pay earn-outs and management incentive payments upon successfully meeting certain product development and United States Food and Drug Administration regulatory approval milestones from the date of acquisition through December 31, 2018. The maximum amount of the earn-out payments is $90.5 million, of which $15.0 million was paid at the acquisition closing date. The maximum amount of the management incentive payments is $9.4 million. | ||||
• | Immunalysis | |||
With respect to Immunalysis, the terms of the acquisition agreement require us to pay earn-outs upon successfully meeting certain gross profit targets during each of the calendar years 2010 through 2012. During the second quarter of 2013, it was determined that the 2012 earn-out totaling $1.7 million had been achieved and payment was made during the same quarter. No further contingent consideration obligations related to this acquisition exist as of September 30, 2013. | ||||
Additionally, we had a contractual contingent obligation to pay up to $3.0 million in compensation to certain executives of Immunalysis in accordance with the acquisition agreement that, to the extent earned, was paid out in connection with the contingent consideration payable to the former shareholders of Immunalysis, for each of the calendar years 2010, 2011 and 2012. Payment of the 2012 compensation totaling $1.0 million, which was previously accrued at December 31, 2012, was made during the second quarter of 2013. No further such compensation obligations related to this acquisition exist as of September 30, 2013. | ||||
• | MedApps | |||
With respect to MedApps, the terms of the acquisition agreement require us to make earn-out payments upon achievement of certain technological and product development milestones through January 15, 2015. A portion of the earn-out, totaling $3.0 million, was earned and paid during the second quarter of 2013. The maximum remaining amount of the earn-out payments is $18.2 million. | ||||
• | NationsHealth | |||
With respect to NationsHealth, the terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain operational targets within one year of the acquisition date. During the second quarter of 2013, the earn-out was accrued for a settlement amount of $2.0 million, which was paid during the third quarter of 2013. No further contingent consideration obligations related to this acquisition exist as of September 30, 2013. | ||||
• | Pantech | |||
With respect to Pantech, the terms of the acquisition agreement requires us to pay a maximum earn-out of approximately $0.6 million based upon successfully meeting certain EBITDA targets in each of the three years post-closing. | ||||
• | ROAR | |||
With respect to Forensics Limited, or ROAR, the terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain EBITDA targets during 2012 through 2014. Payment of the 2012 earn-out totaling approximately £1.0 million (approximately $1.5 million), which was previously accrued at December 31, 2012, was made during the first quarter of 2013. The maximum remaining amount of the earn-out payments is £9.5 million (approximately $15.2 million at September 30, 2013). |
Recent_Accounting_Pronouncemen
Recent Accounting Pronouncements | 9 Months Ended |
Sep. 30, 2013 | |
Accounting Policies [Abstract] | ' |
Recent Accounting Pronouncements | ' |
(18) Recent Accounting Pronouncements | |
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position, results of operations, comprehensive income or cash flows upon adoption. | |
Recent Accounting Pronouncement | |
In July 2013, the FASB issued Accounting Standards Update, or ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, or ASU 2013-11. ASU 2013-11 requires an entity to present unrecognized tax benefits as a reduction to deferred tax assets when a net operating loss carryforward, similar tax loss or a tax credit carryforward exists, with limited exceptions. ASU 2013-11 is effective for fiscal years beginning on or after December 15, 2013, and for interim periods within those fiscal years. We do not expect that the adoption of this ASU will have a material impact on our consolidated financial statements. | |
Recently Adopted Standards | |
Effective January 1, 2013, we adopted ASU No. 2012-02, Intangibles — Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment, or ASU 2012-02. ASU 2012-02 allows an entity the option to first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the indefinite-lived intangible asset is impaired. If an entity concludes that it is not more likely than not that the indefinite-lived intangible asset is impaired, then the entity is not required to take further action. However, if an entity concludes otherwise, then it is required to determine the fair value of the indefinite-lived intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying amount. An entity also has the option to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to performing the quantitative impairment test. An entity will be able to resume performing the qualitative assessment in any subsequent period. The adoption of this standard is not expected to have an impact on our financial position, results of operations, comprehensive income or cash flows. |
Equity_Investments
Equity Investments | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Equity Method Investments And Joint Ventures [Abstract] | ' | ||||||||||||||||
Equity Investments | ' | ||||||||||||||||
(19) Equity Investments | |||||||||||||||||
We account for the results from our equity investments under the equity method of accounting in accordance with ASC 323, Investments — Equity Method and Joint Ventures, based on the percentage of our ownership interest in the business. Our equity investments primarily include the following: | |||||||||||||||||
(a) SPD | |||||||||||||||||
We have a 50/50 joint venture, called SPD, with P&G for the development, manufacturing, marketing and sale of existing and to-be-developed consumer diagnostic products, outside the cardiology, diabetes and oral care fields. We recorded earnings of $4.7 million and $11.4 million during the three and nine months ended September 30, 2013, respectively, and earnings of $2.1 million and $8.2 million during the three and nine months ended September 30, 2012, respectively, in equity earnings of unconsolidated entities, net of tax, in our accompanying consolidated statements of operations, which represented our 50% share of SPD’s net income or losses, as applicable, for the respective periods. | |||||||||||||||||
(b) TechLab | |||||||||||||||||
We own 49% of TechLab, Inc., or TechLab, a privately-held developer, manufacturer and distributor of rapid non-invasive intestinal diagnostics tests in the areas of intestinal inflammation, antibiotic-associated diarrhea and parasitology. We recorded earnings of $0.5 million and $1.3 million during the three and nine months ended September 30, 2013, respectively, and earnings of $0.6 million and $1.8 million during the three and nine months ended September 30, 2012, respectively, in equity earnings of unconsolidated entities, net of tax, in our accompanying consolidated statements of operations, which represented our minority share of TechLab’s net income for the respective periods. | |||||||||||||||||
Summarized financial information for SPD and TechLab on a combined basis is as follows (in thousands): | |||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||
Combined Condensed Results of Operations: | 2013 | 2012 | 2013 | 2012 | |||||||||||||
Net revenue | $ | 49,272 | $ | 54,650 | $ | 153,096 | $ | 165,483 | |||||||||
Gross profit | $ | 40,158 | $ | 34,411 | $ | 112,862 | $ | 105,175 | |||||||||
Net income after taxes | $ | 10,543 | $ | 5,399 | $ | 25,549 | $ | 20,083 | |||||||||
Combined Condensed Balance Sheet: | September 30, 2013 | December 31, 2012 | |||||||||||||||
Current assets | $ | 95,764 | $ | 79,842 | |||||||||||||
Non-current assets | 37,909 | 38,991 | |||||||||||||||
Total assets | $ | 133,673 | $ | 118,833 | |||||||||||||
Current liabilities | $ | 39,468 | $ | 45,084 | |||||||||||||
Non-current liabilities | 6,268 | 6,791 | |||||||||||||||
Total liabilities | $ | 45,736 | $ | 51,875 | |||||||||||||
Loss_on_Disposition
Loss on Disposition | 9 Months Ended |
Sep. 30, 2013 | |
Discontinued Operations And Disposal Groups [Abstract] | ' |
Loss on Disposition | ' |
(20) Loss on Disposition | |
In July 2013, we sold our Spinreact operations located in Spain, which was part of our professional diagnostics reporting unit and business segment, for $32.0 million in cash proceeds and, as a result of this transaction, we recorded a loss on disposition of $5.9 million during the quarter ended September 30, 2013. The financial results for our Spinreact operations are immaterial to our consolidated financial results. | |
Guarantor_Financial_Informatio
Guarantor Financial Information | 9 Months Ended | ||||||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||||||
Text Block [Abstract] | ' | ||||||||||||||||||||
Guarantor Financial Information | ' | ||||||||||||||||||||
(21) Guarantor Financial Information | |||||||||||||||||||||
Our 7.25% senior notes due 2018, our 8.625% senior subordinated notes due 2018, and our 6.5% senior subordinated notes due 2020 are guaranteed by certain of our consolidated wholly owned subsidiaries, or the Guarantor Subsidiaries. The guarantees are full and unconditional and joint and several. The following supplemental financial information sets forth, on a consolidating basis, balance sheets as of September 30, 2013 and December 31, 2012, the related statements of operations and statements of comprehensive income (loss) for each of the three and nine months ended September 30, 2013 and 2012, respectively, and the statements of cash flows for the nine months ended September 30, 2013 and 2012, for Alere Inc., the Guarantor Subsidiaries and our other subsidiaries, or the Non-Guarantor Subsidiaries. The supplemental financial information reflects the investments of Alere Inc. and the Guarantor Subsidiaries in the Guarantor and Non-Guarantor Subsidiaries using the equity method of accounting. | |||||||||||||||||||||
We have extensive transactions and relationships between various members of the consolidated group. These transactions and relationships include intercompany pricing agreements, intellectual property royalty agreements and general and administrative and research and development cost-sharing agreements. Because of these relationships, it is possible that the terms of these transactions are not the same as those that would result from transactions among wholly unrelated parties. | |||||||||||||||||||||
For comparative purposes, certain amounts for prior periods have been reclassified to conform to the current period classification. | |||||||||||||||||||||
CONSOLIDATING STATEMENT OF OPERATIONS | |||||||||||||||||||||
For the Three Months Ended September 30, 2013 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
Net product sales | $ | — | $ | 223,254 | $ | 330,389 | $ | (44,605 | ) | $ | 509,038 | ||||||||||
Services revenue | — | 220,439 | 20,221 | — | 240,660 | ||||||||||||||||
Net product sales and services revenue | — | 443,693 | 350,610 | (44,605 | ) | 749,698 | |||||||||||||||
License and royalty revenue | — | 5,103 | 4,057 | (4,976 | ) | 4,184 | |||||||||||||||
Net revenue | — | 448,796 | 354,667 | (49,581 | ) | 753,882 | |||||||||||||||
Cost of net product sales | 887 | 129,408 | 165,396 | (37,457 | ) | 258,234 | |||||||||||||||
Cost of services revenue | — | 120,032 | 10,292 | (5,331 | ) | 124,993 | |||||||||||||||
Cost of net product sales and services revenue | 887 | 249,440 | 175,688 | (42,788 | ) | 383,227 | |||||||||||||||
Cost of license and royalty revenue | — | 17 | 6,967 | (4,975 | ) | 2,009 | |||||||||||||||
Cost of net revenue | 887 | 249,457 | 182,655 | (47,763 | ) | 385,236 | |||||||||||||||
Gross profit (loss) | (887 | ) | 199,339 | 172,012 | (1,818 | ) | 368,646 | ||||||||||||||
Operating expenses: | |||||||||||||||||||||
Research and development | 5,515 | 15,817 | 19,166 | — | 40,498 | ||||||||||||||||
Sales and marketing | 1,579 | 81,107 | 76,901 | — | 159,587 | ||||||||||||||||
General and administrative | 23,027 | 61,489 | 57,861 | — | 142,377 | ||||||||||||||||
Loss on disposition | — | — | 5,885 | — | 5,885 | ||||||||||||||||
Operating income (loss) | (31,008 | ) | 40,926 | 12,199 | (1,818 | ) | 20,299 | ||||||||||||||
Interest expense, including amortization of original issue discounts and deferred financing costs | (52,318 | ) | (6,326 | ) | (2,721 | ) | 7,945 | (53,420 | ) | ||||||||||||
Other income (expense), net | (6,775 | ) | 5,770 | 81 | (7,945 | ) | (8,869 | ) | |||||||||||||
Income (loss) before provision (benefit) for income taxes | (90,101 | ) | 40,370 | 9,559 | (1,818 | ) | (41,990 | ) | |||||||||||||
Provision (benefit) for income taxes | (29,302 | ) | 14,928 | (2,214 | ) | (560 | ) | (17,148 | ) | ||||||||||||
Income (loss) before equity earnings (losses) of subsidiaries and unconsolidated entities, net of tax | (60,799 | ) | 25,442 | 11,773 | (1,258 | ) | (24,842 | ) | |||||||||||||
Equity earnings (losses) of subsidiaries, net of tax | 41,246 | (337 | ) | — | (40,909 | ) | — | ||||||||||||||
Equity earnings of unconsolidated entities, net of tax | 464 | — | 5,217 | 72 | 5,753 | ||||||||||||||||
Net income (loss) | (19,089 | ) | 25,105 | 16,990 | (42,095 | ) | (19,089 | ) | |||||||||||||
Less: Net income attributable to non-controlling interests | — | — | 359 | — | 359 | ||||||||||||||||
Net income (loss) attributable to Alere Inc. and Subsidiaries | (19,089 | ) | 25,105 | 16,631 | (42,095 | ) | (19,448 | ) | |||||||||||||
Preferred stock dividends | (5,367 | ) | — | — | — | (5,367 | ) | ||||||||||||||
Net income (loss) available to common stockholders | $ | (24,456 | ) | $ | 25,105 | $ | 16,631 | $ | (42,095 | ) | $ | (24,815 | ) | ||||||||
CONSOLIDATING STATEMENT OF OPERATIONS | |||||||||||||||||||||
For the Three Months Ended September 30, 2012 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
Net product sales | $ | — | $ | 219,484 | $ | 282,369 | $ | (42,040 | ) | $ | 459,813 | ||||||||||
Services revenue | — | 210,761 | 15,654 | — | 226,415 | ||||||||||||||||
Net product sales and services revenue | — | 430,245 | 298,023 | (42,040 | ) | 686,228 | |||||||||||||||
License and royalty revenue | — | (4,912 | ) | 4,868 | 5,232 | 5,188 | |||||||||||||||
Net revenue | — | 425,333 | 302,891 | (36,808 | ) | 691,416 | |||||||||||||||
Cost of net product sales | 928 | 107,410 | 152,607 | (37,333 | ) | 223,612 | |||||||||||||||
Cost of services revenue | — | 115,212 | 7,161 | (2,242 | ) | 120,131 | |||||||||||||||
Cost of net product sales and services revenue | 928 | 222,622 | 159,768 | (39,575 | ) | 343,743 | |||||||||||||||
Cost of license and royalty revenue | — | 5 | (3,339 | ) | 5,232 | 1,898 | |||||||||||||||
Cost of net revenue | 928 | 222,627 | 156,429 | (34,343 | ) | 345,641 | |||||||||||||||
Gross profit (loss) | (928 | ) | 202,706 | 146,462 | (2,465 | ) | 345,775 | ||||||||||||||
Operating expenses: | |||||||||||||||||||||
Research and development | 6,292 | 18,007 | 16,263 | — | 40,562 | ||||||||||||||||
Sales and marketing | 1,220 | 85,866 | 73,558 | — | 160,644 | ||||||||||||||||
General and administrative | 11,392 | 48,704 | 45,741 | — | 105,837 | ||||||||||||||||
Total operating expenses | 18,904 | 152,577 | 135,562 | — | 307,043 | ||||||||||||||||
Operating income (loss) | (19,832 | ) | 50,129 | 10,900 | (2,465 | ) | 38,732 | ||||||||||||||
Interest expense, including amortization of original issue discounts and deferred financing costs | (54,324 | ) | (9,278 | ) | (2,783 | ) | 11,524 | (54,861 | ) | ||||||||||||
Other income (expense), net | 1,534 | 8,319 | 599 | (11,524 | ) | (1,072 | ) | ||||||||||||||
Income (loss) before provision (benefit) for income taxes | (72,622 | ) | 49,170 | 8,716 | (2,465 | ) | (17,201 | ) | |||||||||||||
Provision (benefit) for income taxes | (27,401 | ) | 17,014 | 643 | (933 | ) | (10,677 | ) | |||||||||||||
Income (loss) before equity earnings (losses) of subsidiaries and unconsolidated entities, net of tax | (45,221 | ) | 32,156 | 8,073 | (1,532 | ) | (6,524 | ) | |||||||||||||
Equity earnings (losses) of subsidiaries, net of tax | 41,052 | (230 | ) | — | (40,822 | ) | — | ||||||||||||||
Equity earnings of unconsolidated entities, net of tax | 652 | — | 2,405 | (50 | ) | 3,007 | |||||||||||||||
Net income (loss) | (3,517 | ) | 31,926 | 10,478 | (42,404 | ) | (3,517 | ) | |||||||||||||
Less: Net income attributable to non-controlling interests | — | — | 286 | — | 286 | ||||||||||||||||
Net income (loss) attributable to Alere Inc. and Subsidiaries | (3,517 | ) | 31,926 | 10,192 | (42,404 | ) | (3,803 | ) | |||||||||||||
Preferred stock dividends | (5,352 | ) | — | — | — | (5,352 | ) | ||||||||||||||
Net income (loss) available to common stockholders | $ | (8,869 | ) | $ | 31,926 | $ | 10,192 | $ | (42,404 | ) | $ | (9,155 | ) | ||||||||
CONSOLIDATING STATEMENT OF OPERATIONS | |||||||||||||||||||||
For the Nine Months Ended September 30, 2013 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
Net product sales | $ | — | $ | 665,672 | $ | 1,016,614 | $ | (143,410 | ) | $ | 1,538,876 | ||||||||||
Services revenue | — | 644,760 | 60,367 | — | 705,127 | ||||||||||||||||
Net product sales and services revenue | — | 1,310,432 | 1,076,981 | (143,410 | ) | 2,244,003 | |||||||||||||||
License and royalty revenue | — | 10,908 | 12,662 | (10,457 | ) | 13,113 | |||||||||||||||
Net revenue | — | 1,321,340 | 1,089,643 | (153,867 | ) | 2,257,116 | |||||||||||||||
Cost of net product sales | 2,722 | 367,552 | 519,559 | (125,332 | ) | 764,501 | |||||||||||||||
Cost of services revenue | — | 355,930 | 28,511 | (14,480 | ) | 369,961 | |||||||||||||||
Cost of net product sales and services revenue | 2,722 | 723,482 | 548,070 | (139,812 | ) | 1,134,462 | |||||||||||||||
Cost of license and royalty revenue | — | 52 | 15,668 | (10,456 | ) | 5,264 | |||||||||||||||
Cost of net revenue | 2,722 | 723,534 | 563,738 | (150,268 | ) | 1,139,726 | |||||||||||||||
Gross profit (loss) | (2,722 | ) | 597,806 | 525,905 | (3,599 | ) | 1,117,390 | ||||||||||||||
Operating expenses: | |||||||||||||||||||||
Research and development | 16,167 | 49,354 | 56,931 | — | 122,452 | ||||||||||||||||
Sales and marketing | 4,384 | 245,148 | 225,933 | — | 475,465 | ||||||||||||||||
General and administrative | 51,531 | 200,646 | 166,219 | — | 418,396 | ||||||||||||||||
Loss on disposition | — | — | 5,885 | — | 5,885 | ||||||||||||||||
Operating income (loss) | (74,804 | ) | 102,658 | 70,937 | (3,599 | ) | 95,192 | ||||||||||||||
Interest expense, including amortization of original issue discounts and deferred financing costs | (200,836 | ) | (19,729 | ) | (9,209 | ) | 26,502 | (203,272 | ) | ||||||||||||
Other income (expense), net | (7,612 | ) | 17,665 | 8,173 | (26,502 | ) | (8,276 | ) | |||||||||||||
Income (loss) before provision (benefit) for income taxes | (283,252 | ) | 100,594 | 69,901 | (3,599 | ) | (116,356 | ) | |||||||||||||
Provision (benefit) for income taxes | (102,473 | ) | 44,896 | 22,663 | (1,238 | ) | (36,152 | ) | |||||||||||||
Income (loss) before equity earnings (losses) of subsidiaries and unconsolidated entities, net of tax | (180,779 | ) | 55,698 | 47,238 | (2,361 | ) | (80,204 | ) | |||||||||||||
Equity earnings (losses) of subsidiaries, net of tax | 112,535 | (1,510 | ) | — | (111,025 | ) | — | ||||||||||||||
Equity earnings of unconsolidated entities, net of tax | 1,278 | — | 11,932 | 28 | 13,238 | ||||||||||||||||
Net income (loss) | (66,966 | ) | 54,188 | 59,170 | (113,358 | ) | (66,966 | ) | |||||||||||||
Less: Net income attributable to non-controlling interests | — | — | 601 | — | 601 | ||||||||||||||||
Net income (loss) attributable to Alere Inc. and Subsidiaries | (66,966 | ) | 54,188 | 58,569 | (113,358 | ) | (67,567 | ) | |||||||||||||
Preferred stock dividends | (15,926 | ) | — | — | — | (15,926 | ) | ||||||||||||||
Net income (loss) available to common stockholders | $ | (82,892 | ) | $ | 54,188 | $ | 58,569 | $ | (113,358 | ) | $ | (83,493 | ) | ||||||||
CONSOLIDATING STATEMENT OF OPERATIONS | |||||||||||||||||||||
For the Nine Months Ended September 30, 2012 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
Net product sales | $ | — | $ | 649,719 | $ | 854,113 | $ | (104,807 | ) | $ | 1,399,025 | ||||||||||
Services revenue | — | 605,193 | 47,511 | — | 652,704 | ||||||||||||||||
Net product sales and services revenue | — | 1,254,912 | 901,624 | (104,807 | ) | 2,051,729 | |||||||||||||||
License and royalty revenue | — | 8,982 | 10,016 | (7,665 | ) | 11,333 | |||||||||||||||
Net revenue | — | 1,263,894 | 911,640 | (112,472 | ) | 2,063,062 | |||||||||||||||
Cost of net product sales | 2,635 | 311,722 | 456,760 | (99,453 | ) | 671,664 | |||||||||||||||
Cost of services revenue | — | 311,718 | 22,074 | (2,242 | ) | 331,550 | |||||||||||||||
Cost of net product sales and services revenue | 2,635 | 623,440 | 478,834 | (101,695 | ) | 1,003,214 | |||||||||||||||
Cost of license and royalty revenue | — | 15 | 13,044 | (7,665 | ) | 5,394 | |||||||||||||||
Cost of net revenue | 2,635 | 623,455 | 491,878 | (109,360 | ) | 1,008,608 | |||||||||||||||
Gross profit (loss) | (2,635 | ) | 640,439 | 419,762 | (3,112 | ) | 1,054,454 | ||||||||||||||
Operating expenses: | |||||||||||||||||||||
Research and development | 17,361 | 53,528 | 49,120 | — | 120,009 | ||||||||||||||||
Sales and marketing | 3,096 | 260,283 | 215,165 | — | 478,544 | ||||||||||||||||
General and administrative | 37,590 | 174,639 | 135,528 | — | 347,757 | ||||||||||||||||
Total operating expenses | 58,047 | 488,450 | 399,813 | — | 946,310 | ||||||||||||||||
Operating income (loss) | (60,682 | ) | 151,989 | 19,949 | (3,112 | ) | 108,144 | ||||||||||||||
Interest expense, including amortization of original issue discounts and deferred financing costs | (158,009 | ) | (31,291 | ) | (9,853 | ) | 38,034 | (161,119 | ) | ||||||||||||
Other income (expense), net | (2,552 | ) | 33,550 | 21,606 | (38,034 | ) | 14,570 | ||||||||||||||
Income (loss) before provision (benefit) for income taxes | (221,243 | ) | 154,248 | 31,702 | (3,112 | ) | (38,405 | ) | |||||||||||||
Provision (benefit) for income taxes | (74,149 | ) | 59,013 | 3,494 | (979 | ) | (12,621 | ) | |||||||||||||
Income (loss) before equity earnings (losses) of subsidiaries and unconsolidated entities, net of tax | (147,094 | ) | 95,235 | 28,208 | (2,133 | ) | (25,784 | ) | |||||||||||||
Equity earnings (losses) of subsidiaries, net of tax | 129,929 | (763 | ) | — | (129,166 | ) | — | ||||||||||||||
Equity earnings (losses) of unconsolidated entities, net of tax | 1,798 | — | 8,643 | (24 | ) | 10,417 | |||||||||||||||
Net income (loss) | (15,367 | ) | 94,472 | 36,851 | (131,323 | ) | (15,367 | ) | |||||||||||||
Less: Net income attributable to non-controlling interests | — | — | 137 | — | 137 | ||||||||||||||||
Net income (loss) attributable to Alere Inc. and Subsidiaries | (15,367 | ) | 94,472 | 36,714 | (131,323 | ) | (15,504 | ) | |||||||||||||
Preferred stock dividends | (15,940 | ) | — | — | — | (15,940 | ) | ||||||||||||||
Net income (loss) available to common stockholders | $ | (31,307 | ) | $ | 94,472 | $ | 36,714 | $ | (131,323 | ) | $ | (31,444 | ) | ||||||||
CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) | |||||||||||||||||||||
For the Three Months Ended September 30, 2013 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
Net income (loss) | $ | (19,089 | ) | $ | 25,105 | $ | 16,990 | $ | (42,095 | ) | $ | (19,089 | ) | ||||||||
Other comprehensive income, before tax: | |||||||||||||||||||||
Changes in cumulative translation adjustment | 524 | — | 66,742 | 2 | 67,268 | ||||||||||||||||
Unrealized gains on hedging instruments | — | — | 20 | — | 20 | ||||||||||||||||
Minimum pension liability adjustment | — | — | (369 | ) | — | (369 | ) | ||||||||||||||
Other comprehensive income, before tax | 524 | — | 66,393 | 2 | 66,919 | ||||||||||||||||
Income tax provision (benefit) related to items of other comprehensive income | — | — | — | — | — | ||||||||||||||||
Other comprehensive income, net of tax | 524 | — | 66,393 | 2 | 66,919 | ||||||||||||||||
Comprehensive income (loss) | (18,565 | ) | 25,105 | 83,383 | (42,093 | ) | 47,830 | ||||||||||||||
Less: Comprehensive income attributable to non-controlling interests | — | — | 359 | — | 359 | ||||||||||||||||
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | $ | (18,565 | ) | $ | 25,105 | $ | 83,024 | $ | (42,093 | ) | $ | 47,471 | |||||||||
CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) | |||||||||||||||||||||
For the Three Months Ended September 30, 2012 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
Net income (loss) | $ | (3,517 | ) | $ | 31,926 | $ | 10,478 | $ | (42,404 | ) | $ | (3,517 | ) | ||||||||
Other comprehensive income, before tax: | |||||||||||||||||||||
Changes in cumulative translation adjustment | 132 | 1 | 36,027 | 3,535 | 39,695 | ||||||||||||||||
Unrealized gains on available for sale securities | 141 | — | — | — | 141 | ||||||||||||||||
Unrealized gains on hedging instruments | — | — | 10 | — | 10 | ||||||||||||||||
Minimum pension liability adjustment | — | — | (98 | ) | — | (98 | ) | ||||||||||||||
Other comprehensive income, before tax | 273 | 1 | 35,939 | 3,535 | 39,748 | ||||||||||||||||
Income tax provision related to items of other comprehensive income (loss) | 360 | — | — | — | 360 | ||||||||||||||||
Other comprehensive income (loss), net of tax | (87 | ) | 1 | 35,939 | 3,535 | 39,388 | |||||||||||||||
Comprehensive income (loss) | (3,604 | ) | 31,927 | 46,417 | (38,869 | ) | 35,871 | ||||||||||||||
Less: Comprehensive income attributable to non-controlling interests | — | — | 286 | — | 286 | ||||||||||||||||
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | $ | (3,604 | ) | $ | 31,927 | $ | 46,131 | $ | (38,869 | ) | $ | 35,585 | |||||||||
CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) | |||||||||||||||||||||
For the Nine Months Ended September 30, 2013 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
Net income (loss) | $ | (66,966 | ) | $ | 54,188 | $ | 59,170 | $ | (113,358 | ) | $ | (66,966 | ) | ||||||||
Other comprehensive loss, before tax: | |||||||||||||||||||||
Changes in cumulative translation adjustment | (329 | ) | — | (42,188 | ) | 2 | (42,515 | ) | |||||||||||||
Unrealized gains on hedging instruments | — | — | 31 | — | 31 | ||||||||||||||||
Minimum pension liability adjustment | — | — | 335 | — | 335 | ||||||||||||||||
Other comprehensive loss, before tax | (329 | ) | — | (41,822 | ) | 2 | (42,149 | ) | |||||||||||||
Income tax provision (benefit) related to items of other comprehensive loss | — | — | — | — | — | ||||||||||||||||
Other comprehensive loss, net of tax | (329 | ) | — | (41,822 | ) | 2 | (42,149 | ) | |||||||||||||
Comprehensive income (loss) | (67,295 | ) | 54,188 | 17,348 | (113,356 | ) | (109,115 | ) | |||||||||||||
Less: Comprehensive income attributable to non-controlling interests | — | — | 601 | — | 601 | ||||||||||||||||
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | $ | (67,295 | ) | $ | 54,188 | $ | 16,747 | $ | (113,356 | ) | $ | (109,716 | ) | ||||||||
CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) | |||||||||||||||||||||
For the Nine Months Ended September 30, 2012 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
Net income (loss) | $ | (15,367 | ) | $ | 94,472 | $ | 36,851 | $ | (131,323 | ) | $ | (15,367 | ) | ||||||||
Other comprehensive income (loss), before tax: | |||||||||||||||||||||
Changes in cumulative translation adjustment | (100 | ) | (302 | ) | 37,136 | 2,123 | 38,857 | ||||||||||||||
Unrealized gains on available for sale securities | 926 | 5 | — | — | 931 | ||||||||||||||||
Unrealized gains on hedging instruments | 17 | — | 448 | — | 465 | ||||||||||||||||
Minimum pension liability adjustment | — | — | (218 | ) | — | (218 | ) | ||||||||||||||
Other comprehensive income (loss), before tax | 843 | (297 | ) | 37,366 | 2,123 | 40,035 | |||||||||||||||
Income tax provision related to items of other comprehensive income (loss) | 360 | — | — | — | 360 | ||||||||||||||||
Other comprehensive income (loss), net of tax | 483 | (297 | ) | 37,366 | 2,123 | 39,675 | |||||||||||||||
Comprehensive income (loss) | (14,884 | ) | 94,175 | 74,217 | (129,200 | ) | 24,308 | ||||||||||||||
Less: Comprehensive income attributable to non-controlling interests | — | — | 137 | — | 137 | ||||||||||||||||
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | $ | (14,884 | ) | $ | 94,175 | $ | 74,080 | $ | (129,200 | ) | $ | 24,171 | |||||||||
CONSOLIDATING BALANCE SHEET | |||||||||||||||||||||
September 30, 2013 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
ASSETS | |||||||||||||||||||||
Current assets: | |||||||||||||||||||||
Cash and cash equivalents | $ | 47,863 | $ | 76,234 | $ | 229,896 | $ | — | $ | 353,993 | |||||||||||
Restricted cash | 4,439 | 2,309 | 1,157 | — | 7,905 | ||||||||||||||||
Marketable securities | — | 815 | 5 | — | 820 | ||||||||||||||||
Accounts receivable, net of allowances | — | 256,578 | 312,295 | — | 568,873 | ||||||||||||||||
Inventories, net | — | 170,372 | 225,894 | (25,818 | ) | 370,448 | |||||||||||||||
Deferred tax assets | 8,749 | 35,980 | 9,440 | 4,008 | 58,177 | ||||||||||||||||
Prepaid expenses and other current assets | 3,911 | 34,732 | 75,999 | (41 | ) | 114,601 | |||||||||||||||
Intercompany receivables | 332,124 | 714,131 | 61,898 | (1,108,153 | ) | — | |||||||||||||||
Total current assets | 397,086 | 1,291,151 | 916,584 | (1,130,004 | ) | 1,474,817 | |||||||||||||||
Property, plant and equipment, net | 9,048 | 291,621 | 243,981 | (379 | ) | 544,271 | |||||||||||||||
Goodwill | — | 1,810,036 | 1,293,459 | — | 3,103,495 | ||||||||||||||||
Other intangible assets with indefinite lives | — | 12,900 | 46,053 | — | 58,953 | ||||||||||||||||
Finite-lived intangible assets, net | 8,786 | 1,003,272 | 735,480 | — | 1,747,538 | ||||||||||||||||
Restricted cash—non-current | — | — | 29,045 | — | 29,045 | ||||||||||||||||
Deferred financing costs, net and other non-current assets | 58,996 | 9,299 | 18,247 | (53 | ) | 86,489 | |||||||||||||||
Investments in subsidiaries | 4,473,400 | 274,450 | 127,711 | (4,875,561 | ) | — | |||||||||||||||
Investments in unconsolidated entities | 30,221 | — | 58,049 | 13,552 | 101,822 | ||||||||||||||||
Deferred tax assets | — | — | 8,189 | — | 8,189 | ||||||||||||||||
Intercompany notes receivable | 1,541,655 | 665,623 | 97,887 | (2,305,165 | ) | — | |||||||||||||||
Total assets | $ | 6,519,192 | $ | 5,358,352 | $ | 3,574,685 | $ | (8,297,610 | ) | $ | 7,154,619 | ||||||||||
LIABILITIES AND EQUITY | |||||||||||||||||||||
Current liabilities: | |||||||||||||||||||||
Short-term debt | $ | — | $ | — | $ | 25 | $ | — | $ | 25 | |||||||||||
Current portion of long-term debt | 45,000 | 348 | 2,353 | — | 47,701 | ||||||||||||||||
Current portion of capital lease obligations | — | 3,808 | 2,725 | — | 6,533 | ||||||||||||||||
Accounts payable | 18,702 | 77,163 | 99,126 | — | 194,991 | ||||||||||||||||
Accrued expenses and other current liabilities | (381,276 | ) | 604,035 | 225,084 | (615 | ) | 447,228 | ||||||||||||||
Intercompany payables | 677,842 | 149,645 | 280,668 | (1,108,155 | ) | — | |||||||||||||||
Total current liabilities | 360,268 | 834,999 | 609,981 | (1,108,770 | ) | 696,478 | |||||||||||||||
Long-term liabilities: | |||||||||||||||||||||
Long-term debt, net of current portion | 3,750,057 | 150 | 40,325 | — | 3,790,532 | ||||||||||||||||
Capital lease obligations, net of current portion | — | 6,133 | 8,793 | — | 14,926 | ||||||||||||||||
Deferred tax liabilities | (27,768 | ) | 282,942 | 97,211 | 474 | 352,859 | |||||||||||||||
Other long-term liabilities | 20,198 | 57,762 | 131,776 | (53 | ) | 209,683 | |||||||||||||||
Intercompany notes payables | 330,967 | 1,503,599 | 470,599 | (2,305,165 | ) | — | |||||||||||||||
Total long-term liabilities | 4,073,454 | 1,850,586 | 748,704 | (2,304,744 | ) | 4,368,000 | |||||||||||||||
Stockholders’ equity | 2,085,470 | 2,672,767 | 2,211,329 | (4,884,096 | ) | 2,085,470 | |||||||||||||||
Non-controlling interests | — | — | 4,671 | — | 4,671 | ||||||||||||||||
Total equity | 2,085,470 | 2,672,767 | 2,216,000 | (4,884,096 | ) | 2,090,141 | |||||||||||||||
Total liabilities and equity | $ | 6,519,192 | $ | 5,358,352 | $ | 3,574,685 | $ | (8,297,610 | ) | $ | 7,154,619 | ||||||||||
CONSOLIDATING BALANCE SHEET | |||||||||||||||||||||
December 31, 2012 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
ASSETS | |||||||||||||||||||||
Current assets: | |||||||||||||||||||||
Cash and cash equivalents | $ | 3,623 | $ | 67,449 | $ | 257,274 | $ | — | $ | 328,346 | |||||||||||
Restricted cash | — | 1,680 | 1,396 | — | 3,076 | ||||||||||||||||
Marketable securities | — | 787 | 117 | — | 904 | ||||||||||||||||
Accounts receivable, net of allowances | — | 241,050 | 283,282 | — | 524,332 | ||||||||||||||||
Inventories, net | — | 142,413 | 203,230 | (8,522 | ) | 337,121 | |||||||||||||||
Deferred tax assets | 12,193 | 39,601 | 13,138 | 2,790 | 67,722 | ||||||||||||||||
Prepaid expenses and other current assets | (20,636 | ) | 99,271 | 66,634 | (33 | ) | 145,236 | ||||||||||||||
Intercompany receivables | 298,812 | 1,254,727 | 55,847 | (1,609,386 | ) | — | |||||||||||||||
Total current assets | 293,992 | 1,846,978 | 880,918 | (1,615,151 | ) | 1,406,737 | |||||||||||||||
Property, plant and equipment, net | 2,679 | 293,260 | 239,082 | (552 | ) | 534,469 | |||||||||||||||
Goodwill | — | 1,820,438 | 1,227,967 | — | 3,048,405 | ||||||||||||||||
Other intangible assets with indefinite lives | — | 14,600 | 21,851 | — | 36,451 | ||||||||||||||||
Finite-lived intangible assets, net | 24,701 | 1,132,656 | 676,868 | — | 1,834,225 | ||||||||||||||||
Deferred financing costs, net and other non-current assets | 78,522 | 10,341 | 20,065 | (71 | ) | 108,857 | |||||||||||||||
Investments in subsidiaries | 4,114,478 | 222,175 | 73,940 | (4,410,593 | ) | — | |||||||||||||||
Investments in unconsolidated entities | 33,979 | — | 56,512 | — | 90,491 | ||||||||||||||||
Deferred tax assets | — | 782 | 7,511 | — | 8,293 | ||||||||||||||||
Intercompany notes receivable | 1,724,650 | 722,552 | 1,278 | (2,448,480 | ) | — | |||||||||||||||
Total assets | $ | 6,273,001 | $ | 6,063,782 | $ | 3,205,992 | $ | (8,474,847 | ) | $ | 7,067,928 | ||||||||||
LIABILITIES AND EQUITY | |||||||||||||||||||||
Current liabilities: | |||||||||||||||||||||
Current portion of long-term debt | $ | 45,000 | $ | 349 | $ | 14,883 | $ | — | $ | 60,232 | |||||||||||
Current portion of capital lease obligations | — | 3,209 | 3,475 | — | 6,684 | ||||||||||||||||
Accounts payable | 7,993 | 76,256 | 85,725 | — | 169,974 | ||||||||||||||||
Accrued expenses and other current liabilities | (388,830 | ) | 586,116 | 214,659 | (26 | ) | 411,919 | ||||||||||||||
Intercompany payables | 557,578 | 806,507 | 245,300 | (1,609,385 | ) | — | |||||||||||||||
Total current liabilities | 221,741 | 1,472,437 | 564,042 | (1,609,411 | ) | 648,809 | |||||||||||||||
Long-term liabilities: | |||||||||||||||||||||
Long-term debt, net of current portion | 3,617,068 | 374 | 11,233 | — | 3,628,675 | ||||||||||||||||
Capital lease obligations, net of current portion | — | 5,412 | 7,505 | — | 12,917 | ||||||||||||||||
Deferred tax liabilities | (5,329 | ) | 333,388 | 100,216 | (87 | ) | 428,188 | ||||||||||||||
Other long-term liabilities | 17,678 | 72,890 | 76,138 | (71 | ) | 166,635 | |||||||||||||||
Intercompany notes payables | 241,421 | 1,630,376 | 576,684 | (2,448,481 | ) | — | |||||||||||||||
Total long-term liabilities | 3,870,838 | 2,042,440 | 771,776 | (2,448,639 | ) | 4,236,415 | |||||||||||||||
Stockholders’ equity | 2,180,422 | 2,548,905 | 1,867,892 | (4,416,797 | ) | 2,180,422 | |||||||||||||||
Non-controlling interests | — | — | 2,282 | — | 2,282 | ||||||||||||||||
Total equity | 2,180,422 | 2,548,905 | 1,870,174 | (4,416,797 | ) | 2,182,704 | |||||||||||||||
Total liabilities and equity | $ | 6,273,001 | $ | 6,063,782 | $ | 3,205,992 | $ | (8,474,847 | ) | $ | 7,067,928 | ||||||||||
CONSOLIDATING STATEMENT OF CASH FLOWS | |||||||||||||||||||||
For the Nine Months Ended September 30, 2013 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
Cash Flows from Operating Activities: | |||||||||||||||||||||
Net income (loss) | $ | (66,966 | ) | $ | 54,188 | $ | 59,170 | $ | (113,358 | ) | $ | (66,966 | ) | ||||||||
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | |||||||||||||||||||||
Equity (earnings) losses of subsidiaries, net of tax | (112,535 | ) | 1,510 | — | 111,025 | — | |||||||||||||||
Non-cash interest expense, including amortization of original issue discounts and write-off of deferred financing costs | 13,814 | 229 | 45 | — | 14,088 | ||||||||||||||||
Depreciation and amortization | 3,731 | 188,745 | 134,317 | (104 | ) | 326,689 | |||||||||||||||
Non-cash charges for sale of inventories revalued at the date of acquisition | — | — | 1,880 | — | 1,880 | ||||||||||||||||
Non-cash stock-based compensation expense | 5,836 | 3,646 | 4,980 | — | 14,462 | ||||||||||||||||
Impairment of inventory | — | 27 | 216 | — | 243 | ||||||||||||||||
Impairment of long-lived assets | — | 2,954 | 1,147 | — | 4,101 | ||||||||||||||||
Loss on sale of fixed assets | — | 1,118 | 731 | — | 1,849 | ||||||||||||||||
Equity earnings of unconsolidated entities, net of tax | (1,278 | ) | — | (11,932 | ) | (28 | ) | (13,238 | ) | ||||||||||||
Deferred income taxes | (17,386 | ) | (27,285 | ) | (27,830 | ) | (1,154 | ) | (73,655 | ) | |||||||||||
Loss on extinguishment of debt | 35,603 | — | — | — | 35,603 | ||||||||||||||||
Loss on disposition | — | — | 5,885 | — | 5,885 | ||||||||||||||||
Bargain purchase gain | — | — | (5,707 | ) | — | (5,707 | ) | ||||||||||||||
Other non-cash items | 5,201 | (8 | ) | 1,481 | — | 1,481 | |||||||||||||||
Changes in assets and liabilities, net of acquisitions: | |||||||||||||||||||||
Accounts receivable, net | — | (15,528 | ) | (41,782 | ) | — | (57,310 | ) | |||||||||||||
Inventories, net | — | (45,883 | ) | (30,615 | ) | 3,771 | (72,727 | ) | |||||||||||||
Prepaid expenses and other current assets | (64,547 | ) | 67,871 | (4,941 | ) | (7,515 | ) | (9,132 | ) | ||||||||||||
Accounts payable | 5,918 | (1,453 | ) | 11,516 | — | 15,981 | |||||||||||||||
Accrued expenses and other current liabilities | 10,396 | 17,570 | 2,342 | 6,934 | 37,242 | ||||||||||||||||
Other non-current liabilities | (915 | ) | (15,197 | ) | 8,739 | 516 | (6,857 | ) | |||||||||||||
Intercompany payable (receivable) | 298,083 | (182,214 | ) | (115,869 | ) | — | — | ||||||||||||||
Net cash provided by (used in) operating activities | 114,955 | 50,290 | (6,227 | ) | 87 | 159,105 | |||||||||||||||
Cash Flows from Investing Activities: | |||||||||||||||||||||
Increase in restricted cash | (4,439 | ) | (630 | ) | (28,812 | ) | — | (33,881 | ) | ||||||||||||
Purchases of property, plant and equipment | (1,037 | ) | (42,950 | ) | (58,860 | ) | 11,939 | (90,908 | ) | ||||||||||||
Proceeds from sale of property, plant and equipment | — | 6,908 | 11,186 | (12,263 | ) | 5,831 | |||||||||||||||
Cash received from disposition | — | — | 32,000 | — | 32,000 | ||||||||||||||||
Cash paid for acquisitions, net of cash acquired | (157,373 | ) | — | (8,823 | ) | — | (166,196 | ) | |||||||||||||
Cash received from equity method investments | 490 | — | 10,772 | — | 11,262 | ||||||||||||||||
(Increase) decrease in other assets | 19,244 | (2,047 | ) | 2,065 | (18 | ) | 19,244 | ||||||||||||||
Net cash used in investing activities | (143,115 | ) | (38,719 | ) | (40,472 | ) | (342 | ) | (222,648 | ) | |||||||||||
Cash Flows from Financing Activities: | |||||||||||||||||||||
Cash paid for financing costs | (9,798 | ) | — | — | — | (9,798 | ) | ||||||||||||||
Cash paid for contingent purchase price consideration | (27,165 | ) | — | (331 | ) | — | (27,496 | ) | |||||||||||||
Proceeds from issuance of common stock, net of issuance costs | 17,555 | — | — | — | 17,555 | ||||||||||||||||
Proceeds from issuance of long-term debt | 425,000 | 989 | 34,152 | — | 460,141 | ||||||||||||||||
Payments on long-term debt | (446,845 | ) | (1,213 | ) | (7,099 | ) | — | (455,157 | ) | ||||||||||||
Net proceeds (payments) under revolving credit facilities | 147,500 | — | (8,732 | ) | — | 138,768 | |||||||||||||||
Borrowings from short-term debt | — | — | 25 | — | 25 | ||||||||||||||||
Cash paid for dividends | (15,970 | ) | — | — | — | (15,970 | ) | ||||||||||||||
Excess tax benefits on exercised stock options | 205 | 181 | 48 | — | 434 | ||||||||||||||||
Principal payments on capital lease obligations | — | (2,715 | ) | (2,626 | ) | — | (5,341 | ) | |||||||||||||
Other | (18,953 | ) | — | — | — | (18,953 | ) | ||||||||||||||
Net cash provided by (used in) financing activities | 71,529 | (2,758 | ) | 15,437 | — | 84,208 | |||||||||||||||
Foreign exchange effect on cash and cash equivalents | 871 | (28 | ) | 3,884 | 255 | 4,982 | |||||||||||||||
Net increase (decrease) in cash and cash equivalents | 44,240 | 8,785 | (27,378 | ) | — | 25,647 | |||||||||||||||
Cash and cash equivalents, beginning of period | 3,623 | 67,449 | 257,274 | — | 328,346 | ||||||||||||||||
Cash and cash equivalents, end of period | $ | 47,863 | $ | 76,234 | $ | 229,896 | $ | — | $ | 353,993 | |||||||||||
CONSOLIDATING STATEMENT OF CASH FLOWS | |||||||||||||||||||||
For the Nine Months Ended September 30, 2012 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
Cash Flows from Operating Activities: | |||||||||||||||||||||
Net income (loss) | $ | (15,367 | ) | $ | 94,472 | $ | 36,851 | $ | (131,323 | ) | $ | (15,367 | ) | ||||||||
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||||||||||||||||||||
Equity (earnings) losses of subsidiaries, net of tax | (129,929 | ) | 763 | — | 129,166 | — | |||||||||||||||
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs | 15,929 | 158 | — | — | 16,087 | ||||||||||||||||
Depreciation and amortization | 4,314 | 198,576 | 119,462 | 19 | 322,371 | ||||||||||||||||
Non-cash charges for sale of inventories revalued at the date of acquisition | — | 1,400 | 3,281 | — | 4,681 | ||||||||||||||||
Non-cash stock-based compensation expense | 3,119 | 4,309 | 4,440 | — | 11,868 | ||||||||||||||||
Impairment of inventory | — | 5 | 290 | — | 295 | ||||||||||||||||
Impairment of long-lived assets | — | 219 | 55 | — | 274 | ||||||||||||||||
(Gain) loss on sale of property, plant and equipment | 3 | (4,029 | ) | (168 | ) | — | (4,194 | ) | |||||||||||||
Equity earnings of unconsolidated entities, net of tax | (1,798 | ) | — | (8,643 | ) | 24 | (10,417 | ) | |||||||||||||
Deferred income taxes | 20,901 | (38,495 | ) | (25,122 | ) | (903 | ) | (43,619 | ) | ||||||||||||
Other non-cash items | (1,156 | ) | 685 | 6,207 | — | 5,736 | |||||||||||||||
Changes in assets and liabilities, net of acquisitions: | |||||||||||||||||||||
Accounts receivable, net | — | (6,468 | ) | (1,793 | ) | — | (8,261 | ) | |||||||||||||
Inventories, net | — | 4,881 | (23,303 | ) | 2,826 | (15,596 | ) | ||||||||||||||
Prepaid expenses and other current assets | (419,146 | ) | 410,233 | 13,059 | 25 | 4,171 | |||||||||||||||
Accounts payable | 3,961 | (2,327 | ) | (18,377 | ) | — | (16,743 | ) | |||||||||||||
Accrued expenses and other current liabilities | 354,452 | (323,909 | ) | (5,843 | ) | (584 | ) | 24,116 | |||||||||||||
Other non-current liabilities | (7,158 | ) | (1,634 | ) | (13,275 | ) | 428 | (21,639 | ) | ||||||||||||
Intercompany payable (receivable) | 297,741 | (322,706 | ) | 27,088 | (2,123 | ) | — | ||||||||||||||
Net cash provided by operating activities | 125,866 | 16,133 | 114,209 | (2,445 | ) | 253,763 | |||||||||||||||
Cash Flows from Investing Activities: | |||||||||||||||||||||
Decrease in restricted cash | — | 12 | 5,759 | — | 5,771 | ||||||||||||||||
Purchases of property, plant and equipment | (1,149 | ) | (69,092 | ) | (94,311 | ) | 67,243 | (97,309 | ) | ||||||||||||
Proceeds from sale of property, plant and equipment | — | 22,230 | 66,281 | (66,128 | ) | 22,383 | |||||||||||||||
Cash received from (paid for) acquisitions, net of cash acquired | (364,731 | ) | 1,469 | (21,518 | ) | — | (384,780 | ) | |||||||||||||
Cash received from sales of marketable securities | — | 268 | 3 | — | 271 | ||||||||||||||||
Net cash received from equity method investments | 490 | — | 6,066 | — | 6,556 | ||||||||||||||||
(Increase) decrease in other assets | (10,028 | ) | (615 | ) | 1,275 | 55 | (9,313 | ) | |||||||||||||
Net cash used in investing activities | (375,418 | ) | (45,728 | ) | (36,445 | ) | 1,170 | (456,421 | ) | ||||||||||||
Cash Flows from Financing Activities: | |||||||||||||||||||||
Cash paid for financing costs | (2,313 | ) | — | — | — | (2,313 | ) | ||||||||||||||
Cash paid for contingent purchase price consideration | (16,248 | ) | — | — | — | (16,248 | ) | ||||||||||||||
Proceeds from issuance of common stock, net of issuance costs | 14,260 | — | — | — | 14,260 | ||||||||||||||||
Proceeds from issuance of long-term debt | 198,000 | — | 288 | — | 198,288 | ||||||||||||||||
Payments on long-term debt | (33,250 | ) | (455 | ) | (8,848 | ) | — | (42,553 | ) | ||||||||||||
Net proceeds (payments) under revolving credit facilities | 97,500 | (2 | ) | (6,336 | ) | — | 91,162 | ||||||||||||||
Payments on short-term debt | (6,240 | ) | — | — | — | (6,240 | ) | ||||||||||||||
Cash paid for dividends | (15,970 | ) | — | — | — | (15,970 | ) | ||||||||||||||
Excess tax benefits on exercised stock options | 183 | 74 | 20 | — | 277 | ||||||||||||||||
Principal payments on capital lease obligations | — | (1,503 | ) | (3,422 | ) | — | (4,925 | ) | |||||||||||||
Other | — | — | (2,811 | ) | — | (2,811 | ) | ||||||||||||||
Net cash provided by (used in) financing activities | 235,922 | (1,886 | ) | (21,109 | ) | — | 212,927 | ||||||||||||||
Foreign exchange effect on cash and cash equivalents | 1,508 | 331 | (10,302 | ) | 1,275 | (7,188 | ) | ||||||||||||||
Net increase (decrease) in cash and cash equivalents | (12,122 | ) | (31,150 | ) | 46,353 | — | 3,081 | ||||||||||||||
Cash and cash equivalents, beginning of period | 12,451 | 95,212 | 191,510 | — | 299,173 | ||||||||||||||||
Cash and cash equivalents, end of period | $ | 329 | $ | 64,062 | $ | 237,863 | $ | — | $ | 302,254 | |||||||||||
Recent_Accounting_Pronouncemen1
Recent Accounting Pronouncements (Policies) | 9 Months Ended |
Sep. 30, 2013 | |
Accounting Policies [Abstract] | ' |
Presentation of Unrecognized Tax Benefit | ' |
Recent Accounting Pronouncement | |
In July 2013, the FASB issued Accounting Standards Update, or ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, or ASU 2013-11. ASU 2013-11 requires an entity to present unrecognized tax benefits as a reduction to deferred tax assets when a net operating loss carryforward, similar tax loss or a tax credit carryforward exists, with limited exceptions. ASU 2013-11 is effective for fiscal years beginning on or after December 15, 2013, and for interim periods within those fiscal years. We do not expect that the adoption of this ASU will have a material impact on our consolidated financial statements. | |
Intangibles - Goodwill and Other | ' |
Recently Adopted Standards | |
Effective January 1, 2013, we adopted ASU No. 2012-02, Intangibles — Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment, or ASU 2012-02. ASU 2012-02 allows an entity the option to first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the indefinite-lived intangible asset is impaired. If an entity concludes that it is not more likely than not that the indefinite-lived intangible asset is impaired, then the entity is not required to take further action. However, if an entity concludes otherwise, then it is required to determine the fair value of the indefinite-lived intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying amount. An entity also has the option to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to performing the quantitative impairment test. An entity will be able to resume performing the qualitative assessment in any subsequent period. The adoption of this standard is not expected to have an impact on our financial position, results of operations, comprehensive income or cash flows. |
Inventories_Tables
Inventories (Tables) | 9 Months Ended | ||||||||
Sep. 30, 2013 | |||||||||
Inventory Disclosure [Abstract] | ' | ||||||||
Inventories are Stated at the Lower of Cost (First In, First Out) or Market | ' | ||||||||
Inventories are stated at the lower of cost (first in, first out) or market and are comprised of the following (in thousands): | |||||||||
September 30, 2013 | December 31, 2012 | ||||||||
Raw materials | $ | 115,441 | $ | 99,498 | |||||
Work-in-process | 83,571 | 89,895 | |||||||
Finished goods | 171,436 | 147,728 | |||||||
$ | 370,448 | $ | 337,121 | ||||||
StockBased_Compensation_Tables
Stock-Based Compensation (Tables) | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | ' | ||||||||||||||||
Stock-Based Compensation Expense | ' | ||||||||||||||||
We recorded stock-based compensation expense in our consolidated statements of operations for the three and nine months ended September 30, 2013 and 2012, respectively, as follows (in thousands): | |||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||
Cost of net revenue | $ | 287 | $ | 269 | $ | 797 | $ | 801 | |||||||||
Research and development | 1,111 | 752 | 2,641 | 2,379 | |||||||||||||
Sales and marketing | 975 | 751 | 2,597 | 2,581 | |||||||||||||
General and administrative | 3,289 | 1,854 | 8,427 | 6,107 | |||||||||||||
5,662 | 3,626 | 14,462 | 11,868 | ||||||||||||||
Benefit for income taxes | (1,511 | ) | (536 | ) | (2,869 | ) | (1,951 | ) | |||||||||
$ | 4,151 | $ | 3,090 | $ | 11,593 | $ | 9,917 | ||||||||||
Net_Loss_Per_Common_Share_Tabl
Net Loss Per Common Share (Tables) | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Earnings Per Share [Abstract] | ' | ||||||||||||||||
Computation of Basic and Diluted Net Loss Per Common Share | ' | ||||||||||||||||
The following table sets forth the computation of basic and diluted net loss per common share for the periods presented (in thousands, except per share data): | |||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||
Numerator: | |||||||||||||||||
Net loss | $ | (19,089 | ) | $ | (3,517 | ) | $ | (66,966 | ) | $ | (15,367 | ) | |||||
Preferred stock dividends | (5,367 | ) | (5,352 | ) | (15,926 | ) | (15,940 | ) | |||||||||
Less: Net income attributable to non-controlling interest | 359 | 286 | 601 | 137 | |||||||||||||
Net loss available to common stockholders | $ | (24,815 | ) | $ | (9,155 | ) | $ | (83,493 | ) | $ | (31,444 | ) | |||||
Denominator: | |||||||||||||||||
Weighted-average common shares outstanding—basic and diluted | 81,735 | 80,792 | 81,417 | 80,492 | |||||||||||||
Basic and diluted net loss per common share attributable to Alere Inc. and Subsidiaries | $ | (0.30 | ) | $ | (0.11 | ) | $ | (1.03 | ) | $ | (0.39 | ) | |||||
Potential Dilutive Securities Not Included in Calculation of Diluted Net Loss Per Common Share | ' | ||||||||||||||||
The following potential dilutive securities were not included in the calculation of diluted net loss per common share because the inclusion thereof would be antidilutive (in thousands): | |||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||
Denominator: | |||||||||||||||||
Options to purchase shares of common stock | 10,239 | 9,730 | 10,239 | 9,730 | |||||||||||||
Warrants | 4 | 4 | 4 | 4 | |||||||||||||
Conversion shares related to 3% convertible senior subordinated notes | 3,411 | 3,411 | 3,411 | 3,411 | |||||||||||||
Conversion shares related to subordinated convertible promissory notes | 27 | 27 | 27 | 27 | |||||||||||||
Conversion shares related to Series B convertible preferred stock | 10,239 | 10,239 | 10,239 | 10,239 | |||||||||||||
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding | 23,920 | 23,411 | 23,920 | 23,411 | |||||||||||||
Stockholders_Equity_and_NonCon1
Stockholders' Equity and Non-Controlling Interests (Tables) | 9 Months Ended | ||||||||||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||||||||||
Equity [Abstract] | ' | ||||||||||||||||||||||||
Summary of Changes in Stockholders' Equity and Non-Controlling Interests Comprising Total Equity | ' | ||||||||||||||||||||||||
A summary of the changes in stockholders’ equity and non-controlling interests comprising total equity for the nine months ended September 30, 2013 and 2012 is provided below (in thousands): | |||||||||||||||||||||||||
Nine Months Ended September 30, | |||||||||||||||||||||||||
2013 | 2012 | ||||||||||||||||||||||||
Total | Non- | Total | Total | Non- | Total | ||||||||||||||||||||
Stockholders’ | controlling | Equity | Stockholders’ | controlling | Equity | ||||||||||||||||||||
Equity | Interests | Equity | Interests | ||||||||||||||||||||||
Equity, beginning of period | $ | 2,180,422 | $ | 2,282 | $ | 2,182,704 | $ | 2,229,234 | $ | 2,340 | $ | 2,231,574 | |||||||||||||
Exercise of common stock options, warrants and shares issued under employee stock purchase plan | 17,555 | — | 17,555 | 14,261 | — | 14,261 | |||||||||||||||||||
Issuance of common stock for settlement of an acquisition-related contingent consideration obligation | — | — | — | 1,243 | — | 1,243 | |||||||||||||||||||
Preferred stock dividends | (15,970 | ) | — | (15,970 | ) | (15,970 | ) | — | (15,970 | ) | |||||||||||||||
Stock-based compensation related to grants of common stock options | 14,462 | — | 14,462 | 11,868 | — | 11,868 | |||||||||||||||||||
Excess tax benefits on exercised stock options | (1,283 | ) | — | (1,283 | ) | (437 | ) | — | (437 | ) | |||||||||||||||
Non-controlling interest from acquisition | — | 1,788 | 1,788 | — | — | — | |||||||||||||||||||
Purchase of subsidiary shares from non-controlling interests | — | — | — | (35,079 | ) | — | (35,079 | ) | |||||||||||||||||
Dividend relating to non-controlling interest | — | — | — | — | (236 | ) | (236 | ) | |||||||||||||||||
Net income (loss) | (67,567 | ) | 601 | (66,966 | ) | (15,504 | ) | 200 | (15,304 | ) | |||||||||||||||
Total other comprehensive income (loss) | (42,149 | ) | — | (42,149 | ) | 39,675 | — | 39,675 | |||||||||||||||||
Equity, end of period | $ | 2,085,470 | $ | 4,671 | $ | 2,090,141 | $ | 2,229,291 | $ | 2,304 | $ | 2,231,595 |
Business_Combinations_Tables
Business Combinations (Tables) | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Business Combinations [Abstract] | ' | ||||||||||||||||
Preliminary Fair Values of Net Assets Acquired for Acquisitions | ' | ||||||||||||||||
A summary of the preliminary fair values of the net assets acquired for the acquisitions consummated in 2013 is as follows (in thousands): | |||||||||||||||||
Epocal | Other | Total | |||||||||||||||
Current assets(1) | $ | 12,089 | $ | 12,968 | $ | 25,057 | |||||||||||
Property, plant and equipment | 1,267 | 1,669 | 2,936 | ||||||||||||||
Goodwill | 99,449 | 1,629 | 101,078 | ||||||||||||||
Intangible assets | 164,400 | 42,920 | 207,320 | ||||||||||||||
Other non-current assets | 17,610 | 29 | 17,639 | ||||||||||||||
Total assets acquired | 294,815 | 59,215 | 354,030 | ||||||||||||||
Current liabilities | 2,627 | 5,398 | 8,025 | ||||||||||||||
Non-current liabilities | 43,727 | 6,202 | 49,929 | ||||||||||||||
Total liabilities assumed | 46,354 | 11,600 | 57,954 | ||||||||||||||
Net assets acquired | 248,461 | 47,615 | 296,076 | ||||||||||||||
Less: | |||||||||||||||||
Contingent consideration | 75,000 | 1,264 | 76,264 | ||||||||||||||
Non-controlling interest | — | 1,774 | 1,774 | ||||||||||||||
Bargain purchase gain | — | 8,023 | 8,023 | ||||||||||||||
Deferred purchase price consideration | — | 768 | 768 | ||||||||||||||
Cash paid | $ | 173,461 | $ | 35,786 | $ | 209,247 | |||||||||||
(1) | Includes approximately $3.3 million of acquired cash. | ||||||||||||||||
A summary of the preliminary fair values of the net assets acquired for the acquisitions consummated in 2012 is as follows (in thousands): | |||||||||||||||||
Current assets(1) | $ | 47,228 | |||||||||||||||
Property, plant and equipment | 9,029 | ||||||||||||||||
Goodwill | 240,576 | ||||||||||||||||
Intangible assets | 325,223 | ||||||||||||||||
Other non-current assets | 17,261 | ||||||||||||||||
Total assets acquired | 639,317 | ||||||||||||||||
Current liabilities | 28,214 | ||||||||||||||||
Non-current liabilities | 116,580 | ||||||||||||||||
Total liabilities assumed | 144,794 | ||||||||||||||||
Net assets acquired | 494,523 | ||||||||||||||||
Less: | |||||||||||||||||
Contingent consideration | 75,620 | ||||||||||||||||
Cash paid | $ | 418,903 | |||||||||||||||
(1) | Includes approximately $3.8 million of acquired cash. | ||||||||||||||||
Intangible Assets Acquired and Their Respective Fair Values and Weighted-Average Useful Lives | ' | ||||||||||||||||
The following are the intangible assets acquired and their respective fair values and weighted-average useful lives (dollars in thousands): | |||||||||||||||||
Epocal | Other | Total | Weighted- | ||||||||||||||
average | |||||||||||||||||
Useful Life | |||||||||||||||||
Core technology and patents | $ | 119,700 | $ | — | $ | 119,700 | 20.0 years | ||||||||||
Software | — | 804 | 804 | 10.0 years | |||||||||||||
Trademarks and trade names | 20,500 | 10 | 20,510 | 19.2 years | |||||||||||||
Customer relationships | — | 36,290 | 36,290 | 11.4 years | |||||||||||||
Other | — | 5,816 | 5,816 | 3.0 years | |||||||||||||
In-process research and development | 24,200 | — | 24,200 | N/A | |||||||||||||
Total intangible assets | $ | 164,400 | $ | 42,920 | $ | 207,320 | |||||||||||
The following are the intangible assets acquired and their respective fair values and weighted-average useful lives (dollars in thousands): | |||||||||||||||||
Amount | Weighted- | ||||||||||||||||
average | |||||||||||||||||
Useful Life | |||||||||||||||||
Core technology and patents | $ | 148,103 | 18.7 years | ||||||||||||||
Trademarks and trade names | 19,390 | 18.3 years | |||||||||||||||
Customer relationships | 136,485 | 18.1 years | |||||||||||||||
Non-competition agreements | 1,118 | 5.1 years | |||||||||||||||
Other | 15,227 | 9.2 years | |||||||||||||||
In-process research and development | 4,900 | N/A | |||||||||||||||
Total intangible assets | $ | 325,223 |
Restructuring_Plans_Tables
Restructuring Plans (Tables) | 9 Months Ended | ||||||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||||||
Restructuring And Related Activities [Abstract] | ' | ||||||||||||||||||||
Aggregate Charges Associated with Restructuring Plans Recorded in Operating Income | ' | ||||||||||||||||||||
The following table sets forth aggregate restructuring charges recorded in our consolidated statements of operations for the three and nine months ended September 30, 2013 and 2012 (in thousands): | |||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||
Statement of Operations Caption | 2013 | 2012 | 2013 | 2012 | |||||||||||||||||
Cost of net revenue | $ | 3,556 | $ | 1,080 | $ | 4,908 | $ | 2,069 | |||||||||||||
Research and development | 1,100 | — | 1,745 | 638 | |||||||||||||||||
Sales and marketing | 218 | 927 | 1,476 | 1,954 | |||||||||||||||||
General and administrative | 2,820 | 1,232 | 11,501 | 5,471 | |||||||||||||||||
Total operating expenses | 7,694 | 3,239 | 19,630 | 10,132 | |||||||||||||||||
Interest expense, including amortization of original issue discounts and deferred financing costs | 111 | 48 | 228 | 158 | |||||||||||||||||
Total charges | $ | 7,805 | $ | 3,287 | $ | 19,858 | $ | 10,290 | |||||||||||||
Restructuring Activities Related to Restructuring Plans | ' | ||||||||||||||||||||
The following table summarizes the restructuring activities related to our 2013 restructuring plans for the three and nine months ended September 30, 2013 (in thousands): | |||||||||||||||||||||
Three Months Ended September 30, 2013 | |||||||||||||||||||||
Professional | Health | Total | |||||||||||||||||||
Diagnostics | Information | ||||||||||||||||||||
Solutions | |||||||||||||||||||||
Severance-related costs | $ | 3,876 | $ | 1,340 | $ | 5,216 | |||||||||||||||
Facility and transition costs | 1,107 | 327 | 1,434 | ||||||||||||||||||
Other exit costs | — | 2 | 2 | ||||||||||||||||||
Cash charges | 4,983 | 1,669 | 6,652 | ||||||||||||||||||
Fixed asset and inventory impairments | 470 | — | 470 | ||||||||||||||||||
Other non-cash charges | — | (20 | ) | (20 | ) | ||||||||||||||||
Total charges | $ | 5,453 | $ | 1,649 | $ | 7,102 | |||||||||||||||
Nine Months Ended September 30, 2013 | |||||||||||||||||||||
Professional | Health | Total | |||||||||||||||||||
Diagnostics | Information | ||||||||||||||||||||
Solutions | |||||||||||||||||||||
Severance-related costs | $ | 5,960 | $ | 1,398 | $ | 7,358 | |||||||||||||||
Facility and transition costs | 1,457 | 568 | 2,025 | ||||||||||||||||||
Other exit costs | — | 2 | 2 | ||||||||||||||||||
Cash charges | 7,417 | 1,968 | 9,385 | ||||||||||||||||||
Fixed asset and inventory impairments | 470 | 170 | 640 | ||||||||||||||||||
Intangible asset impairments | — | 2,596 | 2,596 | ||||||||||||||||||
Other non-cash charges | — | (20 | ) | (20 | ) | ||||||||||||||||
Total charges | $ | 7,887 | $ | 4,714 | $ | 12,601 | |||||||||||||||
The following table summarizes the restructuring activities related to our 2012 restructuring plans for the three and nine months ended September 30, 2013 and 2012 and since inception (in thousands): | |||||||||||||||||||||
Three Months Ended | Nine Months Ended | Since | |||||||||||||||||||
September 30, | September 30, | Inception | |||||||||||||||||||
Professional Diagnostics | 2013 | 2012 | 2013 | 2012 | |||||||||||||||||
Severance-related costs(1) | $ | (614 | ) | $ | 691 | $ | (526 | ) | $ | 3,009 | $ | 4,206 | |||||||||
Facility and transition costs | — | — | 82 | — | 201 | ||||||||||||||||
Cash charges | (614 | ) | 691 | (444 | ) | 3,009 | 4,407 | ||||||||||||||
Fixed asset impairments | — | 55 | — | 55 | 304 | ||||||||||||||||
Total charges | $ | (614 | ) | $ | 746 | $ | (444 | ) | $ | 3,064 | $ | 4,711 | |||||||||
-1 | Severance-related costs for the three and nine months ended September 30, 2013 includes the reversal of an amount previously accrued which relates to a settlement resulting from a labor dispute. | ||||||||||||||||||||
Three Months Ended | Nine Months Ended | Since | |||||||||||||||||||
September 30, | September 30, | Inception | |||||||||||||||||||
Health Information Solutions | 2013 | 2012 | 2013 | 2012 | |||||||||||||||||
Severance-related costs | $ | 14 | $ | 516 | $ | 2,362 | $ | 1,735 | $ | 5,407 | |||||||||||
Facility and transition costs | — | 465 | 4,271 | 590 | 5,505 | ||||||||||||||||
Other exit costs | 82 | 5 | 134 | 5 | 149 | ||||||||||||||||
Cash charges | 96 | 986 | 6,767 | 2,330 | 11,061 | ||||||||||||||||
Fixed asset and inventory impairments | — | — | 75 | — | 2,764 | ||||||||||||||||
Intangible asset impairments | — | — | — | — | 2,988 | ||||||||||||||||
Other non-cash charges | — | — | (953 | ) | — | (984 | ) | ||||||||||||||
Total charges | $ | 96 | $ | 986 | $ | 5,889 | $ | 2,330 | $ | 15,829 | |||||||||||
The following table summarizes the restructuring activities related to our 2011, 2010 and 2008 restructuring plans for the three and nine months ended September 30, 2013 and 2012 and since inception (in thousands): | |||||||||||||||||||||
Three Months Ended | Nine Months Ended | Since | |||||||||||||||||||
September 30, | September 30, | Inception | |||||||||||||||||||
Professional Diagnostics | 2013 | 2012 | 2013 | 2012 | |||||||||||||||||
Severance-related costs | $ | 46 | $ | 639 | $ | 242 | $ | 2,914 | $ | 19,955 | |||||||||||
Facility and transition costs | 112 | 464 | 442 | 1,348 | 7,669 | ||||||||||||||||
Other exit costs | 14 | 16 | 45 | 52 | 743 | ||||||||||||||||
Cash charges | 172 | 1,119 | 729 | 4,314 | 28,367 | ||||||||||||||||
Fixed asset and inventory impairments | 350 | 290 | 350 | 424 | 6,724 | ||||||||||||||||
Intangible asset impairments | 686 | — | 686 | — | 686 | ||||||||||||||||
Total charges | $ | 1,208 | $ | 1,409 | $ | 1,765 | $ | 4,738 | $ | 35,777 | |||||||||||
Three Months Ended | Nine Months Ended | Since | |||||||||||||||||||
September 30, | September 30, | Inception | |||||||||||||||||||
Health Information Solutions | 2013 | 2012 | 2013 | 2012 | |||||||||||||||||
Severance-related costs | $ | — | $ | — | $ | — | $ | — | $ | 6,901 | |||||||||||
Facility and transition costs | — | 114 | — | (59 | ) | 8,010 | |||||||||||||||
Other exit costs | 13 | 27 | 47 | 101 | 559 | ||||||||||||||||
Cash charges | 13 | 141 | 47 | 42 | 15,470 | ||||||||||||||||
Fixed asset and inventory impairments | — | — | — | 85 | 1,114 | ||||||||||||||||
Intangible asset impairments | — | — | — | — | 2,935 | ||||||||||||||||
Other non-cash charges | — | — | — | — | 761 | ||||||||||||||||
Total charges | $ | 13 | $ | 141 | $ | 47 | $ | 127 | $ | 20,280 | |||||||||||
Three Months Ended | Nine Months Ended | Since | |||||||||||||||||||
September 30, | September 30, | Inception | |||||||||||||||||||
Corporate and Other | 2013 | 2012 | 2013 | 2012 | |||||||||||||||||
Severance-related costs | $ | — | $ | 5 | $ | — | $ | 31 | $ | 1,219 | |||||||||||
Cash charges | — | 5 | — | 31 | 1,219 | ||||||||||||||||
Fixed asset and inventory impairments | — | — | — | — | 3 | ||||||||||||||||
Total charges | $ | — | $ | 5 | $ | — | $ | 31 | $ | 1,222 | |||||||||||
Cash Activity for Restructuring Reserves | ' | ||||||||||||||||||||
The following table summarizes our restructuring reserves related to the plans described above, of which $8.7 million is included in accrued expenses and other current liabilities and $2.0 million is included in other long-term liabilities on our accompanying consolidated balance sheets (in thousands): | |||||||||||||||||||||
Severance- | Facility and | Other Exit | Total | ||||||||||||||||||
related | Transition | Costs | |||||||||||||||||||
Costs | Costs | ||||||||||||||||||||
Balance, December 31, 2012 | $ | 3,167 | $ | 2,429 | $ | 622 | $ | 6,218 | |||||||||||||
Cash charges | 9,436 | 6,820 | 228 | 16,484 | |||||||||||||||||
Payments | (7,515 | ) | (4,149 | ) | (227 | ) | (11,891 | ) | |||||||||||||
Currency adjustments | (72 | ) | 5 | — | (67 | ) | |||||||||||||||
Balance, September 30, 2013 | $ | 5,016 | $ | 5,105 | $ | 623 | $ | 10,744 |
LongTerm_Debt_Tables
Long-Term Debt (Tables) | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Debt Disclosure [Abstract] | ' | ||||||||||||||||
Long-Term Debt Balances Outstanding | ' | ||||||||||||||||
We had the following long-term debt balances outstanding (in thousands): | |||||||||||||||||
September 30, 2013 | December 31, 2012 | ||||||||||||||||
A term loans(1)(2) | $ | 843,750 | $ | 878,438 | |||||||||||||
B term loans(1) | 906,500 | 913,438 | |||||||||||||||
Incremental B-1 term loans(1) | 245,625 | 247,500 | |||||||||||||||
Incremental B-2 term loans(1) | 195,470 | 196,739 | |||||||||||||||
Revolving line of credit(1) | 170,000 | 22,500 | |||||||||||||||
7.25% Senior notes | 450,000 | 450,000 | |||||||||||||||
7.875% Senior notes | — | 1,809 | |||||||||||||||
9% Senior subordinated notes | — | 392,933 | |||||||||||||||
8.625% Senior subordinated notes | 400,000 | 400,000 | |||||||||||||||
6.5% Senior subordinated notes | 425,000 | — | |||||||||||||||
3% Convertible senior subordinated notes | 150,000 | 150,000 | |||||||||||||||
Other lines of credit | 150 | 31,957 | |||||||||||||||
Other | 51,738 | 3,593 | |||||||||||||||
3,838,233 | 3,688,907 | ||||||||||||||||
Less: Current portion | (47,701 | ) | (60,232 | ) | |||||||||||||
$ | 3,790,532 | $ | 3,628,675 | ||||||||||||||
(1) | Incurred under our secured credit facility. | ||||||||||||||||
(2) | Includes “A” term loans and “Delayed Draw” term loans under our secured credit facility. | ||||||||||||||||
Long-Term Debt Interest Expense | ' | ||||||||||||||||
In connection with our significant long-term debt issuances, we recorded interest expense, including amortization and write-offs of deferred financing costs and original issue discounts, in our accompanying consolidated statements of operations for the three and nine months ended September 30, 2013 and 2012, respectively, as follows (in thousands): | |||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||
Secured credit facility (1) | $ | 25,809 | $ | 27,474 | $ | 78,741 | $ | 77,422 | |||||||||
7.25% Senior notes | 8,535 | — | 25,371 | — | |||||||||||||
7.875% Senior notes (2) | — | 5,763 | 137 | 17,276 | |||||||||||||
9% Senior subordinated notes (3) | — | 10,373 | 54,043 | 31,090 | |||||||||||||
8.625% Senior subordinated notes | 9,273 | 9,274 | 27,820 | 27,823 | |||||||||||||
6.5% Senior subordinated notes | 7,172 | — | 10,185 | — | |||||||||||||
3% Senior subordinated convertible notes | 1,246 | 1,246 | 3,738 | 3,738 | |||||||||||||
$ | 52,035 | $ | 54,130 | $ | 200,035 | $ | 157,349 | ||||||||||
(1) | Includes “A” term loans, including the “Delayed-Draw” term loans; “B” term loans; “Incremental B-1” term loans; “Incremental B-2” term loans; and revolving line of credit loans. For the three and nine months ended September 30, 2013, the amounts include $0.4 million and $2.2 million, respectively, related to the amortization of fees paid for certain debt modifications. For the three and nine months ended September 30, 2012, the amount includes $1.3 million and $4.0 million, respectively, related to the amortization of fees paid for certain debt modifications. | ||||||||||||||||
(2) | For the nine months ended September 30, 2013, this amount includes an approximate $0.2 million loss recorded in connection with the repurchase of our 7.875% senior notes. | ||||||||||||||||
(3) | An approximate $35.6 million loss in connection with the repurchase of our 9% senior subordinated notes has been included in the nine-month period ended September 30, 2013. Included in the $35.6 million is $19.0 million related to tender offer consideration and call premium which has been classified within cash flow from financing activities in our consolidated statement of cash flows. |
Derivative_Financial_Instrumen1
Derivative Financial Instruments (Tables) | 9 Months Ended | ||||||||||
Sep. 30, 2013 | |||||||||||
Derivative Instruments And Hedging Activities Disclosure [Abstract] | ' | ||||||||||
Summary of Effect of Derivative Instruments in Consolidated Statement of Operations and in Accumulated Other Comprehensive Loss | ' | ||||||||||
The following table summarizes the effect of derivative instruments in our accompanying consolidated statement of operations (in thousands): | |||||||||||
Derivative Instruments | Location of Gain | Amount of Gain | Amount of Gain | ||||||||
Recognized in Income | Recognized | Recognized | |||||||||
During the Three | During the Nine | ||||||||||
Months Ended | Months Ended | ||||||||||
September 30, | September 30, | ||||||||||
2012 | 2012 | ||||||||||
Foreign currency forward contracts | Other comprehensive income (loss) | $ | 10 | $ | 465 | ||||||
Total gain | Other comprehensive income (loss) | $ | 10 | $ | 465 | ||||||
Fair_Value_Measurements_Tables
Fair Value Measurements (Tables) | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Fair Value Disclosures [Abstract] | ' | ||||||||||||||||
Fair Value Assets and Liabilities Measured on Recurring Basis, Valuation Techniques | ' | ||||||||||||||||
The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2013 and December 31, 2012, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands): | |||||||||||||||||
Description | September 30, 2013 | Quoted Prices in | Significant Other | Unobservable Inputs | |||||||||||||
Active Markets | Observable Inputs | (Level 3) | |||||||||||||||
(Level 1) | (Level 2) | ||||||||||||||||
Assets: | |||||||||||||||||
Marketable securities | $ | 820 | $ | 820 | $ | — | $ | — | |||||||||
Total assets | $ | 820 | $ | 820 | $ | — | $ | — | |||||||||
Liabilities: | |||||||||||||||||
Contingent consideration obligations (1) | $ | 234,559 | $ | — | $ | — | $ | 234,559 | |||||||||
Total liabilities | $ | 234,559 | $ | — | $ | — | $ | 234,559 | |||||||||
Description | December 31, 2012 | Quoted Prices in | Significant Other | Unobservable Inputs | |||||||||||||
Active Markets | Observable Inputs | (Level 3) | |||||||||||||||
(Level 1) | (Level 2) | ||||||||||||||||
Assets: | |||||||||||||||||
Marketable securities | $ | 904 | $ | 904 | $ | — | $ | — | |||||||||
Total assets | $ | 904 | $ | 904 | $ | — | $ | — | |||||||||
Liabilities: | |||||||||||||||||
Contingent consideration obligations (1) | $ | 176,172 | $ | — | $ | — | $ | 176,172 | |||||||||
Total liabilities | $ | 176,172 | $ | — | $ | — | $ | 176,172 | |||||||||
(1) | We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out criteria estimates and a probability assessment with respect to the likelihood of achieving the various earn-out criteria. The measurement is based upon significant inputs not observable in the market. Significant increases or decreases in any of these inputs could result in a significantly higher or lower fair value measurement. Changes in the fair value of these contingent consideration obligations are recorded as income or expense within operating income in our consolidated statements of operations. | ||||||||||||||||
Changes in Fair Value of Contingent Consideration Obligations | ' | ||||||||||||||||
Changes in the fair value of our Level 3 contingent consideration obligations during the nine months ended September 30, 2013 were as follows (in thousands): | |||||||||||||||||
Fair value of contingent consideration obligations, January 1, 2013 | $ | 176,172 | |||||||||||||||
Acquisition date fair value of contingent consideration obligations recorded | 76,269 | ||||||||||||||||
Net reclassifications | (12 | ) | |||||||||||||||
Foreign currency | (150 | ) | |||||||||||||||
Payments | (36,703 | ) | |||||||||||||||
Present value accretion | 7,359 | ||||||||||||||||
Adjustments, net (income) expense | 11,624 | ||||||||||||||||
Fair value of contingent consideration obligations, September 30, 2013 | $ | 234,559 | |||||||||||||||
Defined_Benefit_Pension_Plan_T
Defined Benefit Pension Plan (Tables) | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Compensation And Retirement Disclosure [Abstract] | ' | ||||||||||||||||
Net Periodic Benefit Costs | ' | ||||||||||||||||
The net periodic benefit costs are as follows (in thousands): | |||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||
Service cost | $ | — | $ | — | $ | — | $ | — | |||||||||
Interest cost | 182 | 199 | 543 | 596 | |||||||||||||
Expected return on plan assets | (156 | ) | (152 | ) | (465 | ) | (457 | ) | |||||||||
Amortization of prior service costs | 103 | 104 | 308 | 312 | |||||||||||||
Net periodic benefit cost | $ | 129 | $ | 151 | $ | 386 | $ | 451 | |||||||||
Financial_Information_by_Segme1
Financial Information by Segment (Tables) | 9 Months Ended | ||||||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||||||
Segment Reporting [Abstract] | ' | ||||||||||||||||||||
Performance of Our Operating Segments Based on Revenue and Operating Income (Loss) | ' | ||||||||||||||||||||
We evaluate performance of our operating segments based on revenue and operating income (loss). Segment information for the three and nine months ended September 30, 2013 and 2012 is as follows (in thousands): | |||||||||||||||||||||
Professional | Health | Consumer | Corporate | Total | |||||||||||||||||
Diagnostics | Information | Diagnostics | and | ||||||||||||||||||
Solutions | Other | ||||||||||||||||||||
Three Months Ended September 30, 2013: | |||||||||||||||||||||
Net revenue | $ | 590,801 | $ | 134,233 | $ | 28,848 | $ | — | $ | 753,882 | |||||||||||
Operating income (loss) | $ | 53,189 | $ | (7,203 | ) | $ | 3,347 | $ | (29,034 | ) | $ | 20,299 | |||||||||
Depreciation and amortization | $ | 88,835 | $ | 22,600 | $ | 1,063 | $ | 287 | $ | 112,785 | |||||||||||
Non-cash charge associated with acquired inventory | $ | 708 | $ | — | $ | — | $ | — | $ | 708 | |||||||||||
Restructuring charge | $ | 6,033 | $ | 1,661 | $ | — | $ | — | $ | 7,694 | |||||||||||
Stock-based compensation | $ | — | $ | — | $ | — | $ | 5,662 | $ | 5,662 | |||||||||||
Loss on disposition | $ | 5,885 | $ | — | $ | — | $ | — | $ | 5,885 | |||||||||||
Three Months Ended September 30, 2012: | |||||||||||||||||||||
Net revenue | $ | 531,442 | $ | 135,078 | $ | 24,896 | $ | — | $ | 691,416 | |||||||||||
Professional | Health | Consumer | Corporate | Total | |||||||||||||||||
Diagnostics | Information | Diagnostics | and | ||||||||||||||||||
Solutions | Other | ||||||||||||||||||||
Operating income (loss) | $ | 63,298 | $ | (14,357 | ) | $ | 4,615 | $ | (14,824 | ) | $ | 38,732 | |||||||||
Depreciation and amortization | $ | 85,030 | $ | 24,313 | $ | 1,167 | $ | 239 | $ | 110,749 | |||||||||||
Restructuring charge | $ | 2,139 | $ | 1,095 | $ | — | $ | 5 | $ | 3,239 | |||||||||||
Stock-based compensation | $ | — | $ | — | $ | — | $ | 3,626 | $ | 3,626 | |||||||||||
Nine Months Ended September 30, 2013: | |||||||||||||||||||||
Net revenue | $ | 1,777,055 | $ | 403,215 | $ | 76,846 | $ | — | $ | 2,257,116 | |||||||||||
Operating income (loss) | $ | 185,925 | $ | (32,855 | ) | $ | 9,031 | $ | (66,909 | ) | $ | 95,192 | |||||||||
Depreciation and amortization | $ | 258,485 | $ | 64,062 | $ | 3,296 | $ | 846 | $ | 326,689 | |||||||||||
Non-cash charge associated with acquired inventory | $ | 1,880 | $ | — | $ | — | $ | — | $ | 1,880 | |||||||||||
Restructuring charge | $ | 9,162 | $ | 10,468 | $ | — | $ | — | $ | 19,630 | |||||||||||
Stock-based compensation | $ | — | $ | — | $ | — | $ | 14,462 | $ | 14,462 | |||||||||||
Loss on disposition | $ | 5,885 | $ | — | $ | — | $ | — | $ | 5,885 | |||||||||||
Nine Months Ended September 30, 2012: | |||||||||||||||||||||
Net revenue | $ | 1,589,909 | $ | 404,452 | $ | 68,701 | $ | — | $ | 2,063,062 | |||||||||||
Operating income (loss) | $ | 196,728 | $ | (46,379 | ) | $ | 7,679 | $ | (49,884 | ) | $ | 108,144 | |||||||||
Depreciation and amortization | $ | 245,911 | $ | 72,152 | $ | 3,604 | $ | 704 | $ | 322,371 | |||||||||||
Non-cash charge associated with acquired inventory | $ | 4,681 | $ | — | $ | — | $ | — | $ | 4,681 | |||||||||||
Restructuring charge | $ | 7,750 | $ | 2,351 | $ | — | $ | 31 | $ | 10,132 | |||||||||||
Stock-based compensation | $ | — | $ | — | $ | — | $ | 11,868 | $ | 11,868 | |||||||||||
Assets: | |||||||||||||||||||||
As of September 30, 2013 | $ | 6,243,064 | $ | 555,563 | $ | 213,764 | $ | 142,228 | $ | 7,154,619 | |||||||||||
As of December 31, 2012 | $ | 6,214,847 | $ | 593,172 | $ | 192,748 | $ | 67,161 | $ | 7,067,928 | |||||||||||
Summary of Company's Net Revenue from Professional Diagnostics and Health Information Solutions Reporting Segments by Groups of Similar Products and Services | ' | ||||||||||||||||||||
The following tables summarize our net revenue from the professional diagnostics and health information solutions reporting segments by groups of similar products and services for the three and nine months ended September 30, 2013 and 2012 (in thousands): | |||||||||||||||||||||
Professional Diagnostics Segment: | Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||||||
Cardiology | $ | 116,281 | $ | 122,372 | $ | 349,650 | $ | 386,795 | |||||||||||||
Infectious disease | 172,739 | 136,561 | 520,289 | 425,398 | |||||||||||||||||
Toxicology | 166,536 | 156,074 | 481,469 | 437,736 | |||||||||||||||||
Diabetes | 53,150 | 35,670 | 178,138 | 100,628 | |||||||||||||||||
Other | 78,607 | 78,077 | 235,992 | 230,519 | |||||||||||||||||
Net product sales and services revenue | 587,313 | 528,754 | 1,765,538 | 1,581,076 | |||||||||||||||||
License and royalty revenue | 3,488 | 2,688 | 11,517 | 8,833 | |||||||||||||||||
Professional diagnostics net revenue | $ | 590,801 | $ | 531,442 | $ | 1,777,055 | $ | 1,589,909 | |||||||||||||
Health Information Solutions Segment: | Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||||||
Disease and case management | $ | 56,554 | $ | 57,383 | $ | 163,258 | $ | 165,277 | |||||||||||||
Wellness | 22,223 | 24,290 | 75,753 | 80,881 | |||||||||||||||||
Women’s & children’s health | 28,431 | 29,136 | 86,767 | 90,220 | |||||||||||||||||
Patient self-testing services | 27,025 | 24,269 | 77,437 | 68,074 | |||||||||||||||||
Health information solutions net revenue | $ | 134,233 | $ | 135,078 | $ | 403,215 | $ | 404,452 |
Related_Party_Transactions_Tab
Related Party Transactions (Tables) | 9 Months Ended | ||||||||
Sep. 30, 2013 | |||||||||
Related Party Transactions [Abstract] | ' | ||||||||
Related Party Balances with SPD within Consolidated Balance Sheets | ' | ||||||||
The following table summarizes our related party balances with SPD within our consolidated balance sheets (in thousands): | |||||||||
Balance Sheet Caption: | September 30, 2013 | December 31, 2012 | |||||||
Accounts receivable, net of allowances | $ | 9,984 | $ | 7,317 | |||||
Prepaid expenses and other current assets | $ | 13,221 | $ | 9,161 | |||||
Deferred financing costs, net, and other non-current assets | $ | 12,955 | $ | 14,629 | |||||
Accounts payable | $ | 25,437 | $ | 21,258 |
Equity_Investments_Tables
Equity Investments (Tables) | 9 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Equity Method Investments And Joint Ventures [Abstract] | ' | ||||||||||||||||
Financial Information for SPD and Techlab on Combined Condensed Results of Operations | ' | ||||||||||||||||
Summarized financial information for SPD and TechLab on a combined basis is as follows (in thousands): | |||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||
Combined Condensed Results of Operations: | 2013 | 2012 | 2013 | 2012 | |||||||||||||
Net revenue | $ | 49,272 | $ | 54,650 | $ | 153,096 | $ | 165,483 | |||||||||
Gross profit | $ | 40,158 | $ | 34,411 | $ | 112,862 | $ | 105,175 | |||||||||
Net income after taxes | $ | 10,543 | $ | 5,399 | $ | 25,549 | $ | 20,083 | |||||||||
Financial Information for SPD and Techlab on Combined Condensed Balance Sheets | ' | ||||||||||||||||
Combined Condensed Balance Sheet: | September 30, 2013 | December 31, 2012 | |||||||||||||||
Current assets | $ | 95,764 | $ | 79,842 | |||||||||||||
Non-current assets | 37,909 | 38,991 | |||||||||||||||
Total assets | $ | 133,673 | $ | 118,833 | |||||||||||||
Current liabilities | $ | 39,468 | $ | 45,084 | |||||||||||||
Non-current liabilities | 6,268 | 6,791 | |||||||||||||||
Total liabilities | $ | 45,736 | $ | 51,875 | |||||||||||||
Guarantor_Financial_Informatio1
Guarantor Financial Information (Tables) | 9 Months Ended | ||||||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||||||
Text Block [Abstract] | ' | ||||||||||||||||||||
Guarantor Financial Information Consolidating Statement of Operations | ' | ||||||||||||||||||||
CONSOLIDATING STATEMENT OF OPERATIONS | |||||||||||||||||||||
For the Three Months Ended September 30, 2013 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
Net product sales | $ | — | $ | 223,254 | $ | 330,389 | $ | (44,605 | ) | $ | 509,038 | ||||||||||
Services revenue | — | 220,439 | 20,221 | — | 240,660 | ||||||||||||||||
Net product sales and services revenue | — | 443,693 | 350,610 | (44,605 | ) | 749,698 | |||||||||||||||
License and royalty revenue | — | 5,103 | 4,057 | (4,976 | ) | 4,184 | |||||||||||||||
Net revenue | — | 448,796 | 354,667 | (49,581 | ) | 753,882 | |||||||||||||||
Cost of net product sales | 887 | 129,408 | 165,396 | (37,457 | ) | 258,234 | |||||||||||||||
Cost of services revenue | — | 120,032 | 10,292 | (5,331 | ) | 124,993 | |||||||||||||||
Cost of net product sales and services revenue | 887 | 249,440 | 175,688 | (42,788 | ) | 383,227 | |||||||||||||||
Cost of license and royalty revenue | — | 17 | 6,967 | (4,975 | ) | 2,009 | |||||||||||||||
Cost of net revenue | 887 | 249,457 | 182,655 | (47,763 | ) | 385,236 | |||||||||||||||
Gross profit (loss) | (887 | ) | 199,339 | 172,012 | (1,818 | ) | 368,646 | ||||||||||||||
Operating expenses: | |||||||||||||||||||||
Research and development | 5,515 | 15,817 | 19,166 | — | 40,498 | ||||||||||||||||
Sales and marketing | 1,579 | 81,107 | 76,901 | — | 159,587 | ||||||||||||||||
General and administrative | 23,027 | 61,489 | 57,861 | — | 142,377 | ||||||||||||||||
Loss on disposition | — | — | 5,885 | — | 5,885 | ||||||||||||||||
Operating income (loss) | (31,008 | ) | 40,926 | 12,199 | (1,818 | ) | 20,299 | ||||||||||||||
Interest expense, including amortization of original issue discounts and deferred financing costs | (52,318 | ) | (6,326 | ) | (2,721 | ) | 7,945 | (53,420 | ) | ||||||||||||
Other income (expense), net | (6,775 | ) | 5,770 | 81 | (7,945 | ) | (8,869 | ) | |||||||||||||
Income (loss) before provision (benefit) for income taxes | (90,101 | ) | 40,370 | 9,559 | (1,818 | ) | (41,990 | ) | |||||||||||||
Provision (benefit) for income taxes | (29,302 | ) | 14,928 | (2,214 | ) | (560 | ) | (17,148 | ) | ||||||||||||
Income (loss) before equity earnings (losses) of subsidiaries and unconsolidated entities, net of tax | (60,799 | ) | 25,442 | 11,773 | (1,258 | ) | (24,842 | ) | |||||||||||||
Equity earnings (losses) of subsidiaries, net of tax | 41,246 | (337 | ) | — | (40,909 | ) | — | ||||||||||||||
Equity earnings of unconsolidated entities, net of tax | 464 | — | 5,217 | 72 | 5,753 | ||||||||||||||||
Net income (loss) | (19,089 | ) | 25,105 | 16,990 | (42,095 | ) | (19,089 | ) | |||||||||||||
Less: Net income attributable to non-controlling interests | — | — | 359 | — | 359 | ||||||||||||||||
Net income (loss) attributable to Alere Inc. and Subsidiaries | (19,089 | ) | 25,105 | 16,631 | (42,095 | ) | (19,448 | ) | |||||||||||||
Preferred stock dividends | (5,367 | ) | — | — | — | (5,367 | ) | ||||||||||||||
Net income (loss) available to common stockholders | $ | (24,456 | ) | $ | 25,105 | $ | 16,631 | $ | (42,095 | ) | $ | (24,815 | ) | ||||||||
CONSOLIDATING STATEMENT OF OPERATIONS | |||||||||||||||||||||
For the Three Months Ended September 30, 2012 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
Net product sales | $ | — | $ | 219,484 | $ | 282,369 | $ | (42,040 | ) | $ | 459,813 | ||||||||||
Services revenue | — | 210,761 | 15,654 | — | 226,415 | ||||||||||||||||
Net product sales and services revenue | — | 430,245 | 298,023 | (42,040 | ) | 686,228 | |||||||||||||||
License and royalty revenue | — | (4,912 | ) | 4,868 | 5,232 | 5,188 | |||||||||||||||
Net revenue | — | 425,333 | 302,891 | (36,808 | ) | 691,416 | |||||||||||||||
Cost of net product sales | 928 | 107,410 | 152,607 | (37,333 | ) | 223,612 | |||||||||||||||
Cost of services revenue | — | 115,212 | 7,161 | (2,242 | ) | 120,131 | |||||||||||||||
Cost of net product sales and services revenue | 928 | 222,622 | 159,768 | (39,575 | ) | 343,743 | |||||||||||||||
Cost of license and royalty revenue | — | 5 | (3,339 | ) | 5,232 | 1,898 | |||||||||||||||
Cost of net revenue | 928 | 222,627 | 156,429 | (34,343 | ) | 345,641 | |||||||||||||||
Gross profit (loss) | (928 | ) | 202,706 | 146,462 | (2,465 | ) | 345,775 | ||||||||||||||
Operating expenses: | |||||||||||||||||||||
Research and development | 6,292 | 18,007 | 16,263 | — | 40,562 | ||||||||||||||||
Sales and marketing | 1,220 | 85,866 | 73,558 | — | 160,644 | ||||||||||||||||
General and administrative | 11,392 | 48,704 | 45,741 | — | 105,837 | ||||||||||||||||
Total operating expenses | 18,904 | 152,577 | 135,562 | — | 307,043 | ||||||||||||||||
Operating income (loss) | (19,832 | ) | 50,129 | 10,900 | (2,465 | ) | 38,732 | ||||||||||||||
Interest expense, including amortization of original issue discounts and deferred financing costs | (54,324 | ) | (9,278 | ) | (2,783 | ) | 11,524 | (54,861 | ) | ||||||||||||
Other income (expense), net | 1,534 | 8,319 | 599 | (11,524 | ) | (1,072 | ) | ||||||||||||||
Income (loss) before provision (benefit) for income taxes | (72,622 | ) | 49,170 | 8,716 | (2,465 | ) | (17,201 | ) | |||||||||||||
Provision (benefit) for income taxes | (27,401 | ) | 17,014 | 643 | (933 | ) | (10,677 | ) | |||||||||||||
Income (loss) before equity earnings (losses) of subsidiaries and unconsolidated entities, net of tax | (45,221 | ) | 32,156 | 8,073 | (1,532 | ) | (6,524 | ) | |||||||||||||
Equity earnings (losses) of subsidiaries, net of tax | 41,052 | (230 | ) | — | (40,822 | ) | — | ||||||||||||||
Equity earnings of unconsolidated entities, net of tax | 652 | — | 2,405 | (50 | ) | 3,007 | |||||||||||||||
Net income (loss) | (3,517 | ) | 31,926 | 10,478 | (42,404 | ) | (3,517 | ) | |||||||||||||
Less: Net income attributable to non-controlling interests | — | — | 286 | — | 286 | ||||||||||||||||
Net income (loss) attributable to Alere Inc. and Subsidiaries | (3,517 | ) | 31,926 | 10,192 | (42,404 | ) | (3,803 | ) | |||||||||||||
Preferred stock dividends | (5,352 | ) | — | — | — | (5,352 | ) | ||||||||||||||
Net income (loss) available to common stockholders | $ | (8,869 | ) | $ | 31,926 | $ | 10,192 | $ | (42,404 | ) | $ | (9,155 | ) | ||||||||
CONSOLIDATING STATEMENT OF OPERATIONS | |||||||||||||||||||||
For the Nine Months Ended September 30, 2013 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
Net product sales | $ | — | $ | 665,672 | $ | 1,016,614 | $ | (143,410 | ) | $ | 1,538,876 | ||||||||||
Services revenue | — | 644,760 | 60,367 | — | 705,127 | ||||||||||||||||
Net product sales and services revenue | — | 1,310,432 | 1,076,981 | (143,410 | ) | 2,244,003 | |||||||||||||||
License and royalty revenue | — | 10,908 | 12,662 | (10,457 | ) | 13,113 | |||||||||||||||
Net revenue | — | 1,321,340 | 1,089,643 | (153,867 | ) | 2,257,116 | |||||||||||||||
Cost of net product sales | 2,722 | 367,552 | 519,559 | (125,332 | ) | 764,501 | |||||||||||||||
Cost of services revenue | — | 355,930 | 28,511 | (14,480 | ) | 369,961 | |||||||||||||||
Cost of net product sales and services revenue | 2,722 | 723,482 | 548,070 | (139,812 | ) | 1,134,462 | |||||||||||||||
Cost of license and royalty revenue | — | 52 | 15,668 | (10,456 | ) | 5,264 | |||||||||||||||
Cost of net revenue | 2,722 | 723,534 | 563,738 | (150,268 | ) | 1,139,726 | |||||||||||||||
Gross profit (loss) | (2,722 | ) | 597,806 | 525,905 | (3,599 | ) | 1,117,390 | ||||||||||||||
Operating expenses: | |||||||||||||||||||||
Research and development | 16,167 | 49,354 | 56,931 | — | 122,452 | ||||||||||||||||
Sales and marketing | 4,384 | 245,148 | 225,933 | — | 475,465 | ||||||||||||||||
General and administrative | 51,531 | 200,646 | 166,219 | — | 418,396 | ||||||||||||||||
Loss on disposition | — | — | 5,885 | — | 5,885 | ||||||||||||||||
Operating income (loss) | (74,804 | ) | 102,658 | 70,937 | (3,599 | ) | 95,192 | ||||||||||||||
Interest expense, including amortization of original issue discounts and deferred financing costs | (200,836 | ) | (19,729 | ) | (9,209 | ) | 26,502 | (203,272 | ) | ||||||||||||
Other income (expense), net | (7,612 | ) | 17,665 | 8,173 | (26,502 | ) | (8,276 | ) | |||||||||||||
Income (loss) before provision (benefit) for income taxes | (283,252 | ) | 100,594 | 69,901 | (3,599 | ) | (116,356 | ) | |||||||||||||
Provision (benefit) for income taxes | (102,473 | ) | 44,896 | 22,663 | (1,238 | ) | (36,152 | ) | |||||||||||||
Income (loss) before equity earnings (losses) of subsidiaries and unconsolidated entities, net of tax | (180,779 | ) | 55,698 | 47,238 | (2,361 | ) | (80,204 | ) | |||||||||||||
Equity earnings (losses) of subsidiaries, net of tax | 112,535 | (1,510 | ) | — | (111,025 | ) | — | ||||||||||||||
Equity earnings of unconsolidated entities, net of tax | 1,278 | — | 11,932 | 28 | 13,238 | ||||||||||||||||
Net income (loss) | (66,966 | ) | 54,188 | 59,170 | (113,358 | ) | (66,966 | ) | |||||||||||||
Less: Net income attributable to non-controlling interests | — | — | 601 | — | 601 | ||||||||||||||||
Net income (loss) attributable to Alere Inc. and Subsidiaries | (66,966 | ) | 54,188 | 58,569 | (113,358 | ) | (67,567 | ) | |||||||||||||
Preferred stock dividends | (15,926 | ) | — | — | — | (15,926 | ) | ||||||||||||||
Net income (loss) available to common stockholders | $ | (82,892 | ) | $ | 54,188 | $ | 58,569 | $ | (113,358 | ) | $ | (83,493 | ) | ||||||||
CONSOLIDATING STATEMENT OF OPERATIONS | |||||||||||||||||||||
For the Nine Months Ended September 30, 2012 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
Net product sales | $ | — | $ | 649,719 | $ | 854,113 | $ | (104,807 | ) | $ | 1,399,025 | ||||||||||
Services revenue | — | 605,193 | 47,511 | — | 652,704 | ||||||||||||||||
Net product sales and services revenue | — | 1,254,912 | 901,624 | (104,807 | ) | 2,051,729 | |||||||||||||||
License and royalty revenue | — | 8,982 | 10,016 | (7,665 | ) | 11,333 | |||||||||||||||
Net revenue | — | 1,263,894 | 911,640 | (112,472 | ) | 2,063,062 | |||||||||||||||
Cost of net product sales | 2,635 | 311,722 | 456,760 | (99,453 | ) | 671,664 | |||||||||||||||
Cost of services revenue | — | 311,718 | 22,074 | (2,242 | ) | 331,550 | |||||||||||||||
Cost of net product sales and services revenue | 2,635 | 623,440 | 478,834 | (101,695 | ) | 1,003,214 | |||||||||||||||
Cost of license and royalty revenue | — | 15 | 13,044 | (7,665 | ) | 5,394 | |||||||||||||||
Cost of net revenue | 2,635 | 623,455 | 491,878 | (109,360 | ) | 1,008,608 | |||||||||||||||
Gross profit (loss) | (2,635 | ) | 640,439 | 419,762 | (3,112 | ) | 1,054,454 | ||||||||||||||
Operating expenses: | |||||||||||||||||||||
Research and development | 17,361 | 53,528 | 49,120 | — | 120,009 | ||||||||||||||||
Sales and marketing | 3,096 | 260,283 | 215,165 | — | 478,544 | ||||||||||||||||
General and administrative | 37,590 | 174,639 | 135,528 | — | 347,757 | ||||||||||||||||
Total operating expenses | 58,047 | 488,450 | 399,813 | — | 946,310 | ||||||||||||||||
Operating income (loss) | (60,682 | ) | 151,989 | 19,949 | (3,112 | ) | 108,144 | ||||||||||||||
Interest expense, including amortization of original issue discounts and deferred financing costs | (158,009 | ) | (31,291 | ) | (9,853 | ) | 38,034 | (161,119 | ) | ||||||||||||
Other income (expense), net | (2,552 | ) | 33,550 | 21,606 | (38,034 | ) | 14,570 | ||||||||||||||
Income (loss) before provision (benefit) for income taxes | (221,243 | ) | 154,248 | 31,702 | (3,112 | ) | (38,405 | ) | |||||||||||||
Provision (benefit) for income taxes | (74,149 | ) | 59,013 | 3,494 | (979 | ) | (12,621 | ) | |||||||||||||
Income (loss) before equity earnings (losses) of subsidiaries and unconsolidated entities, net of tax | (147,094 | ) | 95,235 | 28,208 | (2,133 | ) | (25,784 | ) | |||||||||||||
Equity earnings (losses) of subsidiaries, net of tax | 129,929 | (763 | ) | — | (129,166 | ) | — | ||||||||||||||
Equity earnings (losses) of unconsolidated entities, net of tax | 1,798 | — | 8,643 | (24 | ) | 10,417 | |||||||||||||||
Net income (loss) | (15,367 | ) | 94,472 | 36,851 | (131,323 | ) | (15,367 | ) | |||||||||||||
Less: Net income attributable to non-controlling interests | — | — | 137 | — | 137 | ||||||||||||||||
Net income (loss) attributable to Alere Inc. and Subsidiaries | (15,367 | ) | 94,472 | 36,714 | (131,323 | ) | (15,504 | ) | |||||||||||||
Preferred stock dividends | (15,940 | ) | — | — | — | (15,940 | ) | ||||||||||||||
Net income (loss) available to common stockholders | $ | (31,307 | ) | $ | 94,472 | $ | 36,714 | $ | (131,323 | ) | $ | (31,444 | ) | ||||||||
Guarantor Financial Information Consolidating Statement of Comprehensive Income (Loss) | ' | ||||||||||||||||||||
CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) | |||||||||||||||||||||
For the Three Months Ended September 30, 2013 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
Net income (loss) | $ | (19,089 | ) | $ | 25,105 | $ | 16,990 | $ | (42,095 | ) | $ | (19,089 | ) | ||||||||
Other comprehensive income, before tax: | |||||||||||||||||||||
Changes in cumulative translation adjustment | 524 | — | 66,742 | 2 | 67,268 | ||||||||||||||||
Unrealized gains on hedging instruments | — | — | 20 | — | 20 | ||||||||||||||||
Minimum pension liability adjustment | — | — | (369 | ) | — | (369 | ) | ||||||||||||||
Other comprehensive income, before tax | 524 | — | 66,393 | 2 | 66,919 | ||||||||||||||||
Income tax provision (benefit) related to items of other comprehensive income | — | — | — | — | — | ||||||||||||||||
Other comprehensive income, net of tax | 524 | — | 66,393 | 2 | 66,919 | ||||||||||||||||
Comprehensive income (loss) | (18,565 | ) | 25,105 | 83,383 | (42,093 | ) | 47,830 | ||||||||||||||
Less: Comprehensive income attributable to non-controlling interests | — | — | 359 | — | 359 | ||||||||||||||||
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | $ | (18,565 | ) | $ | 25,105 | $ | 83,024 | $ | (42,093 | ) | $ | 47,471 | |||||||||
CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) | |||||||||||||||||||||
For the Three Months Ended September 30, 2012 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
Net income (loss) | $ | (3,517 | ) | $ | 31,926 | $ | 10,478 | $ | (42,404 | ) | $ | (3,517 | ) | ||||||||
Other comprehensive income, before tax: | |||||||||||||||||||||
Changes in cumulative translation adjustment | 132 | 1 | 36,027 | 3,535 | 39,695 | ||||||||||||||||
Unrealized gains on available for sale securities | 141 | — | — | — | 141 | ||||||||||||||||
Unrealized gains on hedging instruments | — | — | 10 | — | 10 | ||||||||||||||||
Minimum pension liability adjustment | — | — | (98 | ) | — | (98 | ) | ||||||||||||||
Other comprehensive income, before tax | 273 | 1 | 35,939 | 3,535 | 39,748 | ||||||||||||||||
Income tax provision related to items of other comprehensive income (loss) | 360 | — | — | — | 360 | ||||||||||||||||
Other comprehensive income (loss), net of tax | (87 | ) | 1 | 35,939 | 3,535 | 39,388 | |||||||||||||||
Comprehensive income (loss) | (3,604 | ) | 31,927 | 46,417 | (38,869 | ) | 35,871 | ||||||||||||||
Less: Comprehensive income attributable to non-controlling interests | — | — | 286 | — | 286 | ||||||||||||||||
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | $ | (3,604 | ) | $ | 31,927 | $ | 46,131 | $ | (38,869 | ) | $ | 35,585 | |||||||||
CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) | |||||||||||||||||||||
For the Nine Months Ended September 30, 2013 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
Net income (loss) | $ | (66,966 | ) | $ | 54,188 | $ | 59,170 | $ | (113,358 | ) | $ | (66,966 | ) | ||||||||
Other comprehensive loss, before tax: | |||||||||||||||||||||
Changes in cumulative translation adjustment | (329 | ) | — | (42,188 | ) | 2 | (42,515 | ) | |||||||||||||
Unrealized gains on hedging instruments | — | — | 31 | — | 31 | ||||||||||||||||
Minimum pension liability adjustment | — | — | 335 | — | 335 | ||||||||||||||||
Other comprehensive loss, before tax | (329 | ) | — | (41,822 | ) | 2 | (42,149 | ) | |||||||||||||
Income tax provision (benefit) related to items of other comprehensive loss | — | — | — | — | — | ||||||||||||||||
Other comprehensive loss, net of tax | (329 | ) | — | (41,822 | ) | 2 | (42,149 | ) | |||||||||||||
Comprehensive income (loss) | (67,295 | ) | 54,188 | 17,348 | (113,356 | ) | (109,115 | ) | |||||||||||||
Less: Comprehensive income attributable to non-controlling interests | — | — | 601 | — | 601 | ||||||||||||||||
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | $ | (67,295 | ) | $ | 54,188 | $ | 16,747 | $ | (113,356 | ) | $ | (109,716 | ) | ||||||||
CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) | |||||||||||||||||||||
For the Nine Months Ended September 30, 2012 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
Net income (loss) | $ | (15,367 | ) | $ | 94,472 | $ | 36,851 | $ | (131,323 | ) | $ | (15,367 | ) | ||||||||
Other comprehensive income (loss), before tax: | |||||||||||||||||||||
Changes in cumulative translation adjustment | (100 | ) | (302 | ) | 37,136 | 2,123 | 38,857 | ||||||||||||||
Unrealized gains on available for sale securities | 926 | 5 | — | — | 931 | ||||||||||||||||
Unrealized gains on hedging instruments | 17 | — | 448 | — | 465 | ||||||||||||||||
Minimum pension liability adjustment | — | — | (218 | ) | — | (218 | ) | ||||||||||||||
Other comprehensive income (loss), before tax | 843 | (297 | ) | 37,366 | 2,123 | 40,035 | |||||||||||||||
Income tax provision related to items of other comprehensive income (loss) | 360 | — | — | — | 360 | ||||||||||||||||
Other comprehensive income (loss), net of tax | 483 | (297 | ) | 37,366 | 2,123 | 39,675 | |||||||||||||||
Comprehensive income (loss) | (14,884 | ) | 94,175 | 74,217 | (129,200 | ) | 24,308 | ||||||||||||||
Less: Comprehensive income attributable to non-controlling interests | — | — | 137 | — | 137 | ||||||||||||||||
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | $ | (14,884 | ) | $ | 94,175 | $ | 74,080 | $ | (129,200 | ) | $ | 24,171 | |||||||||
Guarantor Financial Information Consolidating Balance Sheet | ' | ||||||||||||||||||||
CONSOLIDATING BALANCE SHEET | |||||||||||||||||||||
September 30, 2013 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
ASSETS | |||||||||||||||||||||
Current assets: | |||||||||||||||||||||
Cash and cash equivalents | $ | 47,863 | $ | 76,234 | $ | 229,896 | $ | — | $ | 353,993 | |||||||||||
Restricted cash | 4,439 | 2,309 | 1,157 | — | 7,905 | ||||||||||||||||
Marketable securities | — | 815 | 5 | — | 820 | ||||||||||||||||
Accounts receivable, net of allowances | — | 256,578 | 312,295 | — | 568,873 | ||||||||||||||||
Inventories, net | — | 170,372 | 225,894 | (25,818 | ) | 370,448 | |||||||||||||||
Deferred tax assets | 8,749 | 35,980 | 9,440 | 4,008 | 58,177 | ||||||||||||||||
Prepaid expenses and other current assets | 3,911 | 34,732 | 75,999 | (41 | ) | 114,601 | |||||||||||||||
Intercompany receivables | 332,124 | 714,131 | 61,898 | (1,108,153 | ) | — | |||||||||||||||
Total current assets | 397,086 | 1,291,151 | 916,584 | (1,130,004 | ) | 1,474,817 | |||||||||||||||
Property, plant and equipment, net | 9,048 | 291,621 | 243,981 | (379 | ) | 544,271 | |||||||||||||||
Goodwill | — | 1,810,036 | 1,293,459 | — | 3,103,495 | ||||||||||||||||
Other intangible assets with indefinite lives | — | 12,900 | 46,053 | — | 58,953 | ||||||||||||||||
Finite-lived intangible assets, net | 8,786 | 1,003,272 | 735,480 | — | 1,747,538 | ||||||||||||||||
Restricted cash—non-current | — | — | 29,045 | — | 29,045 | ||||||||||||||||
Deferred financing costs, net and other non-current assets | 58,996 | 9,299 | 18,247 | (53 | ) | 86,489 | |||||||||||||||
Investments in subsidiaries | 4,473,400 | 274,450 | 127,711 | (4,875,561 | ) | — | |||||||||||||||
Investments in unconsolidated entities | 30,221 | — | 58,049 | 13,552 | 101,822 | ||||||||||||||||
Deferred tax assets | — | — | 8,189 | — | 8,189 | ||||||||||||||||
Intercompany notes receivable | 1,541,655 | 665,623 | 97,887 | (2,305,165 | ) | — | |||||||||||||||
Total assets | $ | 6,519,192 | $ | 5,358,352 | $ | 3,574,685 | $ | (8,297,610 | ) | $ | 7,154,619 | ||||||||||
LIABILITIES AND EQUITY | |||||||||||||||||||||
Current liabilities: | |||||||||||||||||||||
Short-term debt | $ | — | $ | — | $ | 25 | $ | — | $ | 25 | |||||||||||
Current portion of long-term debt | 45,000 | 348 | 2,353 | — | 47,701 | ||||||||||||||||
Current portion of capital lease obligations | — | 3,808 | 2,725 | — | 6,533 | ||||||||||||||||
Accounts payable | 18,702 | 77,163 | 99,126 | — | 194,991 | ||||||||||||||||
Accrued expenses and other current liabilities | (381,276 | ) | 604,035 | 225,084 | (615 | ) | 447,228 | ||||||||||||||
Intercompany payables | 677,842 | 149,645 | 280,668 | (1,108,155 | ) | — | |||||||||||||||
Total current liabilities | 360,268 | 834,999 | 609,981 | (1,108,770 | ) | 696,478 | |||||||||||||||
Long-term liabilities: | |||||||||||||||||||||
Long-term debt, net of current portion | 3,750,057 | 150 | 40,325 | — | 3,790,532 | ||||||||||||||||
Capital lease obligations, net of current portion | — | 6,133 | 8,793 | — | 14,926 | ||||||||||||||||
Deferred tax liabilities | (27,768 | ) | 282,942 | 97,211 | 474 | 352,859 | |||||||||||||||
Other long-term liabilities | 20,198 | 57,762 | 131,776 | (53 | ) | 209,683 | |||||||||||||||
Intercompany notes payables | 330,967 | 1,503,599 | 470,599 | (2,305,165 | ) | — | |||||||||||||||
Total long-term liabilities | 4,073,454 | 1,850,586 | 748,704 | (2,304,744 | ) | 4,368,000 | |||||||||||||||
Stockholders’ equity | 2,085,470 | 2,672,767 | 2,211,329 | (4,884,096 | ) | 2,085,470 | |||||||||||||||
Non-controlling interests | — | — | 4,671 | — | 4,671 | ||||||||||||||||
Total equity | 2,085,470 | 2,672,767 | 2,216,000 | (4,884,096 | ) | 2,090,141 | |||||||||||||||
Total liabilities and equity | $ | 6,519,192 | $ | 5,358,352 | $ | 3,574,685 | $ | (8,297,610 | ) | $ | 7,154,619 | ||||||||||
CONSOLIDATING BALANCE SHEET | |||||||||||||||||||||
December 31, 2012 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
ASSETS | |||||||||||||||||||||
Current assets: | |||||||||||||||||||||
Cash and cash equivalents | $ | 3,623 | $ | 67,449 | $ | 257,274 | $ | — | $ | 328,346 | |||||||||||
Restricted cash | — | 1,680 | 1,396 | — | 3,076 | ||||||||||||||||
Marketable securities | — | 787 | 117 | — | 904 | ||||||||||||||||
Accounts receivable, net of allowances | — | 241,050 | 283,282 | — | 524,332 | ||||||||||||||||
Inventories, net | — | 142,413 | 203,230 | (8,522 | ) | 337,121 | |||||||||||||||
Deferred tax assets | 12,193 | 39,601 | 13,138 | 2,790 | 67,722 | ||||||||||||||||
Prepaid expenses and other current assets | (20,636 | ) | 99,271 | 66,634 | (33 | ) | 145,236 | ||||||||||||||
Intercompany receivables | 298,812 | 1,254,727 | 55,847 | (1,609,386 | ) | — | |||||||||||||||
Total current assets | 293,992 | 1,846,978 | 880,918 | (1,615,151 | ) | 1,406,737 | |||||||||||||||
Property, plant and equipment, net | 2,679 | 293,260 | 239,082 | (552 | ) | 534,469 | |||||||||||||||
Goodwill | — | 1,820,438 | 1,227,967 | — | 3,048,405 | ||||||||||||||||
Other intangible assets with indefinite lives | — | 14,600 | 21,851 | — | 36,451 | ||||||||||||||||
Finite-lived intangible assets, net | 24,701 | 1,132,656 | 676,868 | — | 1,834,225 | ||||||||||||||||
Deferred financing costs, net and other non-current assets | 78,522 | 10,341 | 20,065 | (71 | ) | 108,857 | |||||||||||||||
Investments in subsidiaries | 4,114,478 | 222,175 | 73,940 | (4,410,593 | ) | — | |||||||||||||||
Investments in unconsolidated entities | 33,979 | — | 56,512 | — | 90,491 | ||||||||||||||||
Deferred tax assets | — | 782 | 7,511 | — | 8,293 | ||||||||||||||||
Intercompany notes receivable | 1,724,650 | 722,552 | 1,278 | (2,448,480 | ) | — | |||||||||||||||
Total assets | $ | 6,273,001 | $ | 6,063,782 | $ | 3,205,992 | $ | (8,474,847 | ) | $ | 7,067,928 | ||||||||||
LIABILITIES AND EQUITY | |||||||||||||||||||||
Current liabilities: | |||||||||||||||||||||
Current portion of long-term debt | $ | 45,000 | $ | 349 | $ | 14,883 | $ | — | $ | 60,232 | |||||||||||
Current portion of capital lease obligations | — | 3,209 | 3,475 | — | 6,684 | ||||||||||||||||
Accounts payable | 7,993 | 76,256 | 85,725 | — | 169,974 | ||||||||||||||||
Accrued expenses and other current liabilities | (388,830 | ) | 586,116 | 214,659 | (26 | ) | 411,919 | ||||||||||||||
Intercompany payables | 557,578 | 806,507 | 245,300 | (1,609,385 | ) | — | |||||||||||||||
Total current liabilities | 221,741 | 1,472,437 | 564,042 | (1,609,411 | ) | 648,809 | |||||||||||||||
Long-term liabilities: | |||||||||||||||||||||
Long-term debt, net of current portion | 3,617,068 | 374 | 11,233 | — | 3,628,675 | ||||||||||||||||
Capital lease obligations, net of current portion | — | 5,412 | 7,505 | — | 12,917 | ||||||||||||||||
Deferred tax liabilities | (5,329 | ) | 333,388 | 100,216 | (87 | ) | 428,188 | ||||||||||||||
Other long-term liabilities | 17,678 | 72,890 | 76,138 | (71 | ) | 166,635 | |||||||||||||||
Intercompany notes payables | 241,421 | 1,630,376 | 576,684 | (2,448,481 | ) | — | |||||||||||||||
Total long-term liabilities | 3,870,838 | 2,042,440 | 771,776 | (2,448,639 | ) | 4,236,415 | |||||||||||||||
Stockholders’ equity | 2,180,422 | 2,548,905 | 1,867,892 | (4,416,797 | ) | 2,180,422 | |||||||||||||||
Non-controlling interests | — | — | 2,282 | — | 2,282 | ||||||||||||||||
Total equity | 2,180,422 | 2,548,905 | 1,870,174 | (4,416,797 | ) | 2,182,704 | |||||||||||||||
Total liabilities and equity | $ | 6,273,001 | $ | 6,063,782 | $ | 3,205,992 | $ | (8,474,847 | ) | $ | 7,067,928 | ||||||||||
Guarantor Financial Information Consolidating Statement of Cash Flows | ' | ||||||||||||||||||||
CONSOLIDATING STATEMENT OF CASH FLOWS | |||||||||||||||||||||
For the Nine Months Ended September 30, 2013 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
Cash Flows from Operating Activities: | |||||||||||||||||||||
Net income (loss) | $ | (66,966 | ) | $ | 54,188 | $ | 59,170 | $ | (113,358 | ) | $ | (66,966 | ) | ||||||||
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | |||||||||||||||||||||
Equity (earnings) losses of subsidiaries, net of tax | (112,535 | ) | 1,510 | — | 111,025 | — | |||||||||||||||
Non-cash interest expense, including amortization of original issue discounts and write-off of deferred financing costs | 13,814 | 229 | 45 | — | 14,088 | ||||||||||||||||
Depreciation and amortization | 3,731 | 188,745 | 134,317 | (104 | ) | 326,689 | |||||||||||||||
Non-cash charges for sale of inventories revalued at the date of acquisition | — | — | 1,880 | — | 1,880 | ||||||||||||||||
Non-cash stock-based compensation expense | 5,836 | 3,646 | 4,980 | — | 14,462 | ||||||||||||||||
Impairment of inventory | — | 27 | 216 | — | 243 | ||||||||||||||||
Impairment of long-lived assets | — | 2,954 | 1,147 | — | 4,101 | ||||||||||||||||
Loss on sale of fixed assets | — | 1,118 | 731 | — | 1,849 | ||||||||||||||||
Equity earnings of unconsolidated entities, net of tax | (1,278 | ) | — | (11,932 | ) | (28 | ) | (13,238 | ) | ||||||||||||
Deferred income taxes | (17,386 | ) | (27,285 | ) | (27,830 | ) | (1,154 | ) | (73,655 | ) | |||||||||||
Loss on extinguishment of debt | 35,603 | — | — | — | 35,603 | ||||||||||||||||
Loss on disposition | — | — | 5,885 | — | 5,885 | ||||||||||||||||
Bargain purchase gain | — | — | (5,707 | ) | — | (5,707 | ) | ||||||||||||||
Other non-cash items | 5,201 | (8 | ) | 1,481 | — | 1,481 | |||||||||||||||
Changes in assets and liabilities, net of acquisitions: | |||||||||||||||||||||
Accounts receivable, net | — | (15,528 | ) | (41,782 | ) | — | (57,310 | ) | |||||||||||||
Inventories, net | — | (45,883 | ) | (30,615 | ) | 3,771 | (72,727 | ) | |||||||||||||
Prepaid expenses and other current assets | (64,547 | ) | 67,871 | (4,941 | ) | (7,515 | ) | (9,132 | ) | ||||||||||||
Accounts payable | 5,918 | (1,453 | ) | 11,516 | — | 15,981 | |||||||||||||||
Accrued expenses and other current liabilities | 10,396 | 17,570 | 2,342 | 6,934 | 37,242 | ||||||||||||||||
Other non-current liabilities | (915 | ) | (15,197 | ) | 8,739 | 516 | (6,857 | ) | |||||||||||||
Intercompany payable (receivable) | 298,083 | (182,214 | ) | (115,869 | ) | — | — | ||||||||||||||
Net cash provided by (used in) operating activities | 114,955 | 50,290 | (6,227 | ) | 87 | 159,105 | |||||||||||||||
Cash Flows from Investing Activities: | |||||||||||||||||||||
Increase in restricted cash | (4,439 | ) | (630 | ) | (28,812 | ) | — | (33,881 | ) | ||||||||||||
Purchases of property, plant and equipment | (1,037 | ) | (42,950 | ) | (58,860 | ) | 11,939 | (90,908 | ) | ||||||||||||
Proceeds from sale of property, plant and equipment | — | 6,908 | 11,186 | (12,263 | ) | 5,831 | |||||||||||||||
Cash received from disposition | — | — | 32,000 | — | 32,000 | ||||||||||||||||
Cash paid for acquisitions, net of cash acquired | (157,373 | ) | — | (8,823 | ) | — | (166,196 | ) | |||||||||||||
Cash received from equity method investments | 490 | — | 10,772 | — | 11,262 | ||||||||||||||||
(Increase) decrease in other assets | 19,244 | (2,047 | ) | 2,065 | (18 | ) | 19,244 | ||||||||||||||
Net cash used in investing activities | (143,115 | ) | (38,719 | ) | (40,472 | ) | (342 | ) | (222,648 | ) | |||||||||||
Cash Flows from Financing Activities: | |||||||||||||||||||||
Cash paid for financing costs | (9,798 | ) | — | — | — | (9,798 | ) | ||||||||||||||
Cash paid for contingent purchase price consideration | (27,165 | ) | — | (331 | ) | — | (27,496 | ) | |||||||||||||
Proceeds from issuance of common stock, net of issuance costs | 17,555 | — | — | — | 17,555 | ||||||||||||||||
Proceeds from issuance of long-term debt | 425,000 | 989 | 34,152 | — | 460,141 | ||||||||||||||||
Payments on long-term debt | (446,845 | ) | (1,213 | ) | (7,099 | ) | — | (455,157 | ) | ||||||||||||
Net proceeds (payments) under revolving credit facilities | 147,500 | — | (8,732 | ) | — | 138,768 | |||||||||||||||
Borrowings from short-term debt | — | — | 25 | — | 25 | ||||||||||||||||
Cash paid for dividends | (15,970 | ) | — | — | — | (15,970 | ) | ||||||||||||||
Excess tax benefits on exercised stock options | 205 | 181 | 48 | — | 434 | ||||||||||||||||
Principal payments on capital lease obligations | — | (2,715 | ) | (2,626 | ) | — | (5,341 | ) | |||||||||||||
Other | (18,953 | ) | — | — | — | (18,953 | ) | ||||||||||||||
Net cash provided by (used in) financing activities | 71,529 | (2,758 | ) | 15,437 | — | 84,208 | |||||||||||||||
Foreign exchange effect on cash and cash equivalents | 871 | (28 | ) | 3,884 | 255 | 4,982 | |||||||||||||||
Net increase (decrease) in cash and cash equivalents | 44,240 | 8,785 | (27,378 | ) | — | 25,647 | |||||||||||||||
Cash and cash equivalents, beginning of period | 3,623 | 67,449 | 257,274 | — | 328,346 | ||||||||||||||||
Cash and cash equivalents, end of period | $ | 47,863 | $ | 76,234 | $ | 229,896 | $ | — | $ | 353,993 | |||||||||||
CONSOLIDATING STATEMENT OF CASH FLOWS | |||||||||||||||||||||
For the Nine Months Ended September 30, 2012 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Issuer | Guarantor | Non-Guarantor | Eliminations | Consolidated | |||||||||||||||||
Subsidiaries | Subsidiaries | ||||||||||||||||||||
Cash Flows from Operating Activities: | |||||||||||||||||||||
Net income (loss) | $ | (15,367 | ) | $ | 94,472 | $ | 36,851 | $ | (131,323 | ) | $ | (15,367 | ) | ||||||||
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||||||||||||||||||||
Equity (earnings) losses of subsidiaries, net of tax | (129,929 | ) | 763 | — | 129,166 | — | |||||||||||||||
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs | 15,929 | 158 | — | — | 16,087 | ||||||||||||||||
Depreciation and amortization | 4,314 | 198,576 | 119,462 | 19 | 322,371 | ||||||||||||||||
Non-cash charges for sale of inventories revalued at the date of acquisition | — | 1,400 | 3,281 | — | 4,681 | ||||||||||||||||
Non-cash stock-based compensation expense | 3,119 | 4,309 | 4,440 | — | 11,868 | ||||||||||||||||
Impairment of inventory | — | 5 | 290 | — | 295 | ||||||||||||||||
Impairment of long-lived assets | — | 219 | 55 | — | 274 | ||||||||||||||||
(Gain) loss on sale of property, plant and equipment | 3 | (4,029 | ) | (168 | ) | — | (4,194 | ) | |||||||||||||
Equity earnings of unconsolidated entities, net of tax | (1,798 | ) | — | (8,643 | ) | 24 | (10,417 | ) | |||||||||||||
Deferred income taxes | 20,901 | (38,495 | ) | (25,122 | ) | (903 | ) | (43,619 | ) | ||||||||||||
Other non-cash items | (1,156 | ) | 685 | 6,207 | — | 5,736 | |||||||||||||||
Changes in assets and liabilities, net of acquisitions: | |||||||||||||||||||||
Accounts receivable, net | — | (6,468 | ) | (1,793 | ) | — | (8,261 | ) | |||||||||||||
Inventories, net | — | 4,881 | (23,303 | ) | 2,826 | (15,596 | ) | ||||||||||||||
Prepaid expenses and other current assets | (419,146 | ) | 410,233 | 13,059 | 25 | 4,171 | |||||||||||||||
Accounts payable | 3,961 | (2,327 | ) | (18,377 | ) | — | (16,743 | ) | |||||||||||||
Accrued expenses and other current liabilities | 354,452 | (323,909 | ) | (5,843 | ) | (584 | ) | 24,116 | |||||||||||||
Other non-current liabilities | (7,158 | ) | (1,634 | ) | (13,275 | ) | 428 | (21,639 | ) | ||||||||||||
Intercompany payable (receivable) | 297,741 | (322,706 | ) | 27,088 | (2,123 | ) | — | ||||||||||||||
Net cash provided by operating activities | 125,866 | 16,133 | 114,209 | (2,445 | ) | 253,763 | |||||||||||||||
Cash Flows from Investing Activities: | |||||||||||||||||||||
Decrease in restricted cash | — | 12 | 5,759 | — | 5,771 | ||||||||||||||||
Purchases of property, plant and equipment | (1,149 | ) | (69,092 | ) | (94,311 | ) | 67,243 | (97,309 | ) | ||||||||||||
Proceeds from sale of property, plant and equipment | — | 22,230 | 66,281 | (66,128 | ) | 22,383 | |||||||||||||||
Cash received from (paid for) acquisitions, net of cash acquired | (364,731 | ) | 1,469 | (21,518 | ) | — | (384,780 | ) | |||||||||||||
Cash received from sales of marketable securities | — | 268 | 3 | — | 271 | ||||||||||||||||
Net cash received from equity method investments | 490 | — | 6,066 | — | 6,556 | ||||||||||||||||
(Increase) decrease in other assets | (10,028 | ) | (615 | ) | 1,275 | 55 | (9,313 | ) | |||||||||||||
Net cash used in investing activities | (375,418 | ) | (45,728 | ) | (36,445 | ) | 1,170 | (456,421 | ) | ||||||||||||
Cash Flows from Financing Activities: | |||||||||||||||||||||
Cash paid for financing costs | (2,313 | ) | — | — | — | (2,313 | ) | ||||||||||||||
Cash paid for contingent purchase price consideration | (16,248 | ) | — | — | — | (16,248 | ) | ||||||||||||||
Proceeds from issuance of common stock, net of issuance costs | 14,260 | — | — | — | 14,260 | ||||||||||||||||
Proceeds from issuance of long-term debt | 198,000 | — | 288 | — | 198,288 | ||||||||||||||||
Payments on long-term debt | (33,250 | ) | (455 | ) | (8,848 | ) | — | (42,553 | ) | ||||||||||||
Net proceeds (payments) under revolving credit facilities | 97,500 | (2 | ) | (6,336 | ) | — | 91,162 | ||||||||||||||
Payments on short-term debt | (6,240 | ) | — | — | — | (6,240 | ) | ||||||||||||||
Cash paid for dividends | (15,970 | ) | — | — | — | (15,970 | ) | ||||||||||||||
Excess tax benefits on exercised stock options | 183 | 74 | 20 | — | 277 | ||||||||||||||||
Principal payments on capital lease obligations | — | (1,503 | ) | (3,422 | ) | — | (4,925 | ) | |||||||||||||
Other | — | — | (2,811 | ) | — | (2,811 | ) | ||||||||||||||
Net cash provided by (used in) financing activities | 235,922 | (1,886 | ) | (21,109 | ) | — | 212,927 | ||||||||||||||
Foreign exchange effect on cash and cash equivalents | 1,508 | 331 | (10,302 | ) | 1,275 | (7,188 | ) | ||||||||||||||
Net increase (decrease) in cash and cash equivalents | (12,122 | ) | (31,150 | ) | 46,353 | — | 3,081 | ||||||||||||||
Cash and cash equivalents, beginning of period | 12,451 | 95,212 | 191,510 | — | 299,173 | ||||||||||||||||
Cash and cash equivalents, end of period | $ | 329 | $ | 64,062 | $ | 237,863 | $ | — | $ | 302,254 |
Cash_and_Cash_Equivalents_Addi
Cash and Cash Equivalents - Additional Information (Detail) | 9 Months Ended |
Sep. 30, 2013 | |
Cash And Cash Equivalents [Abstract] | ' |
Cash investments maturity period | 'Three months or less |
Restricted_Cash_Additional_Inf
Restricted Cash - Additional Information (Detail) (USD $) | 3 Months Ended |
In Millions, unless otherwise specified | Sep. 30, 2013 |
Cash And Cash Equivalents [Abstract] | ' |
Total restricted cash | $36.90 |
Non-current restricted cash | $29 |
Period for collateralized assets | '2 years |
Inventories_Inventories_are_St
Inventories - Inventories are Stated at the Lower of Cost (First In, First Out) or Market (Detail) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Inventory Disclosure [Abstract] | ' | ' |
Raw materials | $115,441 | $99,498 |
Work-in-process | 83,571 | 89,895 |
Finished goods | 171,436 | 147,728 |
Inventories, net | $370,448 | $337,121 |
StockBased_Compensation_StockB
Stock-Based Compensation - Stock-Based Compensation Expense (Detail) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' | ' |
Stock-based compensation | $5,662 | $3,626 | $14,462 | $11,868 |
Benefit for income taxes | -1,511 | -536 | -2,869 | -1,951 |
Stock-based compensation, net of tax | 4,151 | 3,090 | 11,593 | 9,917 |
Cost of Net Revenue [Member] | ' | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' | ' |
Stock-based compensation | 287 | 269 | 797 | 801 |
Research and Development [Member] | ' | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' | ' |
Stock-based compensation | 1,111 | 752 | 2,641 | 2,379 |
Sales and Marketing [Member] | ' | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' | ' |
Stock-based compensation | 975 | 751 | 2,597 | 2,581 |
General and Administrative [Member] | ' | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' | ' |
Stock-based compensation | $3,289 | $1,854 | $8,427 | $6,107 |
Net_Loss_Per_Common_Share_Comp
Net Loss Per Common Share - Computation of Basic and Diluted Net Loss Per Common Share (Detail) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, except Per Share data, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Numerator: | ' | ' | ' | ' |
Net income (loss) | ($19,089) | ($3,517) | ($66,966) | ($15,367) |
Preferred stock dividends | -5,367 | -5,352 | -15,926 | -15,940 |
Less: Net income attributable to non-controlling interest | 359 | 286 | 601 | 137 |
Net loss available to common stockholders | ($24,815) | ($9,155) | ($83,493) | ($31,444) |
Denominator: | ' | ' | ' | ' |
Weighted-average common shares outstanding - basic and diluted | 81,735 | 80,792 | 81,417 | 80,492 |
Basic and diluted net loss per common share attributable to Alere Inc. and Subsidiaries | ($0.30) | ($0.11) | ($1.03) | ($0.39) |
Net_Loss_Per_Common_Share_Pote
Net Loss Per Common Share - Potential Dilutive Securities Not Included in Calculation of Diluted Net Loss Per Common Share (Detail) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Denominator: | ' | ' | ' | ' |
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding | 23,920 | 23,411 | 23,920 | 23,411 |
Options to Purchase Shares of Common Stock [Member] | ' | ' | ' | ' |
Denominator: | ' | ' | ' | ' |
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding | 10,239 | 9,730 | 10,239 | 9,730 |
Warrants [Member] | ' | ' | ' | ' |
Denominator: | ' | ' | ' | ' |
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding | 4 | 4 | 4 | 4 |
Convertible Shares Related to 3% Convertible Senior Subordinated Notes [Member] | ' | ' | ' | ' |
Denominator: | ' | ' | ' | ' |
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding | 3,411 | 3,411 | 3,411 | 3,411 |
Conversion Shares Related to Subordinated Convertible Promissory Notes [Member] | ' | ' | ' | ' |
Denominator: | ' | ' | ' | ' |
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding | 27 | 27 | 27 | 27 |
Conversion Shares Related to Series B Convertible Preferred Stock [Member] | ' | ' | ' | ' |
Denominator: | ' | ' | ' | ' |
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding | 10,239 | 10,239 | 10,239 | 10,239 |
Net_Loss_Per_Common_Share_Pote1
Net Loss Per Common Share - Potential Dilutive Securities Not Included in Calculation of Diluted Net Loss Per Common Share (Parenthetical) (Detail) (Convertible Shares Related to 3% Convertible Senior Subordinated Notes [Member]) | Sep. 30, 2013 | Sep. 30, 2012 |
Convertible Shares Related to 3% Convertible Senior Subordinated Notes [Member] | ' | ' |
Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' |
Interest rate of debt instrument | 3.00% | 3.00% |
Stockholders_Equity_and_NonCon2
Stockholders' Equity and Non-Controlling Interests - Additional Information (Detail) (USD $) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | |
Class of Stock [Line Items] | ' | ' | ' | ' |
Preferred stock dividends | $5,367,000 | $5,352,000 | $15,926,000 | $15,940,000 |
Series B Preferred Stock [Member] | ' | ' | ' | ' |
Class of Stock [Line Items] | ' | ' | ' | ' |
Preferred stock dividends | 5,300,000 | 5,400,000 | 15,900,000 | 15,900,000 |
Series B preferred stock dividends was accrued | $5,300,000 | ' | $5,300,000 | ' |
Stockholders_Equity_and_NonCon3
Stockholders' Equity and Non-Controlling Interests - Summary of Changes in Stockholders' Equity and Non-Controlling Interests Comprising Total Equity (Detail) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Equity And Noncontrolling Interests [Line Items] | ' | ' | ' | ' |
Equity, beginning of period | ' | ' | $2,182,704 | $2,231,574 |
Exercise of common stock options, warrants and shares issued under employee stock purchase plan | ' | ' | 17,555 | 14,261 |
Issuance of common stock for settlement of an acquisition-related contingent consideration obligation | ' | ' | ' | 1,243 |
Preferred stock dividends | ' | ' | -15,970 | -15,970 |
Stock-based compensation related to grants of common stock options | ' | ' | 14,462 | 11,868 |
Excess tax benefits on exercised stock options | ' | ' | -1,283 | -437 |
Non-controlling interest from acquisition | ' | ' | 1,788 | ' |
Purchase of subsidiary shares from non-controlling interests | ' | ' | ' | -35,079 |
Dividend relating to non-controlling interest | ' | ' | ' | -236 |
Net income (loss) | -19,089 | -3,517 | -66,966 | -15,367 |
Total other comprehensive income (loss) | 66,919 | 39,388 | -42,149 | 39,675 |
Equity, end of period | 2,090,141 | 2,231,595 | 2,090,141 | 2,231,595 |
Issuer [Member] | ' | ' | ' | ' |
Equity And Noncontrolling Interests [Line Items] | ' | ' | ' | ' |
Equity, beginning of period | ' | ' | 2,180,422 | 2,229,234 |
Exercise of common stock options, warrants and shares issued under employee stock purchase plan | ' | ' | 17,555 | 14,261 |
Issuance of common stock for settlement of an acquisition-related contingent consideration obligation | ' | ' | ' | 1,243 |
Preferred stock dividends | ' | ' | -15,970 | -15,970 |
Stock-based compensation related to grants of common stock options | ' | ' | 14,462 | 11,868 |
Excess tax benefits on exercised stock options | ' | ' | -1,283 | -437 |
Purchase of subsidiary shares from non-controlling interests | ' | ' | ' | -35,079 |
Net income (loss) | ' | ' | -67,567 | -15,504 |
Total other comprehensive income (loss) | ' | ' | -42,149 | 39,675 |
Equity, end of period | 2,085,470 | 2,229,291 | 2,085,470 | 2,229,291 |
Non-controlling Interests [Member] | ' | ' | ' | ' |
Equity And Noncontrolling Interests [Line Items] | ' | ' | ' | ' |
Equity, beginning of period | ' | ' | 2,282 | 2,340 |
Non-controlling interest from acquisition | ' | ' | 1,788 | ' |
Dividend relating to non-controlling interest | ' | ' | ' | -236 |
Net income (loss) | ' | ' | 601 | 200 |
Equity, end of period | $4,671 | $2,304 | $4,671 | $2,304 |
Business_Combinations_Addition
Business Combinations - Additional Information (Detail) (USD $) | 3 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 1 Months Ended | 9 Months Ended | |||||||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2012 | Jul. 31, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Feb. 01, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | |
Pantech Proprietary [Member] | AmMed, Diagnostik and NationsHealth [Member] | Cardio Selfcare [Member] | Mega Medika, Alere Health Services and Pantech (Member) | Liberty Business [Member] | Epocal [Member] | Epocal [Member] | Other [Member] | ||||||
Business Acquisition [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
General and administrative expense related to acquisition | $500,000 | $800,000 | $1,800,000 | $6,100,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Preliminary aggregate purchase price | ' | ' | ' | ' | 494,500,000 | ' | ' | ' | ' | ' | 248,500,000 | ' | 47,700,000 |
Total cash payments | 209,247,000 | ' | 209,247,000 | ' | 418,903,000 | ' | ' | ' | ' | ' | 173,500,000 | 173,461,000 | 35,786,000 |
Acquisition date fair value investment | 76,264,000 | ' | 76,264,000 | ' | 75,620,000 | ' | ' | ' | ' | ' | 75,000,000 | 75,000,000 | 1,264,000 |
Deferred purchase price consideration | 768,000 | ' | 768,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 768,000 |
Bargain purchase gain | ' | ' | 5,707,000 | ' | ' | ' | ' | ' | ' | 8,000,000 | ' | ' | 8,023,000 |
Percentage of incremental ownership interest | ' | ' | ' | ' | ' | ' | ' | 51.00% | ' | ' | ' | ' | ' |
Interest in Pantech Proprietary Limited | ' | ' | ' | ' | ' | 74.90% | ' | ' | ' | ' | ' | ' | ' |
Total revenue related to acquisition | 26,600,000 | 14,400,000 | 59,500,000 | 26,300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Goodwill | 3,103,495,000 | 239,300,000 | 3,103,495,000 | 239,300,000 | 3,048,405,000 | ' | ' | ' | 1,600,000 | ' | ' | ' | ' |
Goodwill deductible for tax purposes | ' | ' | ' | ' | ' | ' | $8,200,000 | ' | ' | ' | ' | ' | ' |
Business_Combinations_Prelimin
Business Combinations - Preliminary Fair Values of Net Assets Acquired for Acquisitions (Detail) (USD $) | 9 Months Ended | 9 Months Ended | |||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Feb. 01, 2013 | Sep. 30, 2013 |
Epocal [Member] | Epocal [Member] | Other [Member] | |||
Business Acquisition [Line Items] | ' | ' | ' | ' | ' |
Current assets | $25,057 | $47,228 | $12,089 | ' | $12,968 |
Property, plant and equipment | 2,936 | 9,029 | 1,267 | ' | 1,669 |
Goodwill | 101,078 | 240,576 | 99,449 | ' | 1,629 |
Intangible assets | 207,320 | 325,223 | 164,400 | ' | 42,920 |
Other non-current assets | 17,639 | 17,261 | 17,610 | ' | 29 |
Total assets acquired | 354,030 | 639,317 | 294,815 | ' | 59,215 |
Current liabilities | 8,025 | 28,214 | 2,627 | ' | 5,398 |
Non-current liabilities | 49,929 | 116,580 | 43,727 | ' | 6,202 |
Total liabilities assumed | 57,954 | 144,794 | 46,354 | ' | 11,600 |
Net assets acquired | 296,076 | 494,523 | 248,461 | ' | 47,615 |
Contingent consideration | 76,264 | 75,620 | 75,000 | 75,000 | 1,264 |
Non-controlling interest | 1,774 | ' | ' | ' | 1,774 |
Bargain purchase gain | 5,707 | ' | ' | ' | 8,023 |
Deferred purchase price consideration | 768 | ' | ' | ' | 768 |
Cash paid | $209,247 | $418,903 | $173,461 | $173,500 | $35,786 |
Business_Combinations_Prelimin1
Business Combinations - Preliminary Fair Values of Net Assets Acquired for Acquisitions (Parenthetical) (Detail) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Millions, unless otherwise specified | ||
Business Combinations [Abstract] | ' | ' |
Cash acquired | $3.30 | $3.80 |
Business_Combinations_Intangib
Business Combinations - Intangible Assets Acquired and Their Respective Fair Values and Weighted-Average Useful Lives (Detail) (USD $) | 9 Months Ended | 12 Months Ended |
In Thousands, unless otherwise specified | Sep. 30, 2013 | Dec. 31, 2012 |
Acquired Finite And Indefinite Lived Intangible Assets [Line Items] | ' | ' |
Total intangible assets | $207,320 | $325,223 |
In-Process Research and Development [Member] | ' | ' |
Acquired Finite And Indefinite Lived Intangible Assets [Line Items] | ' | ' |
Acquired indefinite-lived intangible asset, amount | 24,200 | 4,900 |
Epocal [Member] | ' | ' |
Acquired Finite And Indefinite Lived Intangible Assets [Line Items] | ' | ' |
Total intangible assets | 164,400 | ' |
Epocal [Member] | In-Process Research and Development [Member] | ' | ' |
Acquired Finite And Indefinite Lived Intangible Assets [Line Items] | ' | ' |
Acquired indefinite-lived intangible asset, amount | 24,200 | ' |
Other [Member] | ' | ' |
Acquired Finite And Indefinite Lived Intangible Assets [Line Items] | ' | ' |
Total intangible assets | 42,920 | ' |
Core Technology and Patents [Member] | ' | ' |
Acquired Finite And Indefinite Lived Intangible Assets [Line Items] | ' | ' |
Acquired finite-lived intangible asset, amount | 119,700 | 148,103 |
Weighted-average Useful Life | '20 years | '18 years 8 months 12 days |
Core Technology and Patents [Member] | Epocal [Member] | ' | ' |
Acquired Finite And Indefinite Lived Intangible Assets [Line Items] | ' | ' |
Acquired finite-lived intangible asset, amount | 119,700 | ' |
Software [Member] | ' | ' |
Acquired Finite And Indefinite Lived Intangible Assets [Line Items] | ' | ' |
Acquired finite-lived intangible asset, amount | 804 | ' |
Weighted-average Useful Life | '10 years | ' |
Software [Member] | Other [Member] | ' | ' |
Acquired Finite And Indefinite Lived Intangible Assets [Line Items] | ' | ' |
Acquired finite-lived intangible asset, amount | 804 | ' |
Trademarks and Trade Names [Member] | ' | ' |
Acquired Finite And Indefinite Lived Intangible Assets [Line Items] | ' | ' |
Acquired finite-lived intangible asset, amount | 20,510 | 19,390 |
Weighted-average Useful Life | '19 years 2 months 12 days | '18 years 3 months 18 days |
Trademarks and Trade Names [Member] | Epocal [Member] | ' | ' |
Acquired Finite And Indefinite Lived Intangible Assets [Line Items] | ' | ' |
Acquired finite-lived intangible asset, amount | 20,500 | ' |
Trademarks and Trade Names [Member] | Other [Member] | ' | ' |
Acquired Finite And Indefinite Lived Intangible Assets [Line Items] | ' | ' |
Acquired finite-lived intangible asset, amount | 10 | ' |
Customer Relationships [Member] | ' | ' |
Acquired Finite And Indefinite Lived Intangible Assets [Line Items] | ' | ' |
Acquired finite-lived intangible asset, amount | 36,290 | 136,485 |
Weighted-average Useful Life | '11 years 4 months 24 days | '18 years 1 month 6 days |
Customer Relationships [Member] | Other [Member] | ' | ' |
Acquired Finite And Indefinite Lived Intangible Assets [Line Items] | ' | ' |
Acquired finite-lived intangible asset, amount | 36,290 | ' |
Non-Competition Agreements [Member] | ' | ' |
Acquired Finite And Indefinite Lived Intangible Assets [Line Items] | ' | ' |
Acquired finite-lived intangible asset, amount | ' | 1,118 |
Weighted-average Useful Life | ' | '5 years 1 month 6 days |
Other [Member] | ' | ' |
Acquired Finite And Indefinite Lived Intangible Assets [Line Items] | ' | ' |
Acquired finite-lived intangible asset, amount | 5,816 | 15,227 |
Weighted-average Useful Life | '3 years | '9 years 2 months 12 days |
Other [Member] | Other [Member] | ' | ' |
Acquired Finite And Indefinite Lived Intangible Assets [Line Items] | ' | ' |
Acquired finite-lived intangible asset, amount | $5,816 | ' |
Restructuring_Plans_Aggregate_
Restructuring Plans - Aggregate Charges Associated with Restructuring Plans Recorded in Operating Income (Detail) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' |
Restructuring charges | ' | ' | $16,484 | ' |
Cost of Net Revenue [Member] | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' |
Restructuring charges | 3,556 | 1,080 | 4,908 | 2,069 |
Research and Development [Member] | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' |
Restructuring charges | 1,100 | ' | 1,745 | 638 |
Sales and Marketing [Member] | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' |
Restructuring charges | 218 | 927 | 1,476 | 1,954 |
General and Administrative [Member] | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' |
Restructuring charges | 2,820 | 1,232 | 11,501 | 5,471 |
Total Operating Expenses [Member] | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' |
Restructuring charges | 7,694 | 3,239 | 19,630 | 10,132 |
Interest Expense, Including Amortization of Original Issue Discounts and Deferred Financing Costs [Member] | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' |
Restructuring charges | 111 | 48 | 228 | 158 |
Total Charges [Member] | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' |
Restructuring charges | $7,805 | $3,287 | $19,858 | $10,290 |
Restructuring_Plans_Restructur
Restructuring Plans - Restructuring Activities Related to Restructuring Plans (Detail) (USD $) | 3 Months Ended | 9 Months Ended | 69 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | ' | ' | $16,484 | ' | ' |
Severance-Related Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | ' | ' | 9,436 | ' | ' |
Facility and Transition Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | ' | ' | 6,820 | ' | ' |
Other Exit Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | ' | ' | 228 | ' | ' |
2013 Restructuring Plans [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 7,102 | ' | 12,601 | ' | ' |
2013 Restructuring Plans [Member] | Severance-Related Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 5,216 | ' | 7,358 | ' | ' |
2013 Restructuring Plans [Member] | Facility and Transition Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 1,434 | ' | 2,025 | ' | ' |
2013 Restructuring Plans [Member] | Other Exit Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 2 | ' | 2 | ' | ' |
2013 Restructuring Plans [Member] | Cash Charges [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 6,652 | ' | 9,385 | ' | ' |
2013 Restructuring Plans [Member] | Fixed Asset and Inventory Impairments [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 470 | ' | 640 | ' | ' |
2013 Restructuring Plans [Member] | Other Non-Cash Charges [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | -20 | ' | -20 | ' | ' |
2013 Restructuring Plans [Member] | Intangible Asset Impairments [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | ' | ' | 2,596 | ' | ' |
Professional Diagnostics Business Segment [Member] | 2013 Restructuring Plans [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 5,453 | ' | 7,887 | ' | ' |
Professional Diagnostics Business Segment [Member] | 2013 Restructuring Plans [Member] | Severance-Related Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 3,876 | ' | 5,960 | ' | ' |
Professional Diagnostics Business Segment [Member] | 2013 Restructuring Plans [Member] | Facility and Transition Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 1,107 | ' | 1,457 | ' | ' |
Professional Diagnostics Business Segment [Member] | 2013 Restructuring Plans [Member] | Cash Charges [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 4,983 | ' | 7,417 | ' | ' |
Professional Diagnostics Business Segment [Member] | 2013 Restructuring Plans [Member] | Fixed Asset and Inventory Impairments [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 470 | ' | 470 | ' | ' |
Professional Diagnostics Business Segment [Member] | 2012 Restructuring Plans [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | -614 | 746 | -444 | 3,064 | 4,711 |
Professional Diagnostics Business Segment [Member] | 2012 Restructuring Plans [Member] | Severance-Related Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | -614 | 691 | -526 | 3,009 | 4,206 |
Professional Diagnostics Business Segment [Member] | 2012 Restructuring Plans [Member] | Facility and Transition Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | ' | ' | 82 | ' | 201 |
Professional Diagnostics Business Segment [Member] | 2012 Restructuring Plans [Member] | Cash Charges [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | -614 | 691 | -444 | 3,009 | 4,407 |
Professional Diagnostics Business Segment [Member] | 2012 Restructuring Plans [Member] | Fixed Asset and Inventory Impairments [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | ' | 55 | ' | 55 | 304 |
Professional Diagnostics Business Segment [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 1,208 | 1,409 | 1,765 | 4,738 | 35,777 |
Professional Diagnostics Business Segment [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Severance-Related Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 46 | 639 | 242 | 2,914 | 19,955 |
Professional Diagnostics Business Segment [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Facility and Transition Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 112 | 464 | 442 | 1,348 | 7,669 |
Professional Diagnostics Business Segment [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Other Exit Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 14 | 16 | 45 | 52 | 743 |
Professional Diagnostics Business Segment [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Cash Charges [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 172 | 1,119 | 729 | 4,314 | 28,367 |
Professional Diagnostics Business Segment [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Fixed Asset and Inventory Impairments [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 350 | 290 | 350 | 424 | 6,724 |
Professional Diagnostics Business Segment [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Intangible Asset Impairments [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 686 | ' | 686 | ' | 686 |
Health Information Solutions [Member] | 2013 Restructuring Plans [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 1,649 | ' | 4,714 | ' | ' |
Health Information Solutions [Member] | 2013 Restructuring Plans [Member] | Severance-Related Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 1,340 | ' | 1,398 | ' | ' |
Health Information Solutions [Member] | 2013 Restructuring Plans [Member] | Facility and Transition Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 327 | ' | 568 | ' | ' |
Health Information Solutions [Member] | 2013 Restructuring Plans [Member] | Other Exit Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 2 | ' | 2 | ' | ' |
Health Information Solutions [Member] | 2013 Restructuring Plans [Member] | Cash Charges [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 1,669 | ' | 1,968 | ' | ' |
Health Information Solutions [Member] | 2013 Restructuring Plans [Member] | Fixed Asset and Inventory Impairments [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | ' | ' | 170 | ' | ' |
Health Information Solutions [Member] | 2013 Restructuring Plans [Member] | Other Non-Cash Charges [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | -20 | ' | -20 | ' | ' |
Health Information Solutions [Member] | 2013 Restructuring Plans [Member] | Intangible Asset Impairments [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | ' | ' | 2,596 | ' | ' |
Health Information Solutions [Member] | 2012 Restructuring Plans [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 96 | 986 | 5,889 | 2,330 | 15,829 |
Health Information Solutions [Member] | 2012 Restructuring Plans [Member] | Severance-Related Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 14 | 516 | 2,362 | 1,735 | 5,407 |
Health Information Solutions [Member] | 2012 Restructuring Plans [Member] | Facility and Transition Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | ' | 465 | 4,271 | 590 | 5,505 |
Health Information Solutions [Member] | 2012 Restructuring Plans [Member] | Other Exit Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 82 | 5 | 134 | 5 | 149 |
Health Information Solutions [Member] | 2012 Restructuring Plans [Member] | Cash Charges [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 96 | 986 | 6,767 | 2,330 | 11,061 |
Health Information Solutions [Member] | 2012 Restructuring Plans [Member] | Fixed Asset and Inventory Impairments [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | ' | ' | 75 | ' | 2,764 |
Health Information Solutions [Member] | 2012 Restructuring Plans [Member] | Other Non-Cash Charges [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | ' | ' | -953 | ' | -984 |
Health Information Solutions [Member] | 2012 Restructuring Plans [Member] | Intangible Asset Impairments [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | ' | ' | ' | ' | 2,988 |
Health Information Solutions [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 13 | 141 | 47 | 127 | 20,280 |
Health Information Solutions [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Severance-Related Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | ' | ' | ' | ' | 6,901 |
Health Information Solutions [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Facility and Transition Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | ' | 114 | ' | -59 | 8,010 |
Health Information Solutions [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Other Exit Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 13 | 27 | 47 | 101 | 559 |
Health Information Solutions [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Cash Charges [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | 13 | 141 | 47 | 42 | 15,470 |
Health Information Solutions [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Fixed Asset and Inventory Impairments [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | ' | ' | ' | 85 | 1,114 |
Health Information Solutions [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Other Non-Cash Charges [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | ' | ' | ' | ' | 761 |
Health Information Solutions [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Intangible Asset Impairments [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | ' | ' | ' | ' | 2,935 |
Corporate and Other [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | ' | 5 | ' | 31 | 1,222 |
Corporate and Other [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Severance-Related Costs [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | ' | 5 | ' | 31 | 1,219 |
Corporate and Other [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Cash Charges [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | ' | 5 | ' | 31 | 1,219 |
Corporate and Other [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | Fixed Asset and Inventory Impairments [Member] | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' |
Restructuring charges | ' | ' | ' | ' | $3 |
Restructuring_Plans_Additional
Restructuring Plans - Additional Information (Detail) (USD $) | 9 Months Ended |
In Millions, unless otherwise specified | Sep. 30, 2013 |
Restructuring Cost and Reserve [Line Items] | ' |
Restructuring reserve accrued expenses and other current liabilities | $8.70 |
Restructuring reserve other long-term liabilities | 2 |
2013 Restructuring Plans [Member] | Professional Diagnostics Business Segment [Member] | ' |
Restructuring Cost and Reserve [Line Items] | ' |
Additional costs | 4.7 |
2013 Restructuring Plans [Member] | Europe [Member] | Professional Diagnostics Business Segment [Member] | ' |
Restructuring Cost and Reserve [Line Items] | ' |
Cash charges remain unpaid | 0.3 |
2013 Restructuring Plans [Member] | United States [Member] | Professional Diagnostics Business Segment [Member] | ' |
Restructuring Cost and Reserve [Line Items] | ' |
Cash charges remain unpaid | 1.1 |
2012 Restructuring Plans [Member] | Professional Diagnostics Business Segment [Member] | ' |
Restructuring Cost and Reserve [Line Items] | ' |
Additional costs | 3.8 |
2012 Restructuring Plans [Member] | Health Information Solutions [Member] | ' |
Restructuring Cost and Reserve [Line Items] | ' |
Additional costs | 0.5 |
2011, 2010 and 2008 Restructuring Plans [Member] | Professional Diagnostics Business Segment [Member] | ' |
Restructuring Cost and Reserve [Line Items] | ' |
Additional costs | 0.5 |
2011, 2010 and 2008 Restructuring Plans [Member] | Health Information Solutions [Member] | ' |
Restructuring Cost and Reserve [Line Items] | ' |
Cash charges remain unpaid | $2.20 |
Restructuring_Plans_Cash_Activ
Restructuring Plans - Cash Activity for Restructuring Reserves (Detail) (USD $) | 9 Months Ended |
In Thousands, unless otherwise specified | Sep. 30, 2013 |
Restructuring Cost and Reserve [Line Items] | ' |
Restructuring Reserve, Beginning Balance | $6,218 |
Cash charges | 16,484 |
Payments | -11,891 |
Currency adjustments | -67 |
Restructuring Reserve, Ending Balance | 10,744 |
Severance-Related Costs [Member] | ' |
Restructuring Cost and Reserve [Line Items] | ' |
Restructuring Reserve, Beginning Balance | 3,167 |
Cash charges | 9,436 |
Payments | -7,515 |
Currency adjustments | -72 |
Restructuring Reserve, Ending Balance | 5,016 |
Facility and Transition Costs [Member] | ' |
Restructuring Cost and Reserve [Line Items] | ' |
Restructuring Reserve, Beginning Balance | 2,429 |
Cash charges | 6,820 |
Payments | -4,149 |
Currency adjustments | 5 |
Restructuring Reserve, Ending Balance | 5,105 |
Other Exit Costs [Member] | ' |
Restructuring Cost and Reserve [Line Items] | ' |
Restructuring Reserve, Beginning Balance | 622 |
Cash charges | 228 |
Payments | -227 |
Restructuring Reserve, Ending Balance | $623 |
LongTerm_Debt_LongTerm_Debt_Ba
Long-Term Debt - Long-Term Debt Balances Outstanding (Detail) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Dec. 31, 2012 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | 24-May-13 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | A Term Loans [Member] | A Term Loans [Member] | B Term Loans [Member] | B Term Loans [Member] | Incremental B-1 Term Loans [Member] | Incremental B-1 Term Loans [Member] | Incremental B-2 Term Loans [Member] | Incremental B-2 Term Loans [Member] | Revolving Line of Credit [Member] | Revolving Line of Credit [Member] | 7.25% Senior Notes [Member] | 7.25% Senior Notes [Member] | 7.875% Senior Notes [Member] | 9% Senior Subordinated Notes [Member] | 8.625% Senior Subordinated Notes [Member] | 8.625% Senior Subordinated Notes [Member] | 6.5% Senior Subordinated Notes [Member] | 6.5% Senior Subordinated Notes [Member] | 3% Convertibles Senior Subordinated Notes [Member] | 3% Convertibles Senior Subordinated Notes [Member] | Other Lines of Credit [Member] | Other Lines of Credit [Member] | Other [Member] | Other [Member] | ||
Debt Instrument [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Long-term debt, Total | $3,838,233 | $3,688,907 | $843,750 | $878,438 | $906,500 | $913,438 | $245,625 | $247,500 | $195,470 | $196,739 | $170,000 | $22,500 | $450,000 | $450,000 | $1,809 | $392,933 | $400,000 | $400,000 | $425,000 | $425,000 | $150,000 | $150,000 | $150 | $31,957 | $51,738 | $3,593 |
Less: Current portion | -47,701 | -60,232 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Long-term debt, after discount, Total | $3,790,532 | $3,628,675 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
LongTerm_Debt_LongTerm_Debt_Ba1
Long-Term Debt - Long-Term Debt Balances Outstanding (Parenthetical) (Detail) | Sep. 30, 2013 | 24-May-13 | Dec. 31, 2012 | Sep. 30, 2012 |
7.25% Senior Notes [Member] | ' | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' | ' |
Long-term debt, Interest rate | 7.25% | ' | 7.25% | ' |
7.875% Senior Notes [Member] | ' | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' | ' |
Long-term debt, Interest rate | 7.88% | ' | 7.88% | 7.88% |
9% Senior Subordinated Notes [Member] | ' | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' | ' |
Long-term debt, Interest rate | 9.00% | 9.00% | 9.00% | 9.00% |
8.625% Senior Subordinated Notes [Member] | ' | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' | ' |
Long-term debt, Interest rate | 8.63% | ' | 8.63% | 8.63% |
6.5% Senior Subordinated Notes [Member] | ' | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' | ' |
Long-term debt, Interest rate | 6.50% | 6.50% | 6.50% | ' |
3% Convertibles Senior Subordinated Notes [Member] | ' | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' | ' |
Long-term debt, Interest rate | 3.00% | ' | 3.00% | 3.00% |
LongTerm_Debt_LongTerm_Debt_In
Long-Term Debt - Long-Term Debt Interest Expense (Detail) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Debt Instrument [Line Items] | ' | ' | ' | ' |
Long-term debt issuance cost | $52,035 | $54,130 | $200,035 | $157,349 |
Secured Credit Facility [Member] | ' | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' | ' |
Long-term debt issuance cost | 25,809 | 27,474 | 78,741 | 77,422 |
7.25% Senior Notes [Member] | ' | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' | ' |
Long-term debt issuance cost | 8,535 | ' | 25,371 | ' |
7.875% Senior Notes [Member] | ' | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' | ' |
Long-term debt issuance cost | ' | 5,763 | 137 | 17,276 |
9% Senior Subordinated Notes [Member] | ' | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' | ' |
Long-term debt issuance cost | ' | 10,373 | 54,043 | 31,090 |
8.625% Senior Subordinated Notes [Member] | ' | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' | ' |
Long-term debt issuance cost | 9,273 | 9,274 | 27,820 | 27,823 |
6.5% Senior Subordinated Notes [Member] | ' | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' | ' |
Long-term debt issuance cost | 7,172 | ' | 10,185 | ' |
3% Convertibles Senior Subordinated Notes [Member] | ' | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' | ' |
Long-term debt issuance cost | $1,246 | $1,246 | $3,738 | $3,738 |
LongTerm_Debt_LongTerm_Debt_In1
Long-Term Debt - Long-Term Debt Interest Expense (Parenthetical) (Detail) (USD $) | 3 Months Ended | 9 Months Ended | 9 Months Ended | 9 Months Ended | ||||||||||||||||||
In Millions, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Sep. 30, 2013 | 24-May-13 | Dec. 31, 2012 | Sep. 30, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Sep. 30, 2013 | 24-May-13 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2012 |
7.25% Senior Notes [Member] | 7.25% Senior Notes [Member] | 7.875% Senior Notes [Member] | 7.875% Senior Notes [Member] | 7.875% Senior Notes [Member] | 9% Senior Subordinated Notes [Member] | 9% Senior Subordinated Notes [Member] | 9% Senior Subordinated Notes [Member] | 9% Senior Subordinated Notes [Member] | 8.625% Senior Subordinated Notes [Member] | 8.625% Senior Subordinated Notes [Member] | 8.625% Senior Subordinated Notes [Member] | 6.5% Senior Subordinated Notes [Member] | 6.5% Senior Subordinated Notes [Member] | 6.5% Senior Subordinated Notes [Member] | 3% Convertibles Senior Subordinated Notes [Member] | 3% Convertibles Senior Subordinated Notes [Member] | 3% Convertibles Senior Subordinated Notes [Member] | |||||
Debt Instrument [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Long-term debt, Interest rate | ' | ' | ' | ' | 7.25% | 7.25% | 7.88% | 7.88% | 7.88% | 9.00% | 9.00% | 9.00% | 9.00% | 8.63% | 8.63% | 8.63% | 6.50% | 6.50% | 6.50% | 3.00% | 3.00% | 3.00% |
Amortization fee | $0.40 | $1.30 | $2.20 | $4 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Loss in repurchase of senior notes | ' | ' | ' | ' | ' | ' | 0.2 | ' | ' | 35.6 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Tender offer consideration and call premium amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | $19 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
LongTerm_Debt_Additional_Infor
Long-Term Debt - Additional Information (Detail) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 | Mar. 22, 2013 | 24-May-13 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | 24-May-13 | Sep. 30, 2013 | Jun. 24, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Mar. 22, 2013 | Mar. 22, 2013 |
Secured Credit Facility [Member] | 6.5% Senior Subordinated Notes [Member] | 6.5% Senior Subordinated Notes [Member] | 6.5% Senior Subordinated Notes [Member] | 6.5% Senior Subordinated Notes [Member] | 6.5% Senior Subordinated Notes [Member] | 6.5% Senior Subordinated Notes [Member] | 6.5% Senior Subordinated Notes [Member] | 9% Senior Subordinated Notes [Member] | 9% Senior Subordinated Notes [Member] | 9% Senior Subordinated Notes [Member] | 9% Senior Subordinated Notes [Member] | 9% Senior Subordinated Notes [Member] | Minimum [Member] | Maximum [Member] | |||
Period One [Member] | Period Two [Member] | Period Three [Member] | Period Four [Member] | Secured Credit Facility [Member] | Secured Credit Facility [Member] | ||||||||||||
Debt Instrument [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Basis point reductions in interest rate margins | ' | ' | 0.50% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Consolidated secured leverage ratio, base rate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2.00% | 2.75% |
Consolidated secured leverage ratio, Eurodollar rate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3.00% | 3.75% |
Floor rate applicable to term loans based on Eurodollar rate | ' | ' | 1.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Long-term debt, Total | $3,838,233,000 | $3,688,907,000 | ' | $425,000,000 | $425,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | $392,933,000 | ' | ' | ' |
Long-term debt, Interest rate | ' | ' | ' | 6.50% | 6.50% | 6.50% | ' | ' | ' | ' | 9.00% | 9.00% | ' | 9.00% | 9.00% | ' | ' |
Initial offering price | ' | ' | ' | 100.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net proceeds from public offering | ' | ' | ' | 417,700,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net underwriter's commissions | ' | ' | ' | 7,300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Debt instrument, maturity date | ' | ' | ' | ' | 15-Jun-20 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of redemption premium | ' | ' | ' | ' | ' | ' | 3.25% | 1.63% | 10.00% | 0.00% | ' | ' | ' | ' | ' | ' | ' |
Percentage of principal amount used for redemption price | ' | ' | ' | ' | 103.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of aggregate principal amount redeemed | ' | ' | ' | ' | 35.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of aggregate principal amount redeemed paid | ' | ' | ' | ' | 106.50% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of aggregate principal amount outstanding | ' | ' | ' | ' | 65.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Period of redemption of notes | ' | ' | ' | ' | '90 days | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of aggregate of principal amount to be sold | ' | ' | ' | ' | 101.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of purchase price of aggregate principal amount | ' | ' | ' | ' | 100.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net proceeds from public offering | ' | ' | ' | 200,600,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Redemption of remaining outstanding principal | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 190,600,000 | ' | ' | ' | ' | ' | ' |
Percentage of outstanding principal amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 47.70% | ' | ' | ' | ' | ' | ' |
Remaining outstanding principal amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $209,400,000 | ' | ' | ' | ' |
Derivative_Financial_Instrumen2
Derivative Financial Instruments - Summary of Effect of Derivative Instruments in Consolidated Statement of Operations and in Accumulated Other Comprehensive Loss (Detail) (Other Comprehensive Income (Loss) [Member], USD $) | 3 Months Ended | 9 Months Ended |
In Thousands, unless otherwise specified | Sep. 30, 2012 | Sep. 30, 2012 |
Derivative Instruments, Gain (Loss) [Line Items] | ' | ' |
Amount of Gain Recognized | $10 | $465 |
Foreign Currency Forward Contracts [Member] | ' | ' |
Derivative Instruments, Gain (Loss) [Line Items] | ' | ' |
Amount of Gain Recognized | $10 | $465 |
Fair_Value_Measurements_Fair_V
Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis, Valuation Techniques (Detail) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Fair Value, Measurements, Recurring [Member] | ' | ' |
Assets: | ' | ' |
Marketable securities | $820 | $904 |
Total assets | 820 | 904 |
Liabilities: | ' | ' |
Contingent consideration obligations | 234,559 | 176,172 |
Total liabilities | 234,559 | 176,172 |
Quoted Prices in Active Markets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member] | ' | ' |
Assets: | ' | ' |
Marketable securities | 820 | 904 |
Total assets | 820 | 904 |
Liabilities: | ' | ' |
Contingent consideration obligations | ' | ' |
Total liabilities | ' | ' |
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member] | ' | ' |
Assets: | ' | ' |
Marketable securities | ' | ' |
Total assets | ' | ' |
Liabilities: | ' | ' |
Contingent consideration obligations | ' | ' |
Total liabilities | ' | ' |
Unobservable Inputs (Level 3) [Member] | ' | ' |
Liabilities: | ' | ' |
Contingent consideration obligations | 234,559 | 176,172 |
Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member] | ' | ' |
Assets: | ' | ' |
Marketable securities | ' | ' |
Total assets | ' | ' |
Liabilities: | ' | ' |
Contingent consideration obligations | 234,559 | 176,172 |
Total liabilities | $234,559 | $176,172 |
Fair_Value_Measurements_Change
Fair Value Measurements - Changes in Fair Value of Contingent Consideration Obligations (Detail) (Unobservable Inputs (Level 3) [Member], USD $) | 9 Months Ended |
In Thousands, unless otherwise specified | Sep. 30, 2013 |
Unobservable Inputs (Level 3) [Member] | ' |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ' |
Fair value of contingent consideration obligations, January 1, 2013 | $176,172 |
Acquisition date fair value of contingent consideration obligations recorded | 76,269 |
Net reclassifications | -12 |
Foreign currency | -150 |
Payments | -36,703 |
Present value accretion | 7,359 |
Adjustments, net (income) expense | 11,624 |
Fair value of contingent consideration obligations, September 30, 2013 | $234,559 |
Fair_Value_Measurements_Additi
Fair Value Measurements - Additional Information (Detail) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
Debt Disclosure [Abstract] | ' | ' |
Estimated fair value of our long-term debt | $3,800,000,000 | $3,700,000,000 |
Long-term debt, Total | $3,838,233,000 | $3,688,907,000 |
Defined_Benefit_Pension_Plan_N
Defined Benefit Pension Plan - Net Periodic Benefit Costs (Detail) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Compensation And Retirement Disclosure [Abstract] | ' | ' | ' | ' |
Service cost | ' | ' | ' | ' |
Interest cost | 182 | 199 | 543 | 596 |
Expected return on plan assets | -156 | -152 | -465 | -457 |
Amortization of prior service costs | 103 | 104 | 308 | 312 |
Net periodic benefit cost | $129 | $151 | $386 | $451 |
Financial_Information_by_Segme2
Financial Information by Segment - Performance of Our Operating Segments Based on Revenue and Operating Income (Loss) (Detail) (USD $) | 3 Months Ended | 9 Months Ended | |||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2012 |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' |
Net revenue | $753,882 | $691,416 | $2,257,116 | $2,063,062 | ' |
Operating income (loss) | 20,299 | 38,732 | 95,192 | 108,144 | ' |
Depreciation and amortization | ' | ' | 326,689 | 322,371 | ' |
Non-cash charge associated with acquired inventory | ' | ' | 1,880 | 4,681 | ' |
Restructuring charge | ' | ' | 16,484 | ' | ' |
Stock-based compensation | ' | ' | 14,462 | 11,868 | ' |
Loss on disposition | -5,885 | ' | -5,885 | ' | ' |
Assets | 7,154,619 | ' | 7,154,619 | ' | 7,067,928 |
Operating Segments [Member] | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' |
Net revenue | 753,882 | 691,416 | 2,257,116 | 2,063,062 | ' |
Operating income (loss) | 20,299 | 38,732 | 95,192 | 108,144 | ' |
Depreciation and amortization | 112,785 | 110,749 | 326,689 | 322,371 | ' |
Non-cash charge associated with acquired inventory | 708 | ' | 1,880 | 4,681 | ' |
Restructuring charge | 7,694 | 3,239 | 19,630 | 10,132 | ' |
Stock-based compensation | 5,662 | 3,626 | 14,462 | 11,868 | ' |
Loss on disposition | 5,885 | ' | 5,885 | ' | ' |
Assets | 7,154,619 | ' | 7,154,619 | ' | 7,067,928 |
Professional Diagnostics [Member] | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' |
Net revenue | 590,801 | 531,442 | 1,777,055 | 1,589,909 | ' |
Professional Diagnostics [Member] | Operating Segments [Member] | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' |
Net revenue | 590,801 | 531,442 | 1,777,055 | 1,589,909 | ' |
Operating income (loss) | 53,189 | 63,298 | 185,925 | 196,728 | ' |
Depreciation and amortization | 88,835 | 85,030 | 258,485 | 245,911 | ' |
Non-cash charge associated with acquired inventory | 708 | ' | 1,880 | 4,681 | ' |
Restructuring charge | 6,033 | 2,139 | 9,162 | 7,750 | ' |
Loss on disposition | 5,885 | ' | 5,885 | ' | ' |
Assets | 6,243,064 | ' | 6,243,064 | ' | 6,214,847 |
Health Information Solutions [Member] | Operating Segments [Member] | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' |
Net revenue | 134,233 | 135,078 | 403,215 | 404,452 | ' |
Operating income (loss) | -7,203 | -14,357 | -32,855 | -46,379 | ' |
Depreciation and amortization | 22,600 | 24,313 | 64,062 | 72,152 | ' |
Restructuring charge | 1,661 | 1,095 | 10,468 | 2,351 | ' |
Assets | 555,563 | ' | 555,563 | ' | 593,172 |
Consumer Diagnostics [Member] | Operating Segments [Member] | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' |
Net revenue | 28,848 | 24,896 | 76,846 | 68,701 | ' |
Operating income (loss) | 3,347 | 4,615 | 9,031 | 7,679 | ' |
Depreciation and amortization | 1,063 | 1,167 | 3,296 | 3,604 | ' |
Assets | 213,764 | ' | 213,764 | ' | 192,748 |
Corporate and Other [Member] | Operating Segments [Member] | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' |
Operating income (loss) | -29,034 | -14,824 | -66,909 | -49,884 | ' |
Depreciation and amortization | 287 | 239 | 846 | 704 | ' |
Restructuring charge | ' | 5 | ' | 31 | ' |
Stock-based compensation | 5,662 | 3,626 | 14,462 | 11,868 | ' |
Assets | $142,228 | ' | $142,228 | ' | $67,161 |
Financial_Information_by_Segme3
Financial Information by Segment - Summary of Company's Net Revenue from Professional Diagnostics and Health Information Solutions Reporting Segments by Groups of Similar Products and Services (Detail) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Net product sales and services revenue | $749,698 | $686,228 | $2,244,003 | $2,051,729 |
License and royalty revenue | 4,184 | 5,188 | 13,113 | 11,333 |
Net revenue | 753,882 | 691,416 | 2,257,116 | 2,063,062 |
Professional Diagnostics [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Net product sales and services revenue | 587,313 | 528,754 | 1,765,538 | 1,581,076 |
License and royalty revenue | 3,488 | 2,688 | 11,517 | 8,833 |
Net revenue | 590,801 | 531,442 | 1,777,055 | 1,589,909 |
Health Information Solutions [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Net revenue | 134,233 | 135,078 | 403,215 | 404,452 |
Cardiology [Member] | Professional Diagnostics [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Net product sales and services revenue | 116,281 | 122,372 | 349,650 | 386,795 |
Infectious Disease [Member] | Professional Diagnostics [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Net product sales and services revenue | 172,739 | 136,561 | 520,289 | 425,398 |
Toxicology [Member] | Professional Diagnostics [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Net product sales and services revenue | 166,536 | 156,074 | 481,469 | 437,736 |
Diabetes [Member] | Professional Diagnostics [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Net product sales and services revenue | 53,150 | 35,670 | 178,138 | 100,628 |
Other [Member] | Professional Diagnostics [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Net product sales and services revenue | 78,607 | 78,077 | 235,992 | 230,519 |
Disease and Case Management [Member] | Health Information Solutions [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Net product sales and services revenue | 56,554 | 57,383 | 163,258 | 165,277 |
Wellness [Member] | Health Information Solutions [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Net product sales and services revenue | 22,223 | 24,290 | 75,753 | 80,881 |
Women's & Children's Health [Member] | Health Information Solutions [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Net product sales and services revenue | 28,431 | 29,136 | 86,767 | 90,220 |
Patient Self-testing Services [Member] | Health Information Solutions [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Net product sales and services revenue | $27,025 | $24,269 | $77,437 | $68,074 |
Related_Party_Transactions_Add
Related Party Transactions - Additional Information (Detail) (USD $) | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||
Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | 31-May-07 | |
Sales Revenue Goods [Member] | Sales Revenue Goods [Member] | Sales Revenue Goods [Member] | Sales Revenue Goods [Member] | Sales Revenue Services [Member] | Sales Revenue Services [Member] | Sales Revenue Services [Member] | Sales Revenue Services [Member] | Swiss Precision Diagnostics [Member] | Swiss Precision Diagnostics [Member] | Swiss Precision Diagnostics [Member] | ||||
Related Party Transaction [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Joint venture ownership percentage with P&G | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 50.00% |
Net receivable from joint venture | $3,200,000 | ' | $2,300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring charges | 16,484,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,900,000 | 1,600,000 | ' |
Long-term receivables cost related to restructuring plan | 13,000,000 | ' | 14,600,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Customer receivables associated with revenue earned after SPD was completed have been classified as other receivables | 10,000,000 | ' | 6,900,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenue from joint venture | ' | ' | ' | 21,200,000 | 15,900,000 | 56,500,000 | 47,400,000 | 300,000 | 300,000 | 900,000 | 900,000 | ' | ' | ' |
Trade receivables from joint venture | 10,000,000 | ' | 7,300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Trade payable to joint venture | 25,400,000 | ' | 21,300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cash (return of investment) from SPD | $10,800,000 | $6,100,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Related_Party_Transactions_Rel
Related Party Transactions - Related Party Balances with SPD within Consolidated Balance Sheets (Detail) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Related Party Transaction [Line Items] | ' | ' |
Accounts receivable, net of allowances | $568,873 | $524,332 |
Prepaid expenses and other current assets | 114,601 | 145,236 |
Deferred financing costs, net, and other non-current assets | 86,489 | 108,857 |
Accounts payable | 194,991 | 169,974 |
Related Party Transaction [Member] | ' | ' |
Related Party Transaction [Line Items] | ' | ' |
Accounts receivable, net of allowances | 9,984 | 7,317 |
Prepaid expenses and other current assets | 13,221 | 9,161 |
Deferred financing costs, net, and other non-current assets | 12,955 | 14,629 |
Accounts payable | $25,437 | $21,258 |
Other_Arrangements_Additional_
Other Arrangements - Additional Information (Detail) (USD $) | 1 Months Ended | 3 Months Ended | 9 Months Ended |
In Millions, unless otherwise specified | Feb. 19, 2013 | Sep. 30, 2013 | Sep. 30, 2013 |
Gates Foundation [Member] | ' | ' | ' |
Agreements [Line Items] | ' | ' | ' |
Revenue from grant awarded | $21.60 | ' | ' |
Cash received from grant-related funding | ' | ' | 7.9 |
Qualified expenditures | ' | 1.9 | 4.3 |
Gates Loan Agreement [Member] | ' | ' | ' |
Agreements [Line Items] | ' | ' | ' |
Aggregate principal amount of subordinated term loan | 20.6 | ' | ' |
Loan bearing interest rate | ' | 3.00% | 3.00% |
Maturity date | ' | ' | 31-Dec-19 |
Amount borrowed under agreement | ' | $0 | $0 |
Material_Contingencies_Additio
Material Contingencies - Additional Information (Detail) | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Feb. 01, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Jun. 30, 2013 | Sep. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Jun. 30, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Mar. 31, 2013 | Mar. 31, 2013 |
USD ($) | USD ($) | Epocal [Member] | Epocal [Member] | Accordant [Member] | Accordant [Member] | Accordant [Member] | Accordant [Member] | Alere Healthcare [Member] | Alere Healthcare [Member] | Alere S.A. [Member] | Alere S.A. [Member] | Alere S.A. [Member] | Amedica [Member] | Amedica [Member] | Branan [Member] | Branan [Member] | Immunalysis [Member] | Immunalysis [Member] | MedApps [Member] | MedApps [Member] | Nations Health [Member] | Nations Health [Member] | Pantech Proprietary [Member] | ROAR [Member] | ROAR [Member] | ROAR [Member] | ROAR [Member] | |
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | BRL | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | Maximum [Member] | USD ($) | GBP (£) | USD ($) | GBP (£) | |||
Installment | Installment | USD ($) | ||||||||||||||||||||||||||
Business Acquisition, Contingent Consideration [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Payable contingent cash consideration remaining | ' | ' | $90,500,000 | ' | ' | ' | ' | $4,500,000 | ' | ' | ' | ' | ' | ' | ' | ' | $2,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Earn-out cash paid | 209,247,000 | 418,903,000 | 173,461,000 | 173,500,000 | 1,500,000 | 1,500,000 | 1,500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Acquisition date fair value investment | 76,264,000 | 75,620,000 | 75,000,000 | 75,000,000 | 0 | ' | ' | ' | 0 | 300,000 | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' | 0 | ' | ' | ' | ' | ' | ' |
Maximum remaining amount of earn-out payment | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,900,000 | 3,100,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cash earn-out payment | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,900,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,000,000 | ' | ' | ' | ' | ' |
Remaining payments in installments | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of installments paid | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 48 | 48 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Contingent consideration obligations related to acquisition | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Payable contingent cash consideration | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,900,000 | ' | ' | ' | 1,700,000 | ' | 3,000,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Maximum remaining amount of earn-out payment | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8,100,000 | 1,800,000 | ' | ' | ' | ' | ' | ' | ' | ' | 15,200,000 | 9,500,000 | ' | ' |
Incremental accrual | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cash paid on the day of acquisition | ' | ' | 15,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Maximum amount of management incentive payments | ' | ' | 9,400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Contractual obligation | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Compensation related to contractual contingent obligation earned and accrued | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,000,000 | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accrued earn-out payments | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 18,200,000 | ' | ' | ' | ' | ' | 1,500,000 | 1,000,000 |
Maximum earn-out payments | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $600,000 | ' | ' | ' | ' |
Equity_Investments_Additional_
Equity Investments - Additional Information (Detail) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Schedule of Equity Method Investments [Line Items] | ' | ' | ' | ' |
Equity earnings of unconsolidated entities, net of tax | $5,753 | $3,007 | $13,238 | $10,417 |
Swiss Precision Diagnostics [Member] | ' | ' | ' | ' |
Schedule of Equity Method Investments [Line Items] | ' | ' | ' | ' |
Equity earnings of unconsolidated entities, net of tax | 4,700 | 2,100 | 11,400 | 8,200 |
Ownership percentage | 50.00% | ' | 50.00% | ' |
TechLab [Member] | ' | ' | ' | ' |
Schedule of Equity Method Investments [Line Items] | ' | ' | ' | ' |
Equity earnings of unconsolidated entities, net of tax | $500 | $600 | $1,300 | $1,800 |
Ownership percentage | 49.00% | ' | 49.00% | ' |
Equity_Investments_Financial_I
Equity Investments - Financial Information for SPD and Techlab on Combined Condensed Results of Operations (Detail) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Equity Method Investments And Joint Ventures [Abstract] | ' | ' | ' | ' |
Net revenue | $49,272 | $54,650 | $153,096 | $165,483 |
Gross profit | 40,158 | 34,411 | 112,862 | 105,175 |
Net income after taxes | $10,543 | $5,399 | $25,549 | $20,083 |
Equity_Investments_Financial_I1
Equity Investments - Financial Information for SPD and Techlab on Combined Condensed Balance Sheets (Detail) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Equity Method Investments And Joint Ventures [Abstract] | ' | ' |
Current assets | $95,764 | $79,842 |
Non-current assets | 37,909 | 38,991 |
Total assets | 133,673 | 118,833 |
Current liabilities | 39,468 | 45,084 |
Non-current liabilities | 6,268 | 6,791 |
Total liabilities | $45,736 | $51,875 |
Loss_on_Disposition_Additional
Loss on Disposition - Additional Information (Detail) (USD $) | 1 Months Ended | 3 Months Ended |
In Millions, unless otherwise specified | Jul. 31, 2013 | Sep. 30, 2013 |
Discontinued Operations And Disposal Groups [Abstract] | ' | ' |
Cash proceeds from sale of disposal group | $32 | ' |
Loss from sale of disposal group | ' | $5.90 |
Guarantor_Financial_Informatio2
Guarantor Financial Information - Additional Information (Detail) | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Sep. 30, 2013 | 24-May-13 | Dec. 31, 2012 |
7.25% Senior Notes [Member] | 7.25% Senior Notes [Member] | 8.625% Senior Subordinated Notes [Member] | 8.625% Senior Subordinated Notes [Member] | 8.625% Senior Subordinated Notes [Member] | 6.5% Senior Subordinated Notes [Member] | 6.5% Senior Subordinated Notes [Member] | 6.5% Senior Subordinated Notes [Member] | |
Debt Instrument [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' |
Interest rate of debt instrument | 7.25% | 7.25% | 8.63% | 8.63% | 8.63% | 6.50% | 6.50% | 6.50% |
Guarantor_Financial_Informatio3
Guarantor Financial Information - Guarantor Financial Information Consolidating Statement of Operations (Detail) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Condensed Financial Statements, Captions [Line Items] | ' | ' | ' | ' |
Net product sales | $509,038 | $459,813 | $1,538,876 | $1,399,025 |
Services revenue | 240,660 | 226,415 | 705,127 | 652,704 |
Net product sales and services revenue | 749,698 | 686,228 | 2,244,003 | 2,051,729 |
License and royalty revenue | 4,184 | 5,188 | 13,113 | 11,333 |
Net revenue | 753,882 | 691,416 | 2,257,116 | 2,063,062 |
Cost of net product sales | 258,234 | 223,612 | 764,501 | 671,664 |
Cost of services revenue | 124,993 | 120,131 | 369,961 | 331,550 |
Cost of net product sales and services revenue | 383,227 | 343,743 | 1,134,462 | 1,003,214 |
Cost of license and royalty revenue | 2,009 | 1,898 | 5,264 | 5,394 |
Cost of net revenue | 385,236 | 345,641 | 1,139,726 | 1,008,608 |
Gross profit (loss) | 368,646 | 345,775 | 1,117,390 | 1,054,454 |
Operating expenses: | ' | ' | ' | ' |
Research and development | 40,498 | 40,562 | 122,452 | 120,009 |
Sales and marketing | 159,587 | 160,644 | 475,465 | 478,544 |
General and administrative | 142,377 | 105,837 | 418,396 | 347,757 |
Loss on disposition | 5,885 | ' | 5,885 | ' |
Total operating expenses | ' | 307,043 | ' | 946,310 |
Operating income (loss) | 20,299 | 38,732 | 95,192 | 108,144 |
Interest expense, including amortization of original issue discounts and deferred financing costs | -53,420 | -54,861 | -203,272 | -161,119 |
Other income (expense), net | -8,869 | -1,072 | -8,276 | 14,570 |
Income (loss) before provision (benefit) for income taxes | -41,990 | -17,201 | -116,356 | -38,405 |
Provision (benefit) for income taxes | -17,148 | -10,677 | -36,152 | -12,621 |
Income (loss) before equity earnings (losses) of subsidiaries and unconsolidated entities, net of tax | -24,842 | -6,524 | -80,204 | -25,784 |
Equity earnings of unconsolidated entities, net of tax | 5,753 | 3,007 | 13,238 | 10,417 |
Net income (loss) | -19,089 | -3,517 | -66,966 | -15,367 |
Less: Net income attributable to non-controlling interests | 359 | 286 | 601 | 137 |
Net income (loss) attributable to Alere Inc. and Subsidiaries | -19,448 | -3,803 | -67,567 | -15,504 |
Preferred stock dividends | -5,367 | -5,352 | -15,926 | -15,940 |
Net income (loss) available to common stockholders | -24,815 | -9,155 | -83,493 | -31,444 |
Issuer [Member] | ' | ' | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' | ' | ' |
Cost of net product sales | 887 | 928 | 2,722 | 2,635 |
Cost of net product sales and services revenue | 887 | 928 | 2,722 | 2,635 |
Cost of net revenue | 887 | 928 | 2,722 | 2,635 |
Gross profit (loss) | -887 | -928 | -2,722 | -2,635 |
Operating expenses: | ' | ' | ' | ' |
Research and development | 5,515 | 6,292 | 16,167 | 17,361 |
Sales and marketing | 1,579 | 1,220 | 4,384 | 3,096 |
General and administrative | 23,027 | 11,392 | 51,531 | 37,590 |
Total operating expenses | ' | 18,904 | ' | 58,047 |
Operating income (loss) | -31,008 | -19,832 | -74,804 | -60,682 |
Interest expense, including amortization of original issue discounts and deferred financing costs | -52,318 | -54,324 | -200,836 | -158,009 |
Other income (expense), net | -6,775 | 1,534 | -7,612 | -2,552 |
Income (loss) before provision (benefit) for income taxes | -90,101 | -72,622 | -283,252 | -221,243 |
Provision (benefit) for income taxes | -29,302 | -27,401 | -102,473 | -74,149 |
Income (loss) before equity earnings (losses) of subsidiaries and unconsolidated entities, net of tax | -60,799 | -45,221 | -180,779 | -147,094 |
Equity earnings (losses) of subsidiaries, net of tax | 41,246 | 41,052 | 112,535 | 129,929 |
Equity earnings of unconsolidated entities, net of tax | 464 | 652 | 1,278 | 1,798 |
Net income (loss) | -19,089 | -3,517 | -66,966 | -15,367 |
Net income (loss) attributable to Alere Inc. and Subsidiaries | -19,089 | -3,517 | -66,966 | -15,367 |
Preferred stock dividends | -5,367 | -5,352 | -15,926 | -15,940 |
Net income (loss) available to common stockholders | -24,456 | -8,869 | -82,892 | -31,307 |
Guarantor Subsidiaries [Member] | ' | ' | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' | ' | ' |
Net product sales | 223,254 | 219,484 | 665,672 | 649,719 |
Services revenue | 220,439 | 210,761 | 644,760 | 605,193 |
Net product sales and services revenue | 443,693 | 430,245 | 1,310,432 | 1,254,912 |
License and royalty revenue | 5,103 | -4,912 | 10,908 | 8,982 |
Net revenue | 448,796 | 425,333 | 1,321,340 | 1,263,894 |
Cost of net product sales | 129,408 | 107,410 | 367,552 | 311,722 |
Cost of services revenue | 120,032 | 115,212 | 355,930 | 311,718 |
Cost of net product sales and services revenue | 249,440 | 222,622 | 723,482 | 623,440 |
Cost of license and royalty revenue | 17 | 5 | 52 | 15 |
Cost of net revenue | 249,457 | 222,627 | 723,534 | 623,455 |
Gross profit (loss) | 199,339 | 202,706 | 597,806 | 640,439 |
Operating expenses: | ' | ' | ' | ' |
Research and development | 15,817 | 18,007 | 49,354 | 53,528 |
Sales and marketing | 81,107 | 85,866 | 245,148 | 260,283 |
General and administrative | 61,489 | 48,704 | 200,646 | 174,639 |
Total operating expenses | ' | 152,577 | ' | 488,450 |
Operating income (loss) | 40,926 | 50,129 | 102,658 | 151,989 |
Interest expense, including amortization of original issue discounts and deferred financing costs | -6,326 | -9,278 | -19,729 | -31,291 |
Other income (expense), net | 5,770 | 8,319 | 17,665 | 33,550 |
Income (loss) before provision (benefit) for income taxes | 40,370 | 49,170 | 100,594 | 154,248 |
Provision (benefit) for income taxes | 14,928 | 17,014 | 44,896 | 59,013 |
Income (loss) before equity earnings (losses) of subsidiaries and unconsolidated entities, net of tax | 25,442 | 32,156 | 55,698 | 95,235 |
Equity earnings (losses) of subsidiaries, net of tax | -337 | -230 | -1,510 | -763 |
Net income (loss) | 25,105 | 31,926 | 54,188 | 94,472 |
Net income (loss) attributable to Alere Inc. and Subsidiaries | 25,105 | 31,926 | 54,188 | 94,472 |
Net income (loss) available to common stockholders | 25,105 | 31,926 | 54,188 | 94,472 |
Non-Guarantor Subsidiaries [Member] | ' | ' | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' | ' | ' |
Net product sales | 330,389 | 282,369 | 1,016,614 | 854,113 |
Services revenue | 20,221 | 15,654 | 60,367 | 47,511 |
Net product sales and services revenue | 350,610 | 298,023 | 1,076,981 | 901,624 |
License and royalty revenue | 4,057 | 4,868 | 12,662 | 10,016 |
Net revenue | 354,667 | 302,891 | 1,089,643 | 911,640 |
Cost of net product sales | 165,396 | 152,607 | 519,559 | 456,760 |
Cost of services revenue | 10,292 | 7,161 | 28,511 | 22,074 |
Cost of net product sales and services revenue | 175,688 | 159,768 | 548,070 | 478,834 |
Cost of license and royalty revenue | 6,967 | -3,339 | 15,668 | 13,044 |
Cost of net revenue | 182,655 | 156,429 | 563,738 | 491,878 |
Gross profit (loss) | 172,012 | 146,462 | 525,905 | 419,762 |
Operating expenses: | ' | ' | ' | ' |
Research and development | 19,166 | 16,263 | 56,931 | 49,120 |
Sales and marketing | 76,901 | 73,558 | 225,933 | 215,165 |
General and administrative | 57,861 | 45,741 | 166,219 | 135,528 |
Loss on disposition | 5,885 | ' | 5,885 | ' |
Total operating expenses | ' | 135,562 | ' | 399,813 |
Operating income (loss) | 12,199 | 10,900 | 70,937 | 19,949 |
Interest expense, including amortization of original issue discounts and deferred financing costs | -2,721 | -2,783 | -9,209 | -9,853 |
Other income (expense), net | 81 | 599 | 8,173 | 21,606 |
Income (loss) before provision (benefit) for income taxes | 9,559 | 8,716 | 69,901 | 31,702 |
Provision (benefit) for income taxes | -2,214 | 643 | 22,663 | 3,494 |
Income (loss) before equity earnings (losses) of subsidiaries and unconsolidated entities, net of tax | 11,773 | 8,073 | 47,238 | 28,208 |
Equity earnings of unconsolidated entities, net of tax | 5,217 | 2,405 | 11,932 | 8,643 |
Net income (loss) | 16,990 | 10,478 | 59,170 | 36,851 |
Less: Net income attributable to non-controlling interests | 359 | 286 | 601 | 137 |
Net income (loss) attributable to Alere Inc. and Subsidiaries | 16,631 | 10,192 | 58,569 | 36,714 |
Net income (loss) available to common stockholders | 16,631 | 10,192 | 58,569 | 36,714 |
Eliminations [Member] | ' | ' | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' | ' | ' |
Net product sales | -44,605 | -42,040 | -143,410 | -104,807 |
Net product sales and services revenue | -44,605 | -42,040 | -143,410 | -104,807 |
License and royalty revenue | -4,976 | 5,232 | -10,457 | -7,665 |
Net revenue | -49,581 | -36,808 | -153,867 | -112,472 |
Cost of net product sales | -37,457 | -37,333 | -125,332 | -99,453 |
Cost of services revenue | -5,331 | -2,242 | -14,480 | -2,242 |
Cost of net product sales and services revenue | -42,788 | -39,575 | -139,812 | -101,695 |
Cost of license and royalty revenue | -4,975 | 5,232 | -10,456 | -7,665 |
Cost of net revenue | -47,763 | -34,343 | -150,268 | -109,360 |
Gross profit (loss) | -1,818 | -2,465 | -3,599 | -3,112 |
Operating expenses: | ' | ' | ' | ' |
Operating income (loss) | -1,818 | -2,465 | -3,599 | -3,112 |
Interest expense, including amortization of original issue discounts and deferred financing costs | 7,945 | 11,524 | 26,502 | 38,034 |
Other income (expense), net | -7,945 | -11,524 | -26,502 | -38,034 |
Income (loss) before provision (benefit) for income taxes | -1,818 | -2,465 | -3,599 | -3,112 |
Provision (benefit) for income taxes | -560 | -933 | -1,238 | -979 |
Income (loss) before equity earnings (losses) of subsidiaries and unconsolidated entities, net of tax | -1,258 | -1,532 | -2,361 | -2,133 |
Equity earnings (losses) of subsidiaries, net of tax | -40,909 | -40,822 | -111,025 | -129,166 |
Equity earnings of unconsolidated entities, net of tax | 72 | -50 | 28 | -24 |
Net income (loss) | -42,095 | -42,404 | -113,358 | -131,323 |
Net income (loss) attributable to Alere Inc. and Subsidiaries | -42,095 | -42,404 | -113,358 | -131,323 |
Net income (loss) available to common stockholders | ($42,095) | ($42,404) | ($113,358) | ($131,323) |
Guarantor_Financial_Informatio4
Guarantor Financial Information - Guarantor Financial Information Consolidating Statement of Comprehensive Income (Loss) (Detail) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Condensed Financial Statements, Captions [Line Items] | ' | ' | ' | ' |
Net income (loss) | ($19,089) | ($3,517) | ($66,966) | ($15,367) |
Other comprehensive income (loss), before tax: | ' | ' | ' | ' |
Changes in cumulative translation adjustment | 67,268 | 39,695 | -42,515 | 38,857 |
Unrealized gains on available for sale securities | ' | 141 | ' | 931 |
Unrealized gains on hedging instruments | 20 | 10 | 31 | 465 |
Minimum pension liability adjustment | -369 | -98 | 335 | -218 |
Other comprehensive income (loss), before tax | 66,919 | 39,748 | -42,149 | 40,035 |
Income tax provision (benefit) related to items of other comprehensive income (loss) | ' | 360 | ' | 360 |
Other comprehensive income (loss), net of tax | 66,919 | 39,388 | -42,149 | 39,675 |
Comprehensive income (loss) | 47,830 | 35,871 | -109,115 | 24,308 |
Less: Comprehensive income attributable to non-controlling interests | 359 | 286 | 601 | 137 |
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | 47,471 | 35,585 | -109,716 | 24,171 |
Issuer [Member] | ' | ' | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' | ' | ' |
Net income (loss) | -19,089 | -3,517 | -66,966 | -15,367 |
Other comprehensive income (loss), before tax: | ' | ' | ' | ' |
Changes in cumulative translation adjustment | 524 | 132 | -329 | -100 |
Unrealized gains on available for sale securities | ' | 141 | ' | 926 |
Unrealized gains on hedging instruments | ' | ' | ' | 17 |
Other comprehensive income (loss), before tax | 524 | 273 | -329 | 843 |
Income tax provision (benefit) related to items of other comprehensive income (loss) | ' | 360 | ' | 360 |
Other comprehensive income (loss), net of tax | 524 | -87 | -329 | 483 |
Comprehensive income (loss) | -18,565 | -3,604 | -67,295 | -14,884 |
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | -18,565 | -3,604 | -67,295 | -14,884 |
Guarantor Subsidiaries [Member] | ' | ' | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' | ' | ' |
Net income (loss) | 25,105 | 31,926 | 54,188 | 94,472 |
Other comprehensive income (loss), before tax: | ' | ' | ' | ' |
Changes in cumulative translation adjustment | ' | 1 | ' | -302 |
Unrealized gains on available for sale securities | ' | ' | ' | 5 |
Other comprehensive income (loss), before tax | ' | 1 | ' | -297 |
Other comprehensive income (loss), net of tax | ' | 1 | ' | -297 |
Comprehensive income (loss) | 25,105 | 31,927 | 54,188 | 94,175 |
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | 25,105 | 31,927 | 54,188 | 94,175 |
Non-Guarantor Subsidiaries [Member] | ' | ' | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' | ' | ' |
Net income (loss) | 16,990 | 10,478 | 59,170 | 36,851 |
Other comprehensive income (loss), before tax: | ' | ' | ' | ' |
Changes in cumulative translation adjustment | 66,742 | 36,027 | -42,188 | 37,136 |
Unrealized gains on hedging instruments | 20 | 10 | 31 | 448 |
Minimum pension liability adjustment | -369 | -98 | 335 | -218 |
Other comprehensive income (loss), before tax | 66,393 | 35,939 | -41,822 | 37,366 |
Other comprehensive income (loss), net of tax | 66,393 | 35,939 | -41,822 | 37,366 |
Comprehensive income (loss) | 83,383 | 46,417 | 17,348 | 74,217 |
Less: Comprehensive income attributable to non-controlling interests | 359 | 286 | 601 | 137 |
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | 83,024 | 46,131 | 16,747 | 74,080 |
Eliminations [Member] | ' | ' | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' | ' | ' |
Net income (loss) | -42,095 | -42,404 | -113,358 | -131,323 |
Other comprehensive income (loss), before tax: | ' | ' | ' | ' |
Changes in cumulative translation adjustment | 2 | 3,535 | 2 | 2,123 |
Other comprehensive income (loss), before tax | 2 | 3,535 | 2 | 2,123 |
Other comprehensive income (loss), net of tax | 2 | 3,535 | 2 | 2,123 |
Comprehensive income (loss) | -42,093 | -38,869 | -113,356 | -129,200 |
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | ($42,093) | ($38,869) | ($113,356) | ($129,200) |
Guarantor_Financial_Informatio5
Guarantor Financial Information - Guarantor Financial Information Consolidating Balance Sheet (Detail) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Dec. 31, 2011 |
In Thousands, unless otherwise specified | ||||
Current assets: | ' | ' | ' | ' |
Cash and cash equivalents | $353,993 | $328,346 | $302,254 | $299,173 |
Restricted cash | 7,905 | 3,076 | ' | ' |
Marketable securities | 820 | 904 | ' | ' |
Accounts receivable, net of allowances | 568,873 | 524,332 | ' | ' |
Inventories, net | 370,448 | 337,121 | ' | ' |
Deferred tax assets | 58,177 | 67,722 | ' | ' |
Prepaid expenses and other current assets | 114,601 | 145,236 | ' | ' |
Total current assets | 1,474,817 | 1,406,737 | ' | ' |
Property, plant and equipment, net | 544,271 | 534,469 | ' | ' |
Goodwill | 3,103,495 | 3,048,405 | 239,300 | ' |
Other intangible assets with indefinite lives | 58,953 | 36,451 | ' | ' |
Finite-lived intangible assets, net | 1,747,538 | 1,834,225 | ' | ' |
Restricted cash-non-current | 29,045 | ' | ' | ' |
Deferred financing costs, net and other non-current assets | 86,489 | 108,857 | ' | ' |
Investments in unconsolidated entities | 101,822 | 90,491 | ' | ' |
Deferred tax assets | 8,189 | 8,293 | ' | ' |
Total assets | 7,154,619 | 7,067,928 | ' | ' |
Current liabilities: | ' | ' | ' | ' |
Short-term debt | 25 | ' | ' | ' |
Current portion of long-term debt | 47,701 | 60,232 | ' | ' |
Current portion of capital lease obligations | 6,533 | 6,684 | ' | ' |
Accounts payable | 194,991 | 169,974 | ' | ' |
Accrued expenses and other current liabilities | 447,228 | 411,919 | ' | ' |
Total current liabilities | 696,478 | 648,809 | ' | ' |
Long-term liabilities: | ' | ' | ' | ' |
Long-term debt, net of current portion | 3,790,532 | 3,628,675 | ' | ' |
Capital lease obligations, net of current portion | 14,926 | 12,917 | ' | ' |
Deferred tax liabilities | 352,859 | 428,188 | ' | ' |
Other long-term liabilities | 209,683 | 166,635 | ' | ' |
Total long-term liabilities | 4,368,000 | 4,236,415 | ' | ' |
Stockholders' equity | 2,085,470 | 2,180,422 | ' | ' |
Non-controlling interests | 4,671 | 2,282 | ' | ' |
Total equity | 2,090,141 | 2,182,704 | 2,231,595 | 2,231,574 |
Total liabilities and equity | 7,154,619 | 7,067,928 | ' | ' |
Issuer [Member] | ' | ' | ' | ' |
Current assets: | ' | ' | ' | ' |
Cash and cash equivalents | 47,863 | 3,623 | 329 | 12,451 |
Restricted cash | 4,439 | ' | ' | ' |
Deferred tax assets | 8,749 | 12,193 | ' | ' |
Prepaid expenses and other current assets | 3,911 | -20,636 | ' | ' |
Intercompany receivables | 332,124 | 298,812 | ' | ' |
Total current assets | 397,086 | 293,992 | ' | ' |
Property, plant and equipment, net | 9,048 | 2,679 | ' | ' |
Finite-lived intangible assets, net | 8,786 | 24,701 | ' | ' |
Deferred financing costs, net and other non-current assets | 58,996 | 78,522 | ' | ' |
Investments in subsidiaries | 4,473,400 | 4,114,478 | ' | ' |
Investments in unconsolidated entities | 30,221 | 33,979 | ' | ' |
Intercompany notes receivable | 1,541,655 | 1,724,650 | ' | ' |
Total assets | 6,519,192 | 6,273,001 | ' | ' |
Current liabilities: | ' | ' | ' | ' |
Current portion of long-term debt | 45,000 | 45,000 | ' | ' |
Accounts payable | 18,702 | 7,993 | ' | ' |
Accrued expenses and other current liabilities | -381,276 | -388,830 | ' | ' |
Intercompany payables | 677,842 | 557,578 | ' | ' |
Total current liabilities | 360,268 | 221,741 | ' | ' |
Long-term liabilities: | ' | ' | ' | ' |
Long-term debt, net of current portion | 3,750,057 | 3,617,068 | ' | ' |
Deferred tax liabilities | -27,768 | -5,329 | ' | ' |
Other long-term liabilities | 20,198 | 17,678 | ' | ' |
Intercompany notes payables | 330,967 | 241,421 | ' | ' |
Total long-term liabilities | 4,073,454 | 3,870,838 | ' | ' |
Stockholders' equity | 2,085,470 | 2,180,422 | ' | ' |
Total equity | 2,085,470 | 2,180,422 | ' | ' |
Total liabilities and equity | 6,519,192 | 6,273,001 | ' | ' |
Guarantor Subsidiaries [Member] | ' | ' | ' | ' |
Current assets: | ' | ' | ' | ' |
Cash and cash equivalents | 76,234 | 67,449 | 64,062 | 95,212 |
Restricted cash | 2,309 | 1,680 | ' | ' |
Marketable securities | 815 | 787 | ' | ' |
Accounts receivable, net of allowances | 256,578 | 241,050 | ' | ' |
Inventories, net | 170,372 | 142,413 | ' | ' |
Deferred tax assets | 35,980 | 39,601 | ' | ' |
Prepaid expenses and other current assets | 34,732 | 99,271 | ' | ' |
Intercompany receivables | 714,131 | 1,254,727 | ' | ' |
Total current assets | 1,291,151 | 1,846,978 | ' | ' |
Property, plant and equipment, net | 291,621 | 293,260 | ' | ' |
Goodwill | 1,810,036 | 1,820,438 | ' | ' |
Other intangible assets with indefinite lives | 12,900 | 14,600 | ' | ' |
Finite-lived intangible assets, net | 1,003,272 | 1,132,656 | ' | ' |
Deferred financing costs, net and other non-current assets | 9,299 | 10,341 | ' | ' |
Investments in subsidiaries | 274,450 | 222,175 | ' | ' |
Deferred tax assets | ' | 782 | ' | ' |
Intercompany notes receivable | 665,623 | 722,552 | ' | ' |
Total assets | 5,358,352 | 6,063,782 | ' | ' |
Current liabilities: | ' | ' | ' | ' |
Current portion of long-term debt | 348 | 349 | ' | ' |
Current portion of capital lease obligations | 3,808 | 3,209 | ' | ' |
Accounts payable | 77,163 | 76,256 | ' | ' |
Accrued expenses and other current liabilities | 604,035 | 586,116 | ' | ' |
Intercompany payables | 149,645 | 806,507 | ' | ' |
Total current liabilities | 834,999 | 1,472,437 | ' | ' |
Long-term liabilities: | ' | ' | ' | ' |
Long-term debt, net of current portion | 150 | 374 | ' | ' |
Capital lease obligations, net of current portion | 6,133 | 5,412 | ' | ' |
Deferred tax liabilities | 282,942 | 333,388 | ' | ' |
Other long-term liabilities | 57,762 | 72,890 | ' | ' |
Intercompany notes payables | 1,503,599 | 1,630,376 | ' | ' |
Total long-term liabilities | 1,850,586 | 2,042,440 | ' | ' |
Stockholders' equity | 2,672,767 | 2,548,905 | ' | ' |
Total equity | 2,672,767 | 2,548,905 | ' | ' |
Total liabilities and equity | 5,358,352 | 6,063,782 | ' | ' |
Non-Guarantor Subsidiaries [Member] | ' | ' | ' | ' |
Current assets: | ' | ' | ' | ' |
Cash and cash equivalents | 229,896 | 257,274 | 237,863 | 191,510 |
Restricted cash | 1,157 | 1,396 | ' | ' |
Marketable securities | 5 | 117 | ' | ' |
Accounts receivable, net of allowances | 312,295 | 283,282 | ' | ' |
Inventories, net | 225,894 | 203,230 | ' | ' |
Deferred tax assets | 9,440 | 13,138 | ' | ' |
Prepaid expenses and other current assets | 75,999 | 66,634 | ' | ' |
Intercompany receivables | 61,898 | 55,847 | ' | ' |
Total current assets | 916,584 | 880,918 | ' | ' |
Property, plant and equipment, net | 243,981 | 239,082 | ' | ' |
Goodwill | 1,293,459 | 1,227,967 | ' | ' |
Other intangible assets with indefinite lives | 46,053 | 21,851 | ' | ' |
Finite-lived intangible assets, net | 735,480 | 676,868 | ' | ' |
Restricted cash-non-current | 29,045 | ' | ' | ' |
Deferred financing costs, net and other non-current assets | 18,247 | 20,065 | ' | ' |
Investments in subsidiaries | 127,711 | 73,940 | ' | ' |
Investments in unconsolidated entities | 58,049 | 56,512 | ' | ' |
Deferred tax assets | 8,189 | 7,511 | ' | ' |
Intercompany notes receivable | 97,887 | 1,278 | ' | ' |
Total assets | 3,574,685 | 3,205,992 | ' | ' |
Current liabilities: | ' | ' | ' | ' |
Short-term debt | 25 | ' | ' | ' |
Current portion of long-term debt | 2,353 | 14,883 | ' | ' |
Current portion of capital lease obligations | 2,725 | 3,475 | ' | ' |
Accounts payable | 99,126 | 85,725 | ' | ' |
Accrued expenses and other current liabilities | 225,084 | 214,659 | ' | ' |
Intercompany payables | 280,668 | 245,300 | ' | ' |
Total current liabilities | 609,981 | 564,042 | ' | ' |
Long-term liabilities: | ' | ' | ' | ' |
Long-term debt, net of current portion | 40,325 | 11,233 | ' | ' |
Capital lease obligations, net of current portion | 8,793 | 7,505 | ' | ' |
Deferred tax liabilities | 97,211 | 100,216 | ' | ' |
Other long-term liabilities | 131,776 | 76,138 | ' | ' |
Intercompany notes payables | 470,599 | 576,684 | ' | ' |
Total long-term liabilities | 748,704 | 771,776 | ' | ' |
Stockholders' equity | 2,211,329 | 1,867,892 | ' | ' |
Non-controlling interests | 4,671 | 2,282 | ' | ' |
Total equity | 2,216,000 | 1,870,174 | ' | ' |
Total liabilities and equity | 3,574,685 | 3,205,992 | ' | ' |
Eliminations [Member] | ' | ' | ' | ' |
Current assets: | ' | ' | ' | ' |
Inventories, net | -25,818 | -8,522 | ' | ' |
Deferred tax assets | 4,008 | 2,790 | ' | ' |
Prepaid expenses and other current assets | -41 | -33 | ' | ' |
Intercompany receivables | -1,108,153 | -1,609,386 | ' | ' |
Total current assets | -1,130,004 | -1,615,151 | ' | ' |
Property, plant and equipment, net | -379 | -552 | ' | ' |
Deferred financing costs, net and other non-current assets | -53 | -71 | ' | ' |
Investments in subsidiaries | -4,875,561 | -4,410,593 | ' | ' |
Investments in unconsolidated entities | 13,552 | ' | ' | ' |
Intercompany notes receivable | -2,305,165 | -2,448,480 | ' | ' |
Total assets | -8,297,610 | -8,474,847 | ' | ' |
Current liabilities: | ' | ' | ' | ' |
Accrued expenses and other current liabilities | -615 | -26 | ' | ' |
Intercompany payables | -1,108,155 | -1,609,385 | ' | ' |
Total current liabilities | -1,108,770 | -1,609,411 | ' | ' |
Long-term liabilities: | ' | ' | ' | ' |
Deferred tax liabilities | 474 | -87 | ' | ' |
Other long-term liabilities | -53 | -71 | ' | ' |
Intercompany notes payables | -2,305,165 | -2,448,481 | ' | ' |
Total long-term liabilities | -2,304,744 | -2,448,639 | ' | ' |
Stockholders' equity | -4,884,096 | -4,416,797 | ' | ' |
Total equity | -4,884,096 | -4,416,797 | ' | ' |
Total liabilities and equity | ($8,297,610) | ($8,474,847) | ' | ' |
Guarantor_Financial_Informatio6
Guarantor Financial Information - Guarantor Financial Information Consolidating Statement of Cash Flows (Detail) (USD $) | 9 Months Ended | |
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 |
Cash Flows from Operating Activities: | ' | ' |
Net income (loss) | ($66,966) | ($15,367) |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ' | ' |
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs | 14,088 | 16,087 |
Depreciation and amortization | 326,689 | 322,371 |
Non-cash charges for sale of inventories revalued at the date of acquisition | 1,880 | 4,681 |
Non-cash stock-based compensation expense | 14,462 | 11,868 |
Impairment of inventory | 243 | 295 |
Impairment of long-lived assets | 4,101 | 274 |
(Gain) loss on sale of property, plant and equipment | 1,849 | -4,194 |
Equity earnings of unconsolidated entities, net of tax | -13,238 | -10,417 |
Deferred income taxes | -73,655 | -43,619 |
Loss on extinguishment of debt | 35,603 | ' |
Loss on disposition | 5,885 | ' |
Bargain purchase gain | -5,707 | ' |
Other non-cash items | 6,674 | 5,736 |
Changes in assets and liabilities, net of acquisitions: | ' | ' |
Accounts receivable, net | -57,310 | -8,261 |
Inventories, net | -72,727 | -15,596 |
Prepaid expenses and other current assets | -9,132 | 4,171 |
Accounts payable | 15,981 | -16,743 |
Accrued expenses and other current liabilities | 37,242 | 24,116 |
Other non-current liabilities | -6,857 | -21,639 |
Net cash provided by (used in) operating activities | 159,105 | 253,763 |
Cash Flows from Investing Activities: | ' | ' |
(Increase) decrease in restricted cash | -33,881 | 5,771 |
Purchases of property, plant and equipment | -90,908 | -97,309 |
Proceeds from sale of property, plant and equipment | 5,831 | 22,383 |
Cash received from disposition | 32,000 | ' |
Cash received from (paid for) acquisitions, net of cash acquired | -166,196 | -384,780 |
Cash received from sales of marketable securities | ' | 271 |
Cash received from (paid for) equity method investments | 11,262 | 6,556 |
(Increase) decrease in other assets | 19,244 | -9,313 |
Net cash used in investing activities | -222,648 | -456,421 |
Cash Flows from Financing Activities: | ' | ' |
Cash paid for financing costs | -9,798 | -2,313 |
Cash paid for contingent purchase price consideration | -27,496 | -16,248 |
Proceeds from issuance of common stock, net of issuance costs | 17,555 | 14,260 |
Proceeds from issuance of long-term debt | 460,141 | 198,288 |
Payments on long-term debt | -455,157 | -42,553 |
Net proceeds (payments) under revolving credit facilities | 138,768 | 91,162 |
Borrowings from (payments on) short-term debt | 25 | -6,240 |
Cash paid for dividends | -15,970 | -15,970 |
Excess tax benefits on exercised stock options | 434 | 277 |
Principal payments on capital lease obligations | -5,341 | -4,925 |
Other | -18,953 | -2,811 |
Net cash provided by (used in) financing activities | 84,208 | 212,927 |
Foreign exchange effect on cash and cash equivalents | 4,982 | -7,188 |
Net increase (decrease) in cash and cash equivalents | 25,647 | 3,081 |
Cash and cash equivalents, beginning of period | 328,346 | 299,173 |
Cash and cash equivalents, end of period | 353,993 | 302,254 |
Issuer [Member] | ' | ' |
Cash Flows from Operating Activities: | ' | ' |
Net income (loss) | -66,966 | -15,367 |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ' | ' |
Equity (earnings) losses of subsidiaries, net of tax | -112,535 | -129,929 |
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs | 13,814 | 15,929 |
Depreciation and amortization | 3,731 | 4,314 |
Non-cash stock-based compensation expense | 5,836 | 3,119 |
(Gain) loss on sale of property, plant and equipment | ' | 3 |
Equity earnings of unconsolidated entities, net of tax | -1,278 | -1,798 |
Deferred income taxes | -17,386 | 20,901 |
Loss on extinguishment of debt | 35,603 | ' |
Other non-cash items | 5,201 | -1,156 |
Changes in assets and liabilities, net of acquisitions: | ' | ' |
Prepaid expenses and other current assets | -64,547 | -419,146 |
Accounts payable | 5,918 | 3,961 |
Accrued expenses and other current liabilities | 10,396 | 354,452 |
Other non-current liabilities | -915 | -7,158 |
Intercompany payable (receivable) | 298,083 | 297,741 |
Net cash provided by (used in) operating activities | 114,955 | 125,866 |
Cash Flows from Investing Activities: | ' | ' |
(Increase) decrease in restricted cash | -4,439 | ' |
Purchases of property, plant and equipment | -1,037 | -1,149 |
Cash received from (paid for) acquisitions, net of cash acquired | -157,373 | -364,731 |
Cash received from (paid for) equity method investments | 490 | 490 |
(Increase) decrease in other assets | 19,244 | -10,028 |
Net cash used in investing activities | -143,115 | -375,418 |
Cash Flows from Financing Activities: | ' | ' |
Cash paid for financing costs | -9,798 | -2,313 |
Cash paid for contingent purchase price consideration | -27,165 | -16,248 |
Proceeds from issuance of common stock, net of issuance costs | 17,555 | 14,260 |
Proceeds from issuance of long-term debt | 425,000 | 198,000 |
Payments on long-term debt | -446,845 | -33,250 |
Net proceeds (payments) under revolving credit facilities | 147,500 | 97,500 |
Borrowings from (payments on) short-term debt | ' | -6,240 |
Cash paid for dividends | -15,970 | -15,970 |
Excess tax benefits on exercised stock options | 205 | 183 |
Other | -18,953 | ' |
Net cash provided by (used in) financing activities | 71,529 | 235,922 |
Foreign exchange effect on cash and cash equivalents | 871 | 1,508 |
Net increase (decrease) in cash and cash equivalents | 44,240 | -12,122 |
Cash and cash equivalents, beginning of period | 3,623 | 12,451 |
Cash and cash equivalents, end of period | 47,863 | 329 |
Guarantor Subsidiaries [Member] | ' | ' |
Cash Flows from Operating Activities: | ' | ' |
Net income (loss) | 54,188 | 94,472 |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ' | ' |
Equity (earnings) losses of subsidiaries, net of tax | 1,510 | 763 |
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs | 229 | 158 |
Depreciation and amortization | 188,745 | 198,576 |
Non-cash charges for sale of inventories revalued at the date of acquisition | ' | 1,400 |
Non-cash stock-based compensation expense | 3,646 | 4,309 |
Impairment of inventory | 27 | 5 |
Impairment of long-lived assets | 2,954 | 219 |
(Gain) loss on sale of property, plant and equipment | 1,118 | -4,029 |
Deferred income taxes | -27,285 | -38,495 |
Other non-cash items | -8 | 685 |
Changes in assets and liabilities, net of acquisitions: | ' | ' |
Accounts receivable, net | -15,528 | -6,468 |
Inventories, net | -45,883 | 4,881 |
Prepaid expenses and other current assets | 67,871 | 410,233 |
Accounts payable | -1,453 | -2,327 |
Accrued expenses and other current liabilities | 17,570 | -323,909 |
Other non-current liabilities | -15,197 | -1,634 |
Intercompany payable (receivable) | -182,214 | -322,706 |
Net cash provided by (used in) operating activities | 50,290 | 16,133 |
Cash Flows from Investing Activities: | ' | ' |
(Increase) decrease in restricted cash | -630 | 12 |
Purchases of property, plant and equipment | -42,950 | -69,092 |
Proceeds from sale of property, plant and equipment | 6,908 | 22,230 |
Cash received from (paid for) acquisitions, net of cash acquired | ' | 1,469 |
Cash received from sales of marketable securities | ' | 268 |
(Increase) decrease in other assets | -2,047 | -615 |
Net cash used in investing activities | -38,719 | -45,728 |
Cash Flows from Financing Activities: | ' | ' |
Proceeds from issuance of long-term debt | 989 | ' |
Payments on long-term debt | -1,213 | -455 |
Net proceeds (payments) under revolving credit facilities | ' | -2 |
Excess tax benefits on exercised stock options | 181 | 74 |
Principal payments on capital lease obligations | -2,715 | -1,503 |
Net cash provided by (used in) financing activities | -2,758 | -1,886 |
Foreign exchange effect on cash and cash equivalents | -28 | 331 |
Net increase (decrease) in cash and cash equivalents | 8,785 | -31,150 |
Cash and cash equivalents, beginning of period | 67,449 | 95,212 |
Cash and cash equivalents, end of period | 76,234 | 64,062 |
Non-Guarantor Subsidiaries [Member] | ' | ' |
Cash Flows from Operating Activities: | ' | ' |
Net income (loss) | 59,170 | 36,851 |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ' | ' |
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs | 45 | ' |
Depreciation and amortization | 134,317 | 119,462 |
Non-cash charges for sale of inventories revalued at the date of acquisition | 1,880 | 3,281 |
Non-cash stock-based compensation expense | 4,980 | 4,440 |
Impairment of inventory | 216 | 290 |
Impairment of long-lived assets | 1,147 | 55 |
(Gain) loss on sale of property, plant and equipment | 731 | -168 |
Equity earnings of unconsolidated entities, net of tax | -11,932 | -8,643 |
Deferred income taxes | -27,830 | -25,122 |
Loss on disposition | 5,885 | ' |
Bargain purchase gain | -5,707 | ' |
Other non-cash items | 1,481 | 6,207 |
Changes in assets and liabilities, net of acquisitions: | ' | ' |
Accounts receivable, net | -41,782 | -1,793 |
Inventories, net | -30,615 | -23,303 |
Prepaid expenses and other current assets | -4,941 | 13,059 |
Accounts payable | 11,516 | -18,377 |
Accrued expenses and other current liabilities | 2,342 | -5,843 |
Other non-current liabilities | 8,739 | -13,275 |
Intercompany payable (receivable) | -115,869 | 27,088 |
Net cash provided by (used in) operating activities | -6,227 | 114,209 |
Cash Flows from Investing Activities: | ' | ' |
(Increase) decrease in restricted cash | -28,812 | 5,759 |
Purchases of property, plant and equipment | -58,860 | -94,311 |
Proceeds from sale of property, plant and equipment | 11,186 | 66,281 |
Cash received from disposition | 32,000 | ' |
Cash received from (paid for) acquisitions, net of cash acquired | -8,823 | -21,518 |
Cash received from sales of marketable securities | ' | 3 |
Cash received from (paid for) equity method investments | 10,772 | 6,066 |
(Increase) decrease in other assets | 2,065 | 1,275 |
Net cash used in investing activities | -40,472 | -36,445 |
Cash Flows from Financing Activities: | ' | ' |
Cash paid for contingent purchase price consideration | -331 | ' |
Proceeds from issuance of long-term debt | 34,152 | 288 |
Payments on long-term debt | -7,099 | -8,848 |
Net proceeds (payments) under revolving credit facilities | -8,732 | -6,336 |
Borrowings from (payments on) short-term debt | 25 | ' |
Excess tax benefits on exercised stock options | 48 | 20 |
Principal payments on capital lease obligations | -2,626 | -3,422 |
Other | ' | -2,811 |
Net cash provided by (used in) financing activities | 15,437 | -21,109 |
Foreign exchange effect on cash and cash equivalents | 3,884 | -10,302 |
Net increase (decrease) in cash and cash equivalents | -27,378 | 46,353 |
Cash and cash equivalents, beginning of period | 257,274 | 191,510 |
Cash and cash equivalents, end of period | 229,896 | 237,863 |
Eliminations [Member] | ' | ' |
Cash Flows from Operating Activities: | ' | ' |
Net income (loss) | -113,358 | -131,323 |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ' | ' |
Equity (earnings) losses of subsidiaries, net of tax | 111,025 | 129,166 |
Depreciation and amortization | -104 | 19 |
Equity earnings of unconsolidated entities, net of tax | -28 | 24 |
Deferred income taxes | -1,154 | -903 |
Changes in assets and liabilities, net of acquisitions: | ' | ' |
Inventories, net | 3,771 | 2,826 |
Prepaid expenses and other current assets | -7,515 | 25 |
Accrued expenses and other current liabilities | 6,934 | -584 |
Other non-current liabilities | 516 | 428 |
Intercompany payable (receivable) | ' | -2,123 |
Net cash provided by (used in) operating activities | 87 | -2,445 |
Cash Flows from Investing Activities: | ' | ' |
Purchases of property, plant and equipment | 11,939 | 67,243 |
Proceeds from sale of property, plant and equipment | -12,263 | -66,128 |
(Increase) decrease in other assets | -18 | 55 |
Net cash used in investing activities | -342 | 1,170 |
Cash Flows from Financing Activities: | ' | ' |
Foreign exchange effect on cash and cash equivalents | $255 | $1,275 |